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Abstract 
    Mitogen Activated Protein 3 Kinase 8 (MAP3K8) is a member of the 
serine/threonine protein kinase family and has been demonstrated to be involved in 
the mitogen activated protein kinase (MAPK) pathway. The latter pathway plays an 
important role in many aspects of the immune mediated inflammatory response. 
Inhibition of MAP3K8 in primary human cell types decreases the production of 
TNF-α and other pro-inflammatory mediators during inflammatory events. 
Pharmacologic inhibition of MAP3K8 has been shown to be an appropriate 
therapeutic target for rheumatoid arthritis and other human inflammatory diseases. 
Inhibition of MAP3K8 may therefore potentially be a new therapeutic strategy for 
airway inflammation. 
    Investigation of the role of MAP3K8 in regulation of the inflammatory response 
was conducted using epithelial cell lines. A MAP3K8 gene knockdown experiment 
using small interfering RNA (siRNA) was carried out to establish the effect of 
MAP3K8 on the inflammatory response following IL-1β stimulation. In addition the 
effect of MAP3K8 gene knockdown on the therapeutic outcome of dexamethasone 
(Dex) was investigated. ELISAs were used to establish whether knockdown of 
MAP3K8 resulted in inhibition of IL-1β-induced IL-6, IL-8 and RANTES. The effect 
of treatment with Dex in combination with MAP3K8 gene silencing on ERK and 
MEK phosphorylation was determined by Western Blotting. The impact of MAP3K8 
gene silencing on global gene expression was also assessed using Affymetrix Human 
Gene 1.1ST arrays. Differential expression and network analyses were performed on 
the data generated.  
    A significant rise in MAP3K8 gene expression was found 2 hours after IL-1β 
stimulation in both A549 and normal human bronchial epithelial (NHBE) cells. In 
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addition, siRNA against MAP3K8 resulted in approximately 40% inhibition of IL-6, 
IL-8 and RANTES expression after IL-1β stimulation. Furthermore, MAP3K8 gene 
silencing enhanced by approximately 40% the decrease in IL-8 and RANTES release 
seen at different concentrations of Dex. The combination of MAP3K8 gene silencing 
and Dex also resulted in a greater inhibition of phosphorylated ERK compared to that 
seen with Dex alone. Data from global gene expression arrays revealed that the 
MAP3K8 regulated inflammatory response was predominantly involved in the 
ERK/MAPK and SAPK/JNK pathways but not the p38 MAPK pathway. Among the 
genes regulated by MAP3K8, it is interesting to note that IL-6, MMP-1, MMP-3, 
MMP-12 and CCL20 have previously been reported to be linked with airway diseases, 
such as COPD and asthma. Furthermore, MAP3K8 regulated the AP-1 transcription 
factor up-regulation of IL-1β-induced IL-6 and MMP-1 through the ERK1/2 and JNK 
signaling pathways. MAP3K8 however appears to regulate NF-kB activation through 
IKKα/β activation independent of the MAPK pathway regulated by itself. 
    In conclusion, MAP3K8 plays a key role in the inflammatory cytokine response 
post IL-1β stimulation. MAP3K8 gene silencing by siRNA not only suppresses these 
key inflammatory cytokines but also enhances the therapeutic effect of steroids. 
MAP3K8 inhibitors might therefore provide a new therapeutic strategy for airway 
inflammation. 
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1.1 Airway Inflammation 
    Airway inflammation is a feature of lung diseases characterized by airway 
obstruction and excessive airway secretions. Asthma and Chronic Obstructive 
Pulmonary Disease (COPD) are both very common airway diseases characterized by 
chronic airway inflammation. Airway inflammation can occur in response to exposure 
to particulates like pollens, pollutants, allergens and other substances. Airway 
production of chemokines, cytokines, adhesion molecules and inflammatory 
mediators play an important role in the modulation of acute and chronic airway 
inflammation. Despite the fact that some clinical features of asthma and COPD are 
similar, the predominant inflammatory cells recruited, regulatory mediators produced 
and the patterns of inflammation in disease severity are different between the two 
diseases as discussed below.  
 
1.1.1 Histopathology 
    Asthma and COPD are both obstructive airway diseases that involve chronic 
inflammation of the respiratory tract. Asthma is characterized by airway 
hyper-responsiveness (AHR), intermittent and reversible airway obstruction, and 
airway inflammation
1
. COPD is characterized by air ﬂow obstruction and is caused by 
a mixture of small airways disease and emphysema
2
. Small airways disease is the 
narrowing of the small airways due to chronic or repeated inﬂammation, scarring and 
blockage due to mucous secretions. Emphysema is defined as enlargement of 
airspaces distal to terminal bronchioles accompanied by destruction of alveolar walls. 
The anatomical focus of the changes in each disease is different. The inflammation in 
 2 
 
asthma is mainly located in the larger conducting airways and small airways in more 




    In asthmatic patients, bronchial biopsies reveal an inflammatory infiltration 
predominated by eosinophils, mast cells and activated Th2 type lymphocytes. 
Collagen deposition under the epithelium is a characteristic structural change in 
asthmatic patients. Thickening of the airway smooth muscle cell layer, as a result of 
hyperplasia and hypertrophy, is more commonly seen in patients with severe asthma
4
. 
In patients with COPD, there is an infiltration of macrophages, Th1 lymphocytes and 
increased numbers of neutrophils in the airway lumen. Fibrosis occurs mainly around 
the small airways and mucus hyperplasia is common although the latter is also found 
in biopsies from asthmatics. A marked difference between COPD and asthma is the 
destruction of the alveolar walls as a result of the protease-mediated degradation of 
connective tissue elements
5
. For example, elastolytic enzymes, including several 
matrix metalloproteinases (MMPs), are increased in the lungs of COPD patients. 
Figure 1.1.1 shows and lists the different histological changes of the airways in 




Figure 1.1.1 Contrasting Histopathology of Asthma and COPD. Picture taken 




1.1.2 Inflammatory and Immune Cells 
    Airway epithelial cells are activated by allergens, cigarette smoke and other 
irritants to product inflammatory mediators. Airway epithelial cells are also important 
in defense of the airways, with mucus production from goblet cells and secretion of 
anti-oxidants
5
. There is a variety of inflammatory cells that are involved in the airway 
inflammation seen in asthma and COPD and these are described below.  
 
1.1.2.1 Mast Cells 
    In asthma, mast cells have a key role in initiating the acute broncho-constrictor 
response to allergens as they release several broncho-constrictors, including 
histamine, leukotrienes and prostaglandin D2
6
. Mucosal mast cells are recruited and 
maintained at the mucosal surface of the airways by stem-cell factor (SCF) the latter 
 4 
 
being released from epithelial cells. Mast cells present in the airway smooth muscle 
have also been reported to be linked to the airway hyper-responsiveness seen in 
asthma
6




    Eosinophil infiltration is a characteristic feature of asthmatic airways. 
Eosinophils are derived from bone marrow precursors. The IL-5 released from Th2 
lymphocytes is a unique mediator of eosinophil differentiation and survival in 
response to allergen provocation. In asthma, airway epithelial cells secrete eosinophil 
chemotactic factors, such as CC-chemokine ligand 11 (CCL11) resulting in the 
recruitment and accumulation of eosinophils in the airways. Other mediators such as 
eotaxins, CCL5 (RANTES) and CCL13 (MCP-4), expressed in epithelial cells are 






    In contrast to asthma, the inflammation that occurs in COPD is described as 
neutrophilic. Sputum of patients with COPD characteristically exhibits increased 
levels of neutrophils and this is correlated both with disease severity and the rate of 
decline in lung function
7
. Several neutrophil chemotactic factors may play roles in 
neutrophil migration into the respiratory tract. These mediators include leukotriene 
B4, CXCL8, CXCL1 and CXCL5 and they are derived from alveolar macrophages 
and epithelial cells
8
. Neutrophils secrete serine proteases as well as matrix 
metalloproteinase MMP-9, which may contribute to alveolar destruction 




    Macrophage numbers are increased in the lungs of patients with airway diseases 
being most notably predominant in COPD patients. These macrophages, derived from 
circulating monocytes, migrate to the lungs in response to chemoattractants such as 
CCL2 and CXCL1
9
. In addition, macrophages secrete proteases (MMP-9) and 
chemokines that attract neutrophils, monocytes and T cells resulting in airway 
inflammation.  
 
1.1.2.5 T cells 
    In asthmatic patients, there is an increase in the number of CD4
+
 T cells 
(predominantly T helper 2 (Th2) cells) in the airways. Secreted cytokines IL-4 and 
IL-13 from Th2 cells drive IgE production by B cells. Secreted IL-5 is also necessary 
for eosinophilic inflammation whilst IL-9 attracts and stimulates mast cell 
proliferation
10
. The recruitment of Th2 cells in the airway is dependent on several 
chemotactic mediators including the chemokines CCL17 and CCL22, which are 
released from myeloid dendritic cells through thymic stromal lymphopoietin (TSLP), 
the latter being secreted by epithelial cells and mast cells
11
.   
    In contrast to asthma, Th1 cells are predominant and accumulate in the airways 
and lungs of patients with COPD. These Th1 cells are attracted to the lungs by 
CXCL9, CXCL10 and CXCL11 released from epithelial cells and macrophages. 
CD8
+
 T cells are predominant over CD4
+
 T cells in the airways of patients with 
COPD
12
. Type 1 cytotoxic T (Tc1) cells release granzyme B and perforins which may 
induce apoptosis of type 1 pneumocytes leading to the development of emphysema
13
. 
The inflammatory and immune cells involved in asthma and COPD are illustrated in 




Figure 1.1.2 Interactions of Inflammatory and Immune Cells Involved in Asthma. 
Inhaled allergens activate sensitized mast cells by crosslinking surface-bound IgE 
molecules to release several bronchoconstrictor mediators, including cysteinyl 
leukotrienes and prostaglandin D2. Epithelial cells release stem-cell factor (SCF), 
which is important for maintaining mucosal mast cells at the airway surface. Allergens 
are processed by myeloid dendritic cells, which are conditioned by thymic stromal 
lymphopoietin (TSLP) secreted by epithelial cells and mast cells to release the 
chemokines CC‑chemokine ligand 17 (CCL17) and CCL22, which act on CC‑
chemokine receptor 4 (CCR4) to attract T helper 2 (TH2) cells. TH2 cells have a 
central role in orchestrating the inflammatory response in allergy through the release 
of interleukin‑4 (IL‑4) and IL‑13 (which stimulate B cells to synthesize IgE), IL‑5 
(which is necessary for eosinophilic inflammation) and IL‑9 (which stimulates 
 7 
 
mast-cell proliferation). Epithelial cells release CCL11, which recruits eosinophils via 
CCR3. Patients with asthma may have a defect in regulatory T (TReg) cells, which 
may favour further TH2-cell proliferation. Picture with description taken from Barnes, 
P.J. Nat Rev Immunol 8, 183-92 (2008)
5
.   
 
Figure 1.1.3 Interactions of Inflammatory and Immune Cells Involved in COPD. 
Inhaled cigarette smoke and other irritants activate epithelial cells and macrophages to 
release several chemotactic factors that attract inflammatory cells to the lungs, 
including CC‑chemokine ligand 2 (CCL2), which acts on CC‑chemokine receptor 2 
(CCR2) to attract monocytes, CXC-chemokine ligand 1 (CXCL1) and CXCL8, which 
act on CCR2 to attract neutrophils and monocytes (which differentiate into 
 8 
 
macrophages in the lungs) and CXCL9, CXCL10 and CXCL11, which act on CXCR3 
to attract T helper 1 (TH1) cells and type 1 cytotoxic T (TC1) cells. These 
inflammatory cells together with macrophages and epithelial cells release proteases, 
such as matrix metalloproteinase 9 (MMP9), which cause elastin degradation and 
emphysema. Neutrophil elastase also causes mucus hypersecretion. Epithelial cells 
and macrophages also release transforming growth factor‑β (TGFβ), which stimulates 
fibroblast proliferation, resulting in fibrosis in the small airways. Picture with 




1.1.2.6 Inflammatory Patterns: Asthma and COPD 
    Although the inflammatory cells involved in asthma and COPD are markedly 
different, there are several situations where they potentially are more similar. For 
example, the inflammatory pattern that occurs in cases of severe asthma is similar to 
COPD, with increased numbers of neutrophils seen in sputum and increased amounts 
of CXCL8 and TNF
14
. Furthermore, a mixture of Th1 and Th2 cells is commonly seen 
in bronchial biopsies, as well as CD8
+
 T cells, which resembles more the composition 
of the immune cells infiltrate seen in COPD patients. Moreover, a neutrophilic pattern 
of inflammation is also commonly seen in patients with severe asthma due to the 
release of the chemokine neutrophilic CXCL8 from airway epithelial cells through 
IL-17 produced by Th17 cells
15
. In asthma and COPD, exacerbations are associated 
with further increases and changes in the pattern of airway inflammation. In 
exacerbations of asthma triggered by viruses, there are increases in the numbers of 
neutrophils and eosinophils
16
. An increase in eosinophil numbers is also found in 
COPD exacerbations triggered by viruses
17
. A comparison between patterns of 




Table 1.1.1 Comparison between Patterns of Inflammation in Asthma and 
COPD. 
 
0, no response; + to +++, magnitude scale; ?, uncertain; CCL, CC-chemokine ligand; 
CXCL, CXC-chemokine ligand; iNKT, invariant natural killer T; LTB4, leukotriene 
B4; LTD4, leukotriene D4; PGD2, prostaglandin D2; Tc1, type 1 cytotoxic T; Th, T 





1.1.3 Pro-inflammatory Cytokines  
    In patients with asthma and COPD, pro-inflammatory cytokines, such as TNF-α, 
IL-1β and IL-6 are found in increased levels in the sputum and bronchial alveolar 
lavage (BAL) fluid and amplify inflammation
18,19
. Blocking these cytokines is 
believed to be of clinical benefit for chronic airway inflammation. The 
pro-inflammatory cytokines involved in airway inflammation in asthma and COPD 





    Many cells including macrophages, mast cells, T cells, epithelial cells, and 
airway smooth muscle cells have the capacity to produce and secrete TNF-α. TNF-α 
may play a key role in the airway hyper-responsiveness (AHR) of asthma. Blocking 
TNF-α has been reported to reduce AHR and improve lung function in patients with 
severe asthma
20
. In patients with COPD, TNF-α levels are increased in sputum, 
especially during exacerbations. Blocking TNF-α, in COPD patients however, has no 





    In asthma, IL-1β levels are increased in the airways of asthma patients and the 
cytokine activates cell signaling pathways of inflammation. IL-1 receptor antagonist 
(IL-1Ra) administration has been shown to result in reduction of AHR in mice, 
although human recombinant IL-1 Ra results in no improvement of disease in asthma 
patients
22
. In patients with COPD, IL-1β has a pronounced impact on activating 
macrophages causing them to secrete inflammatory cytokines, chemokines and matrix 
metalloproteinases (MMPs). The effect of IL-1β blocking in COPD patients is at 
present unknown.  
 
1.1.3.3 IL-6 
    IL-6 levels are increased in induced sputum of asthmatic patients and the 
cytokine may play a role in the expansion of Th2 cells. It is positively correlated with 
increased IL-13 levels resulting in inflammatory amplification in asthma
23
. IL-6 is 








    Chemokines (chemotactic cytokines) play a crucial role in the recruitment of 
different types of inflammatory cells from the blood to the airways in both asthma and 
COPD
9,25
. There are two major families of chemokines that are defined and 
distinguished by the position of four conserved cysteine residues. The largest family is 
the CC chemokines which are named because the first two of the four cysteine 
residues are adjacent to each other. The second family is the CXC chemokines which 
have two cysteine residues in the same region, but with an interposed amino acid
26
. 
The chemokines involved in airway inflammation in asthma and COPD are described 
below. 
 
1.1.4.1 CC Chemokines 
    CCL2 (also known as monocyte chemoattractant protein 1 [MCP-1]) is 
expressed by alveolar macrophages, T cells and epithelial cells. CCL2 is a 
chemoattractant of monocytes and is involved in the accumulation of macrophages in 
the lungs of COPD patients
27
.  
    Eosinophils express C-C chemokine receptor type 3 (CCR3) which mediates the 
chemotactic response to several chemokines, including CCL11 (also known as 
eotaxin) and CCL5 (also known as RANTES), all of which show increased levels in 
the airways of patients with asthma
28
.  
    CCL3 (also known as macrophage inflammatory protein 1 α [MIP-1α]), CCL4 
(also known as MIP-1β), and CCL5 all activate CCR5, which is expressed on T cells 
and monocytes, and consequently contribute to the recruitment of T cells, eosinophils 
and macrophages into the airways of patients with COPD. It has been shown that of 
these three CCLs, CCL5 is increased in airways and sputum of COPD patients during 
exacerbations and it is also increased in asthmatic airways, especially in airway 





1.1.4.2 CXC Chemokines 
    CXCL8 and CXCL1 (also known as growth regulated oncogene α [GRO-α]) 
activate mainly CXCR1 and CXCR2 respectively and play a crucial role in the 
recruitment of neutrophils into the airways. CXCL1 and CXCL8 levels are 
significantly increased in induced sputum of COPD patients and positively correlate 
with increase in neutrophil count
8
. CXCL8 is also increased in the airways and 
sputum of patients with severe asthma and during exacerbations
14,31
.   
    CXCL9, CXCL10 and CXCL11 induced by IFN-γ activate CXCR3 expressed on 
Th1 and Tc1 cells. CXCR3 is found expressed on T cells in the airways of COPD 





1.1.5 Matrix Metalloproteinases  
    Matrix metalloproteinases (MMPs) are zinc-dependent endopeptidases belonging 
to a larger family of proteases. MMPs are produced from inflammatory and structural 
cells in the airways and play an important role in tumor progression and invasion of 
inflammatory cells by degrading the extracellular matrix (ECM). MMPs are regulated 
tightly and counterbalanced by their physiological inhibitors, tissue inhibitors of 
MMPs (TIMPs). MMPs are classified based on their substrate specificity into 
collagenases (MMP-1), gelatinases (MMP-9), stromelysins (MMP-3), elastases 
(MMP-12) and membrane type MMPs
33
. MMPs are expressed by many inflammatory 
cells including macrophages, neutrophils, eosinophils, T cells, epithelial cells and 
airway smooth muscle cells. MMPs’ expression may also affect the activity of 
chemokines and pro-inflammatory cytokines. For example, MMP-9 increases IL-8 
activity and MMP-12 activates the latent form of TNF-α on the surface of 
macrophages
34,35
. In addition, there is increasing evidence that MMPs may contribute 
 13 
 




    In asthma, increased mRNA expression levels of MMP-1 and TIMP-1 have been 
found in sputum cells from patients with asthma
36
. Increased MMP-9 levels have been 
detected in BAL fluid, sputum, serum and bronchial epithelium
37
. Furthermore, 
MMP-9 expression has been shown to correlate with severity and increase in the 
number of neutrophils in the airways of asthma patients
38
. One major source of 
MMP-9 is from the eosinophil and MMP-9 levels are found in increased levels in 
sputum from allergic asthmatics correlating with eosinophil percentage counts
39
.   
    MMP-9 activities have also been reported to be elevated in sputum and BAL 
fluid of patients with COPD. A recent study showed that MMP-9 was present in 
emphysematous lung but not correlated with the emphysema itself
40
.  MMP-1 
expression is however an important enzyme involved in the destruction of the lung 
and has been reported to be present in the lung parenchyma of emphysema patients
41
. 
Increased levels and activities of MMP-12, also known as macrophage 
metalloelastase, were found in sputum and BAL fluid of COPD patients
42
. 
Furthermore, polymorphisms of MMP-12 are positively associated with lung function 




1.2 The IL-1β Signalling Pathway 
    Interleukin-1β (IL-1β) is a pro-inflammatory cytokine produced by activated 
macrophages, epithelial cells, endothelial cells, B cells and fibroblasts
44
. It is well 
established that it is involved in the initiation and persistence of inflammation. IL-1β 
stimulates a broad spectrum of immune and inflammatory responses including a 
variety of cellular activities such as cell differentiation, proliferation, apoptosis and 
inflammation
45





. The IL-1β-dependent signal transduction, including the sequential 
formation and activation of signalling complexes upon IL-1β stimulation, is illustrated 
and detailed below.   
 
1.2.1 Interleukin-1 Family 
    Interleukin-1 (IL-1) consists of two molecules, IL-1α and IL-1β whilst IL-1 
receptor antagonist (IL-1RA) is a natural inhibitor of these molecules. IL-1α and 
IL-1β are major mediators of innate immunity and have largely identical biological 
functions. They elicit a similar spectrum of systemic and cellular response although 
interestingly IL-1β appears to be the more potent of the two47. The main function of 
IL-1 cytokines is to control pro-inflammatory reactions in response to tissue injury by 
pathogens or damage
48
. IL-1α and IL-1β rapidly induce the mRNA expression of 
hundreds of genes. In parallel, they also induce expression of their own genes creating 
a positive-feedback loop
49
. Transcription of genes occurs within 30 min of exposure to 




1.2.2 Interleukin-1 Receptors 
    Two types of IL-1 receptors have been identified. One is type I IL-1 receptor 
(IL-1R1) which mediates all the known IL-1 biological responses and is the 
predominant receptor on T cells, fibroblasts and endothelial cells. Type II IL-1 
(IL-1R2) receptor has a short cytoplasmic domain and consequently does not 
transduce IL-1 signals. The receptor is mainly found on B lymphocytes, neutrophils, 
monocytes, large granular leukocytes and endothelial cells
51
. IL-1α and IL-1β 
independently bind to IL-1R1. In addition the IL-1 receptor accessory protein 
(IL-1RAcP) serves as a co-receptor and is required for signal transduction of 
IL-1/IL-1R1 complexes
51
. IL-1RA, a third specific ligand, acts as a natural inhibitor 
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1.2.3 Cytosolic Signalling of IL-1β 
    IL-1β induces cellular responses through its two component receptor, 
IL-1R1/IL-1RAcP. The trimeric complex rapidly assembles two intracellular 
signalling proteins, myeloid differentiation primary response gene 88 (MYD88) and 
interleukin-1 receptor-activated protein kinase 4 (IRAK4), through conserved 
cytosolic regions called Toll- and IL-1R-like (TIR) domains
53
. Auto-phosphorylation 
of IRAK4 occurs and then subsequent phosphorylation of IRAK1 and IRAK2 
happens followed by the recruitment and oligomerization of tumor necrosis 
factor-receptor-associated factor 6 (TRAF6).  
    TRAF6 is a ubiquitin ligase (E3) that functions with the ubiquitin conjugating 
(E2) complex, consisting of ubiquitin-conjugating enzyme E2 variant 1 (UEV1A ) and 
ubiquitin-conjugating enzyme E2N (UBC13), to catalyze the synthesis of 
Lys63-linked polyubiquitin chains on target proteins including adaptor proteins TAB2 
and TAB3 (transforming growth factor-β (TGF-β)-activated protein kinase-binding 
proteins 2 and 3 respectively) and TAK1 (TGF-β-activated protein kinase 1)49. 
Ubiquitination of TAK1 also promotes its association with TRAF6 and with MEKK3, 
a member of mitogen-activated protein kinase kinase kinase (MAP3K) family. TAK1 
and MEKK3 have been shown to be core components for subsequent signalling 
pathways activation, including the mitogen-activated protein kinase (MAPK) and 
NF-κB pathways48. Figure 1.2.1 summarizes the protein kinases and protein 






Figure 1.2.1 The Signalling Complexes Involved in the IL-1β Signalling Pathway. 
IL-1 induces cellular responses through IL-1R1/IL-1RAcP and rapidly assembles 
MYD88 and IRAK4. Auto-phosphorylation of IRAK4 occurs and phosphorylates 
IRAK1 and IRAK2 followed by the recruitment and oligomerization of TRAF6. 
TRAF6 catalyzes adaptor proteins TAB2 and TAB3 and TAK1. Ubiquitination of 
TAK1 also promotes its association with TRAF6 and with MEKK3. IL-1RAcP, IL-1 
receptor accessory protein; IRAK4, interleukin-1 receptor-activated protein kinase 4; 
MYD88, myeloid differentiation primary response gene 88; TAB2, transforming 
growth factor-β (TGF-β)-activated protein kinase-binding proteins 2; TAB3, 
transforming growth factor-β (TGF-β)-activated protein kinase-binding proteins 3. 
TRAF6, tumor necrosis factor-receptor-associated factor 6; TAK1, TGF-β-activated 
protein kinase 1. Picture adapted from Gaestel, M., Kotlyarov, A. & Kracht, M. Nat 





1.2.4 IL-1β Stimulated MAPK Signalling  
    MAP kinases regulate a range of cellular activities in innate immune responses 
and are activated by an enormous array of stimuli. They phosphorylate numerous 
substrate proteins including cytoskeletal proteins, kinases and transcription factors, 
and are particularly important in regulating cytokine gene expression and cellular 
processes such as metabolism, motility and cell survival
54
. MAP kinase signalling 
pathways contain a three-component protein kinase cascade comprising a 
serine/threonine MAP kinase kinase kinase (MAP3K), a MAP kinase kinase 
(MAP2K) and the MAP kinase (MAPK). Frequently, a MAP3K phosphorylates and 
activates a dual-specificity protein kinase (MAP2K) that, in turn phosphorylates and 
activates a MAP kinase
54
. Three main families of MAP kinases are well-characterized. 
These MAP kinases include the extracellular signal-regulated kinases, ERK1 and 
ERK2; the c-Jun NH2-terminal kinases, JNK1, JNK2 and JNK3; and the four p38 
enzymes, p38α, p38β, p38γ, and p38δ55. Numerous different kinases have been shown 
to function as a MAP3K the latter generally having the capacity to activate multiple 
MAP kinase pathways. MAP2Ks exhibit great specificity for their cognate MAPK but 
may be regulated by many MAP3Ks. The three main MAPK signalling cascades are 
described below. 
 
1.2.4.1 ERK1/2 Signal Transduction Pathway 
    ERK1 and ERK2 regulate a number of cellular activities including growth, 
proliferation, differentiation and survival. They are activated by many different 
stimuli including growth factors, cytokines and carcinogens. In this signalling 
transduction cascade, rapidly accelerated fibrosarcoma kinase (Raf) proteins (A-Raf, 
B-Raf, C-Raf) function as MAP3K whilst MEK1 and MEK2 function as upstream 
MAP2K
56
. In IL-1β stimulated MAPK signalling, ERK1/2 signalling appears to be 
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activated by MAP3K8, which is released from its complex with NF-κB-1/p105 
through the phosphorylation of IκB kinase (IKK) by TAK1 and MEKK3. ERK1/ 
ERK2 mainly regulate the activation of activating protein 1 (AP-1) family of 
transcription factors, including ternary complex factors (TCFs) such as extracellular 
signal regulated-like kinase 1 (Elk-1) and SRF accessory protein 1 (SAP-1) and 




1.2.4.2 The JNK Signal Transduction Pathway 
    The JNKs are characterized as stress-activated protein kinases and are involved 
in the regulation of cell proliferation and apoptosis. The JNK pathway is activated by 
environmental stress, radiation, growth factors and various cytokines
56
. MAP3K 
activators of JNK are composed of a large group of intracellular proteins, including 
MEKK group (MEKK1-4). The two MAP2K proteins that function as upstream JNK 
activators are MKK4, which is primarily activated by environmental stress, and 
MKK7 that is primarily activated by cytokines
57
. In IL-1β stimulated MAPK 
signalling, JNK signalling appears to be activated by TAK1 and MEKK3. JNKs also 
regulate the activation of activating protein 1 (AP-1). The two primary AP-1 




1.2.4.3 The p38 MAPK Signal Transduction Pathway 
    The p38 MAPKs function in the control of cell growth, differentiation and 
apoptosis and regulate the expression of many cytokines. The p38 pathway can be 
activated by environmental stress, UV irradiation, osmotic and heat shock, growth 
factors and a variety of cytokines. Numerous MAP3Ks participate in p38 modules, 
including mixed lineage kinase (MLK), serine/threonine-protein kinase 1 and 2 





. MKK3, MKK6 and partial involvement of MKK4 serve as 
upstream MAP2Ks responsible for p38 activation
56,58
. In IL-1β stimulated MAPK 
signalling, p38 MAPK signalling is activated by TAK1 and MEKK3 and in addition is 
involved in the regulation of activating protein 1 (AP-1). The downstream targets of 
p38 include several important transcription factors such as myocyte-specific enhancer 
factor 2 (MEF2) and ATF-2
56
. ATF-2 can form heterodimers with Jun transcription 
factors and thus associate with AP-1. Figure 1.2.2 summarizes the MAP kinase types 
and the ERK1/2, JNK and P38 pathways. 
 
 
Figure 1.2.2 MAP Kinase Signal Transduction Pathways. This picture shows the 
result of phosphorylation of various MAP kinase isoforms in activation of the three 
main MAP kinases: ERK, JNK and p38 MAP kinase, which have different 
transcription targets. ATF-2, activating transcription factor 2; ASK, apoptosis 
signal-regulatory kinase; Elk-1, extracellular signal regulated-like kinase 1; MEF2, 
myocyte-specific enhancer factor 2; Raf, rapidly accelerated fibrosarcoma kinase. 
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1.2.5 IL-1β Stimulated AP-1 Signalling  
    IL-1β is known to induce AP-1 transcriptional activity through MAPK pathway 
activation
59
. The AP-1 transcription factor complex has a function in cell proliferation, 
differentiation and development to stress response as well as being a key player in 
regulating inflammatory processes
60
. AP-1 signalling can be activated by growth 
factors, cytokines, chemokines and multiple environmental stresses. The regulation of 
AP-1 complexes occurs at multiple levels, such as at the level of transcription, mRNA 
translocation and turnover, protein stability and interactions with other transcription 
factors. The activity of AP-1 can also be modulated by post-translational 
modifications. The AP-1 transcription factor complex and the regulation of AP-1 by 
MAPK kinases are described below. 
 
1.2.5.1 The AP-1 transcription factor complex 
    The AP-1 transcription factors belong to a large family of structurally related 
transcription factors that share a basic leucine zipper (bZIP) domain which AP-1 
proteins dimerize and bind to DNA. AP-1 is composed of homodimeric and 
heterodimeric complexes consisting of members of the Jun (c-Jun, JunB and JunD) 
and Fos (c-Fos, FosB, Fos-related antigen 1 [Fra-1] and Fra-2) families, the closely 
related activating transcription factor (ATF) and the musculoaponeurotic fibrosarcoma 
(MAF) subfamilies
61
. The different dimer combinations recognize different sequence 
elements in the promoters and enhancers of target genes. Jun can form 
transcriptionally active homodimers. Homodimers of c-Jun, as well as Jun-Fos 
heterodimers bind to DNA on a TPA (12-O-tetradecanoylphorbol-13-acetate)-response 
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element (TRE) with the 5'-TGA(C/G)TCA-3' sequence. ATF proteins such as ATF-2, 
conversely, form ATF-2 homodimers, as well as c-Jun/ATF-2 heterodimers that 
preferentially bind to cyclic AMP response elements (CRE; 5'-TGACGTCA-3'). In 
contrast to Jun proteins, Fos family members are not able to form homodimers but 
heterodimerize with Jun family members. In vitro studies have also shown that 
Jun-Fos combinations  form more stable heterodimers and display stronger DNA 




1.2.5.2 The Regulation of AP-1 by MAP kinases 
    MAP kinases (MAPKs) have been shown to regulate AP-1 transcription activity 
by many mechanisms. These MAPKs can not only induce the expression of AP-1 
proteins but can also increase the transcriptional activity of AP-1 complexes
63
. The 
serum response element (SRE), which is bound by a transcription factor complex 
including dimeric serum response factor (SRF) and the ternary complex factors Elk-1 
or SAP-1, is the major MAP kinase-response element in the c-fos promoter
64
. The 
major control element in the c-jun promoter is cAMP response element (CRE) that 
preferentially binds heterodimers of c-Jun and ATF-2
64
.  
    The activities of pre-existing and newly synthesized AP-1 components are 







 phosphorylate and activate Elk resulting in enhanced SRE-dependent c-fos 
expression. c-Jun bound on CRE in the c-jun promoter is activated by JNK MAP 
kinase, whereas ATF-2 could be phosphorylated and activated by both JNK and p38 
MAP kinases and additionally by ERK1/2
67-69
. c-Fos and c-Jun proteins are known to 
form stable heterodimers and bind to TPA-response elements in promoters of target 
genes. JNK is also able to enhance the transcriptional activity of AP-1 by 
phosphorylation of the AP-1 component c-Jun thereby increasing AP-1 associated 
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with the basal transcriptional complex
70
. Figure 1.2.3 illustrates the regulation of 
AP-1 by MAP kinases. 
 
 
Figure 1.2.3 Regulation of AP-1 by MAP kinases. The SRE is the major MAP 
kinase-response element in the c-fos promoter and the major control element in the 
c-jun promoter is CRE. c-Fos and c-Jun proteins are known to form stable 
heterodimers and bind to TPA-response elements in promoters of target genes. This 
picture illustrates the regulation of AP-1 by MAP kinases. ATF-2, activating 
transcription factor 2; CRE, cAMP response element; SRE, serum response element; 
SRF, serum response factor; TCF, ternary complex factors; TRE, TPA-response 





1.2.6 IL-1β Stimulated NF-κB Signalling  
    NF-κB regulates genes involved at multiple stages of immune responses 
including innate immune cell activation, dendritic cell maturation and lymphocyte 
activation. It also plays a crucial role in the regulation of many genes involved in the 
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mammalian inflammatory response such as cytokines, cell adhesion molecules, 
complement factors and a variety of immune receptors. NF-κB is the nuclear effector 
of signalling pathways emanating from many receptors in response to a variety of 
extracellular and intracellular stimuli
71
. Two separate pathways of NF-κB activation 
are well established: the canonical and non-canonical NF-κB pathways. The major 
signalling pathways leading to the translocation of NF-κB dimmers from cytoplasm to 
the nucleus are described below. 
 
1.2.6.1 Components of the NF-κB Signalling Pathway 
    The mammalian NF-κB family consists of five members: NF-κB1 (p50 and the 
precursor p105), NF-κB2 (p52 and the precursor p100), RelA (p65), RelB and c-Rel. 
Among them only RelA, RelB and c-Rel contain a transactivation domain (TAD). 
Whereas dimers containing RelA, RelB or c-Rel are transcriptional activators the 
homodimers of p50 and of p52 function as repressors as they lack TADs. All these 
molecules contain an amino-terminal REL homology domain (RHD) and are 
regulated by eight IκB family members72. The IKK complex, which phosphorylates 
IκB following activation, consists of two homologous kinase subunits, IKKα and 
IKKβ, as well as a regulatory subunit IKKγ. The signalling pathways that lead to the 
activation of the IKK complex are crucial regulatory events in NF-κB activation73. In 
canonical NF-κB signalling pathway, IKKβ is a key molecule and necessary for the 
phosphorylation of IκBα. By contrast, the non-canonical NF-κB pathway proceeds 
through the induction of p100 processing which depends primarily on IKKα. Figure 
1.2.4 shows all the members of the NF-κB, IαB and IKK protein families. The 





Figure 1.2.4 Members of the NF-κB, IκB and IKK Protein Families. ANK, 
ankyrin-repeat; BCL-3, B-cell lymphoma 3; CC, coiled-coil; DD, death domain; 
GRR, glycine-rich region; HLH, helix-loop-helix; IKK, IκB kinase; LZ, 
leucine-zipper; NBD, NF-κB-essential-modulator-binding domain PEST, proline-, 
glutamic acid-, serine- and threonine-rich; RHD, REL homology domain; TAD, 
transactivation domain; ZF, zinc-finger. Picture adapted from Ghosh, S. & Hayden, 




1.2.6.2 The Two NF-κB Activation Pathways 
    In the canonical NF-κB signalling pathway, proinflammatory cytokines, such as 
TNFα and IL-1β and pathogen-associated molecular patterns (PAMPs including 
lipopolysaccharide LPS) cause the activation of the IKK complex. In unstimulated 
cells, NF-κB is sequestered in the cytoplasm by the IκB proteins. The activation of 
IKK complex results in the phosphorylation of IκB proteins and consequently their 
degradation by the proteasome. Released NF-κB dimers (predominantly p50/RelA) 
translocate to the nucleus and bind κB sites in the promoters or enhancers of target 
genes leading to their transcription
74
. The activation and nuclear translocation of 
canonical NF-κB dimers increases transcription of genes encoding cytokines, 
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    The non-canonical NF-κB pathway is activated mainly by TNF-related cytokines 
LTβ (lymphotoxin β), CD40 ligand (CD40L) and B cell–activating factor (BAFF). 
IKKα activated by NF-κB-inducing kinase (NIK), a MAP kinase kinase kinase 
(MAP3K) regulates mainly the non-canonical pathway through the phosphorylation 
and processing of p100 releasing p52/RelB complexes. IKKα has been reported to be 
required for the generation of cell-mediated immune responses
76
. The transcription of 
many genes involved in lymphoid organogenesis and adaptive immunity also involve 
the non-canonical NF-κB dimers, such as B-lymphocyte chemoattractant (BLC), B 
cell–activating factor (BAFF) and secondary lymphoid tissue chemokines (SLC). 
These findings suggest that the non-canonical pathway to NF-κB activation mainly 
regulates adaptive immune responses
75
.  
    The p105 pathway, an atypical NF-κB pathway, is specifically involved in 
immune and inflammatory responses by the inducible degradation of p105. Following 
cellular stimulation with agonists, such as TNF-α, IL-1 and LPS, p105 is 
phosphorylated by activated IKK complexes and proteolysed rapidly by the 
proteasome. The polyubiquitination and subsequent degradation of p105 results in the 
release of p50 homodimers which then undergo nuclear translocation and positively or 
negatively regulate gene transcription
77
. In addition to NF-κB activation, p105 
degraded by activated IKK complexes also results in the liberation of tumour 
progression locus-2 (TPL-2). TPL-2 is known to function as a MAP3K that 
phosphorylates MEK1/2 and activates ERK1/2 signalling
78
. In IL-1β stimulated 
NF-κB signalling, TAK1 and MEKK3 signalling complexes activate the canonical 
NF-κB signalling by the phosphorylation of IKKβ. In addition, inducible degradation 
of p105 can also activate atypical p105 NF-κB signalling and release of TPL-249. 
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Figure 1.2.5 shows the activation of NF-κB signalling by the canonical and atypical 
pathways as described previously. 
 
 
Figure 1.2.5 Activation of NF-κB by Canonical and Atypical Pathways. The 
canonical pathway is activated by TNF, IL-1 or LPS through the triggering of various 
cytokine receptors and stimulates the IKK complex (IKK1-IKK2-NEMO) to 
phosphorylate IκBa and promote its degradation. The atypical NF-κB pathways 
involve stimulus-induced proteolysis of the NF-κB2 p100 (the so-called noncanonical 
pathway) and NF-κB1 p105 precursor proteins. IKK, IκB kinase; IL-1, interleukin 1; 
NEMO, NF-κB essential modifier; TAK-1, transforming growth factor β 
(TGF-β)-activated kinase 1; TNF, tumor necrosis fator; LPS, lipopolysaccharide. 






1.2.7 Termination of IL-1β Signalling  
    IL-1β signalling is transient in nature and terminates by a variety of mechanisms. 
The IL-1R binds to adaptor toll-interacting protein (TOLLIP) leading to efficient 
degradation of IL-1R
79
. IL-1β also activates several negative-feedback inhibitors for 
terminating IL-1β signalling including p38 MAPK phosphorylation of TAB1,which in 
turn inactivates TAK1
80
; NF-κB-mediated mRNA and protein expression of IκB 
which shuts off the NF-κB signalling81; and inducible expression of MAPK 




    Corticosteroids (or glucocorticoids) are widely used to treat various immune and 
inflammatory diseases. The most effective use of corticosteroids is in the treatment of 
asthma although they are ineffective in suppressing the inflammation seen in severe 
asthma and COPD. The molecular mechanisms of corticosteroids and their effect on 
inflammatory mechanisms of airway diseases are detailed below. 
 
1.3.1 Cellular Effects of Corticosteroids 
    Inflammation is mainly mediated by inflammatory cells and characterized by the 
increased expression of multiple inflammatory proteins, including cytokines, 
chemokines, adhesion molecules, and inflammatory enzymes and receptors. 
Corticosteroids can reduce the numbers of inflammatory cells (eosinophils, 
T-lymphocytes, mast cells, macrophages and dendritic cells) in the airways by 
suppressing the production of chemotactic mediators from the cells themselves or 




1.3.2 Glucocorticoid Receptors 
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    Corticosteroids diffuse across the cell membrane and bind to glucocorticoid 
receptors (GRs) in the cytoplasm. Cytoplasm GRs are normally bound to chaperone 
proteins that prevent nuclear localization by covering the sites on the receptor that are 
needed for nuclear import. Several variants of GRs are recognized. Only GR-α binds 
corticosteroids whereas GR-β is an alternatively spliced form that binds to DNA84. 
 
1.3.3 Corticosteroid-induced Gene Transcription 
    Upon ligand binding, GRs are activated and released from chaperone proteins. 
GRs then rapidly translocate to the nucleus, form homodimers and bind directly to 
glucocorticoid response elements (GREs) in the promoter of glucocorticoid-sensitive 
genes. DNA-bound GRs can also bind to transcriptional co-activator molecules such 
as cyclic AMP response element binding protein (CBP) to activate 
glucocorticoid-sensitive genes. Co-activator molecules have intrinsic histone 
acetyltransferase (HAT) activity and cause acetylation of core histones, particularly 
histone 4, resulting in the activation of glucocorticoid-sensitive genes
85
. Genes that 
are activated by corticosteroids include genes encoding β2-adrenergic receptors, 
anti-inflammatory protein secretory leucoprotease inhibitor (SLPI) and 
mitogen-activated protein kinase phosphatase 1 (MKP-1). GRs interaction with 
negative GREs, at which binding of GR leads to gene suppression, may suppress 
some gene transcriptions which are relevant to corticosteroid side-effects. 
Osteocalcin, for instance, inhibited by corticosteroids is involved in bone synthesis
86
. 





Figure 1.3.1 Glucocorticoid Activation of Anti-inflammatory Gene Expression. 
After ligand binding, activated glucocorticoid receptors (GRs) translocate to the 
nucleus where they bind to glucocorticoid response elements (GREs) in the promoter 
region of glucocorticoid-responsive genes and also directly or indirectly to 
transcriptional coactivator molecules such as cyclic AMP response element binding 
protein (CBP). Coactivator molecules have intrinsic histone acetyltransferase (HAT) 
activity and cause acetylation of core histones, resulting in the activation of 
anti-inflammatory genes. SLP1, secretory leucoprotease inhibitor; MKP-1, 
mitogen-activated protein kinase phosphatase 1; GILZ, glucocorticoid-induced 
leucine zipper protein. Picture with description taken from Barnes, P.J. & Adcock, I.M. 




1.3.4 Switching off Inflammatory Genes 
    The major effect of corticosteroids is to switch off multiple activated genes 
encoding adhesion molecules, inflammatory mediators, enzymes and receptors.  
Expression of these genes is controlled by pro-inflammatory transcription factors, 
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such as NF-κB and AP-1. A dimer of p50 and p65 NF-κB proteins translocates to the 
nucleus and binds to κB sites on the promoter regions of inflammatory genes. The 
dimer also binds to co-activators, such as CBP, which have intrinsic HAT activity 
causing acetylation of core histones and thereby activating gene expression of 
inflammatory proteins. Glucocorticoid-activated GRs (monomers) can not only bind 
to co-activators in the nucleus to inhibit HAT activity directly but they can also recruit 
histone deacetylase 2 (HDAC2) to the activated inflammatory gene complex leading 
to effective suppression of activated inflammatory genes
83,85
. HDAC2 recruited by 
activated gluocorticoids reverses the histone acetylation induced by NF-κB and 
switches off the genes. Figure 1.3.2 shows the suppression of activated inflammatory 
genes by glucocorticoid. 
 
Figure 1.3.2 Glucocorticoid Suppression of Activated Inflammatory Genes. 
Inflammatory stimuli activate inhibitor of nuclear factor κB (NFκB) kinase (IKKβ), 
which therefore activates NFκB. A dimer of p50 and p65 NFκB proteins translocates 
to the nucleus and binds to specific κB recognition sites on the promoter regions of 
infl ammatory genes and also to coactivators, such as cyclic AMP response element 
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binding protein (CBP). The coactivators cause acetylation of core histones, activating 
gene expression of infl ammatory proteins. Activated glucocorticoid receptors (GRs) 
bind to coactivators in the nucleus to inhibit histone acetyltransferase (HAT) activity 
directly. GRs also recruit histone deacetylase 2 (HDAC2), leading to suppression of 
the activated infl ammatory genes. Picture wih description taken from Barnes, P.J. & 




    Corticosteroid also regulates the inflammatory response through its interaction 
with another pro-inflammatory transcription factor AP-1. AP-1 is predominantly 
composed of a heterodimer of the Fos and Jun family of proteins that are bound 
together through leucine zipper interactions
61
. AP-1 binds to DNA to switch on or off 
transcription of several specific genes. The homodimer GRs interacts with AP-1 in the 
cytoplasm or nucleus, preventing the DNA binding of AP-1 to the promoter region of 
target genes. GRs have also been reported to inhibit the transcription of c-jun, a 





1.3.5 Corticosteroid Resistance 
    There are several mechanisms for corticosteroid resistance. MAP kinases may 
play an important role in corticosteroid resistance. Glucocorticoid receptors might be 
phosphorylated by MAP kinases that reduce corticosteroid binding affinity, stability, 
nuclear translocation and DNA binding activity
89,90
. Excessive activation of AP-1 has 
been identified as a mechanism of glucocorticoid resistance. Excessive AP-1 binds to 
GRs and thus prevents GRs from binding to GREs or other transcription factors. This 
mechanism may be activated by JNK since higher expression of c-Fos and activity of 
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JNK has been identified in patients with glucocorticoid-resistant asthma, with no 
reduction in JNK activity or c-Jun after a high dose of oral glucocorticoids
91
.  
    MKP-1 is one of the most prominent genes activated by corticosteroids and 
inhibits all MAP kinase pathways
92
. Among them, p38 MAP kinase regulates multiple 
inflammatory genes including TNF-α, IL-6, IL-8 and granulocyte-macrophage colony 
stimulating factor (GM-CSF) by stabilizing their mRNA through MAP 
kinase-activated protein kinase 2 (MAPKAPK2) activation
93,94
. A significant 
reduction in MKP-1 expression in alveolar macrophages, after glucocorticoid 
exposure, is reported in patients with glucocorticoid-resistant asthma and this is 
correlated with increased p38 MAPK activity
95
.  
    Reduction of HDAC2 activity and expression also contribute to corticosteroid 
insensitivity. Recruitment of HDAC2 to activated inflammatory genes, resulting in the 
reverse of histone acetylation induced by NF-κB, is a major mechanism of 
glucocorticoids suppression of activated inflammatory genes. Low HDAC2 
expression has been found in airway alveolar macrophages from patients with COPD 




1.4 Kinase Inhibitors 
    Signal transduction pathways are involved in the inflammatory process in the 
airways of patients with asthma and COPD. Kinases are believed to play a crucial role 
in the activation of inflammatory mediators through signal transduction pathways in 
the airways. Although there are some dual kinases, protein kinases are mainly 
classified as either protein tyrosine kinases (Tyr) or serine/threonine (Ser/Thr) kinases. 
Important kinases such as IKKβ and MAP kinases regulate inflammation through 
activation of pro-inflammatory nuclear transcription factors such as NF-κB and AP-1. 
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Inhibition of NF-κB and MAP kinases appear to be the most obvious targets and their 
effect on inflammation of airway diseases is detailed below. 
 
1.4.1 NF-κB 
    NF-κB is a major family of transcription factors activated during the 
inflammatory response in asthma and COPD. By combining with IκBα, NF-κB 
remains in an inactive state in the cell cytoplasm. Activated IκB kinase α/β (IKKα/β) 
phosphorylates IκBα resulting in ubiquitination and proteolysis of IκBα98. This results 
in the release of NF-κB which then goes on to promote gene transcription in the 
nucleus. IKKβ is the important kinase for the control of NF-κB activation by 
inflammatory stimuli. A small molecule IKKβ inhibitor has been shown to suppress 
the release of inflammatory cytokines and chemokines from alveolar macrophage, 
suggesting this inhibitor might be effective in patients with COPD
99
. A selective 
ATP-competitive IKKβ inhibitor has been reported to inhibit cockroach 
allergen-induced airway inflammation and hyperreactivity in a rat model
100
. One 
concern however is that by inhibiting NF-κB one might cause immune suppression 




1.4.2 MAP Kinase Inhibitors 
    MAP kinases are a family of serine/threonine kinases that transduce extracellular 
signals to the nucleus. Activation of MAP kinases requires dual phosphorylation of 
tyrosine and threonine by upstream kinases (MAP2K). Activated MAP kinases 
phosphorylate intracellular proteins and mainly regulate the activation of the AP-1 
family of transcription factors. The effects on airway inflammation of the three major 




1.4.2.1 ERK1/2 Inhibitors 
    ERK1/2 is important for eosinophil and mast cell differentiation and activation 
and is involved in cytokine production from a variety of cell types. The T cell receptor 
(TCR) induced signal in naive CD4
+
 T cells has been shown to produce IL-4 via 
activation of ERK1/2
102
. Asthmatic patients have demonstrated increased 
immuno-staining of phospho (p)-ERK1/2 especially in airway epithelium and smooth 
muscle cells. Furthermore, the intensity of p-ERK1/2 is significantly correlated with 
the clinical severity of asthma, the number of tissue eosinophils and neutrophils in the 
airways
103
. In the IL-13/TNF-α-induced BEAS-2B epithelial cell line, genes encoding 
chemokines, including eotaxin-3, RANTES, MCP-1, MMP-9 are significantly 
inhibited by inhibitors of MEK1/2
103
. Moreover, inhibition of MEK1/2 has also been 
reported to reduce ovalbumin-induced Th2 cytokines production, lung tissue 
eosinophilia, serum IgE and airway hyperresponsiveness in an asthma mouse 
model
104
. In a mouse model of LPS-induced lung injury, inhibition of MEK1/2 has 
also been shown to efficiently attenuate the LPS-induced pulmonary inflammatory 
response, including reduced lung neutrophilia and diminished levels of TNF-α in BAL 
fluid
105
. These findings suggest investigation of ERK1/2 inhibitors would be 
worthwhile as such inhibitors may provide a new strategy for treating airway diseases, 
including asthma and COPD.  
 
1.4.2.2 Jun-N-terminal Kinase Inhibitors 
    JNKs consist of three isoforms of which JNK1 and 2 are widely distributed 
whilst the third isoform, JNK3, is mainly located in neuronal tissue. Increased JNK 
activity and AP-1 expression has been detected in patients with severe asthma
106
. In 
an ovalbumin-sensitized mouse model, allergen challenge induced eosinophilic 
inflammation and airway hyperresponsiveness have been shown to be suppressed by 
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the JNK inhibitor SP600125
107
. SP600125 has also been reported to reduce airway 
smooth muscle cell proliferation and allergic cellular inflammation following chronic 
allergen exposure
108
. These findings suggest JNK inhibitors similar to ERK1/2 and 
MEK1/2 may be of therapeutic use in the treatment of asthma and COPD. 
 
1.4.2.3 p38 MAPK Inhibitors 
    p38 MAPK kinase is a serine/threonine kinase involved in the expression of 
inflammatory cytokines, including IL-8, TNF-α, and MMPs. p38 MAPK kinase 
inhibitors appear to preferentially inhibit the synthesis of Th2 but not Th1 
cytokines
109
. In an ovalbumin challenged rat model of asthma, p38 MAPK inhibitors 
have been shown to decrease BAL TNF-α production110. They also reduce 
neutrophilia and mediator expression such as IL-6 and MMP-9 in rat models of 
COPD
111
. Despite this broad spectrum anti-inflammatory effect of p38 MAPK 




1.5 MAP3K8 Kinase 
    MAP3K8, also known as cancer osaka thyroid (Cot) or tumour progression 
locus-2 (Tpl-2), is a member of the serine/threonine protein kinase family. In a 
previous pilot study of global gene expression in the Molecular Genetics and 
Genomics Group, MAP3K8 was found to be highly associated with inflammatory 
gene expression in the acute response of A549 and BEAS-2B cells to inflammatory 
stimuli. MAP3K8 has been shown to be involved in the mitogen activated protein 
kinase (MAPK) pathway, which plays a crucial role in many aspects of the immune 
mediated inflammatory response
56
. Although the inhibition of MAP3K8 kinase may 
have the potential to be effective as a therapy for rheumatoid arthritis due to its role in 
the disease, it is believed that MAP3K8 may also play a role in the airway 
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inflammation and therefore also be a relevant therapeutic target
113
. More details about 
the molecular mechanisms of MAP3K8 and its effect on inflammation are detailed 
below. 
 
1.5.1 Identification of MAP3K8 
    MAP3K8 is a serine/threonine kinase and full-length MAP3K8 contains three 
domains: the N-terminal domain, the kinase domain and the C-terminal region. The 
function of the N-terminal domain is still unknown. The C-terminus carries a reported 
‘degron’ sequence (amino acids 435-457) that targets MAP3K8 for proteasomal 
degradation. The kinase domain of MAP3K8 shows sequence homology to the kinase 
domains of other MAP3K. MAP3K8 is identified by its oncogenic transforming 
activity in cells by an over-expressed C-terminal truncated form of MAP3K8. For 
example, over-expression of MAP3K8 has been detected in human large granular 
lymphocyte proliferation disorders and in some breast cancer tissues
114,115
. Human 
MAP3K8 genes produce two isoforms, 58 kDa and 52 kDa respectively, generated by 
alternative initiation sites at methionine 1 and methionine 30. The 58 kDa isoform has 
a shorter half-life than the 52 kDa protein and shows stronger transforming activity
116
.   
 
1.5.2 MAP3K8 Knockout Mice 
    The physiological role of MAP3K8 in mammalian cells has been determined 
through the generation of MAP3K8 knockout mice
117
. Knockout animals show 
normal histological phenotype in bone marrow, thymus, spleen and lymph nodes. An 
essential role for MAP3K8 in the regulation of macrophage responses to LPS was 
however identified in the knockout studies. TNF-α induction by LPS was found to be 
deficient in MAP3K8 knockout mice macrophages through a 
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MAP3K8/ERK-dependent pathway. There was no involvement of the JNKs and p38 
pathways.  
 
1.5.3 MAP3K8 Regulation 
    Using a two-hybrid yeast system it has been shown that MAP3K8 binding to 
nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB1/p105), a 
precursor of p50, maintains the kinase in its inactive form
118
. NF-κB1/p105 binds to 
the kinase domain of MAP3K8 preventing access of MAP3K8 to its substrate MEK 
but by also binding to the C-terminal region and masking ‘degron’ NF-κB1/p105 
death domain stabilizes MAP3K8. In macrophages stimulated with TNF or LPS, 
induced NF-κB1/p105 degradation is regulated by the IKK complex through 
phosphorylation of NF-κB1/p105 at Serines 927 and 932119,120. Although MAP3K8 
kinase activity has been shown to regulate TNF-induced NF-κB1/p105 degradation, 
the physiological role of MAP3K8 specifically in the proteolysis of NF-κB1/p105 is 
undetermined. Thr290 and Ser400 are key phosphorylation sites for the regulation of 
MAP3K8 activity. Thr290 is located in the kinase domain, while Ser400 is located in 
the C-terminus of MAP3K8
121
. It is believed that the phosphorylation of MAP3K8 at 
Thr290 is IKK-dependent
122
. MAP3K8 activation has however also been reported to 
be initiated by Thr290 phosphorylation catalysed by an IL-1-stimulated protein kinase 
distinct from IKKβ123. An additional protein, A20-binding inhibitor of NF-κB2 
(ABIN-2) was also found to be part of the MAP3K8/NF-κB1 complex. This protein 







Figure 1.5.1 Schematic Representation of the MAP3K8 Primary Structure. 
MAP3K8 is expressed as 2 isoforms generated by the utilization of alternative 
translation start sites, methionine 1 and methionine 30. The C-terminus carries a 
reported ‘degron’ sequence (aa 435–457) that targets MAP3K8 for proteasomal 
degradation. NF-κB1 binds to and masks ‘degron’ thus stabilizing MAP3K8. NF-κB1 
also binds to the kinase domain of MAP3K8 preventing access to MEK, the ERK 
kinase. Met, methionine; Ser, serine; Thr, threonine. Picture adapted from 





1.5.4 MAP3K8 Signalling Pathway 
    MAP3K8 is known to activate MEK/ERK pathway in macrophages in response 
to inflammatory cytokines stimulation
117
. In MAP3K8 knockout mice, embryonic 
fibroblasts (MEFs) exhibit defects not only in ERK but also JNK and NF-κB 
activation upon TNF stimulation
125
. MAP3K8 signals however activate these 
pathways in a cell-type and stimulus-specific manner. In addition the signalling 
pathways connecting the interleukin-1 receptor/Toll-like receptor superfamily (TLR) 
with the activation of the MAP3K8, NF-κB1/p105, ABIN-2 and IKKs complex are 
not well understood. An overview of what is known about the MAP3K8 signalling 




Figure 1.5.2 Overview of the Cot/Tpl-2 (MAP3K8) Signalling Pathway. In 
unstimulated macrophages, Cot/Tpl-2 is bound to NFκB-1/p105 and kept in a kinase 
inactive form. Stimulation with pro-inflammatory mediators like TNF or LPS induces 
NFκB-1/p105 degradation and release/activation of MAP3K8 (Cot/Tpl-2). 
NFκB-1/p105 degradation is regulated by the IKK complex through phosphorylation 
of Serines 927 and 932, poly-ubiquitination, and proteasome degradation. Picture 




1.6 Aims of the Thesis 
    MAP3K8 is a member of the serine/threonine protein kinase family and has been 
demonstrated to be involved in MAP kinase pathways which regulate many aspects of 
immune mediated inflammatory responses
56
. Inhibition of MAP3K8 may potentially 
be a new therapeutic strategy for airway inflammation. The major aim of this thesis 
project is to explore the effect of MAP3K8 on airway inflammation. In addition, the 
signal transduction and molecular regulation of MAP3K8 kinase on airway 




Materials and Methods 
 
2.1 Materials 
Materials were purchased from the following suppliers: 
Material Supplier 
100 bp DNA Ladder New England Biolabs, UK 
Albumin, Bovine Fraction V solution 
(BSA) 
Sigma-Aldrich, Dorset, UK 
ATP (10 mM) Cell Signalling, Hitchin, UK 
BEGM BulletKit Lonza, Walkersville, MD 
Cot (M-20), Rabbit Polyclonal Antibody Santa Cruz Biotechnology Inc., UK 
COT/TPL2/MAP3K8 [PT290], Rabbit 
Polyclonal Antibody 
Invitrogen, Paisley, UK 
DEPC-treated water Ambion, Applied Biosystems, 
Warrington, UK 
Dexamethasone Sigma-Aldrich, Dorset, UK  
Dimethyl sulphoxide (DMSO) Sigma-Aldrich, Dorset, UK 
Dulbecco’s modified Eagle’s medium Sigma-Aldrich, Dorset, UK 
Dulbecco’s phosphate buffered saline Sigma-Aldrich, Dorset, UK 
ECL Detection Reagents GE Healthcare, Buckinghamshire, UK 
Foetal calf serum (FCS)  Gibco, Invitrogen, Paisley, UK 
Ethanol BDH, Poole, Dorset, UK 
Fuji medical X-ray film, Super RX, 
100NIF, 18x24 cm 
Allmedt 




GATA-3 XP Rabbit mAb Cell Signalling, Hitchin, UK 
Goat Anti-Mouse IgG/HRP Dako, Cambridgeshire, UK 
Goat Anti-Rabbit IgG/HRP Dako, Cambridgeshire, UK 
High capacity cDNA reverse transcription 
kit 
Applied Biosystems, California, USA 
HRP-Labeled Protein A GE Healthcare, Buckinghamshire, UK 
Human CCL5/RANTES DuoSet ELISA 
kit 
R&D Systems, Europe Ltd., UK 
Human IL-6 DuoSet ELISA kit R&D Systems, Europe Ltd., UK 
Human IL-8 DuoSet ELISA kit R&D Systems, Europe Ltd., UK 
Human Total MMP-1 DuoSet ELISA kit R&D Systems, Europe Ltd., UK 
iBlot Transfer Stack, Regular 
(Nitrocellulose) 
Invitrogen, Paisley, UK 
iBlot Transfer Stack, Mini 
(Nitrocellulose) 
Invitrogen, Paisley, UK 
IKKα Antibody Cell Signalling, Hitchin, UK 
IKKβ Antibody Cell Signalling, Hitchin, UK 
Kinase Buffer (10X) Cell Signalling, Hitchin, UK 
Lipofectamine RNAiMAX Invitrogen, Paisley, UK 
MEK1 protein Abcam, Cambridge, UK 
MEK1/2 Antibody Cell Signalling, Hitchin, UK 
Microscope slides Raymond A. Lamb, Eastbourne, UK 
NHBE-Bronchial Epi Cells w/ RA, 
BEGM, cryo 
Lonza, Walkersville, MD 
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Nonidet®  P 40 Substitute Fluka, Buchs, Switzerland 
Nuclear extraction kit  Active Motif Europe, Rixensart, Belgium 
Nuclease-free water Ambion, Applied Biosystems, 
Warrington, UK 
NuPAGE LDS Sample buffer Invitrogen, Paisley, UK 
NuPAGE MOPS SDS running buffer Invitrogen, Paisley, UK 
NuPAGE 10% Bis-Tris Gels Invitrogen, Paisley, UK 
NuPAGE Sample Reducing Agent Invitrogen, Paisley, UK 
MAPK Family Antibody Sampler Kit Cell Signalling, Hitchin, UK 
MKK7 Antibody Cell Signalling, Hitchin, UK 
ON-TARGET plus Non-targeting pool Dharmacon Research Inc., Lafayette, CO 
ON-TARGET plus SMART pool, 
MAP3K8 
Dharmacon Research Inc., Lafayette, CO 
Phosphate Buffered Saline with Tween 
20, pH:7.4 
Sigma-Aldrich, Dorset, UK 
Phospho-IKKα (Ser180)/IKKβ (Ser 181) 
Antibody 
Cell Signalling, Hitchin, UK 
Phospho-MAPK Family Antibody 
Sampler Kit 
Cell Signalling, Hitchin, UK 
Phospho-MEK1/2 (Ser217/221) Rabbit 
mAB 
Cell Signalling, Hitchin, UK 
Phospho-MKK7 (Ser271/Thr275) 
Antibody 
Cell Signalling, Hitchin, UK 
Phospho-SAPK/JNK (Thr183/Tyr185) 
Antibody 





Cell Signalling, Hitchin, UK 
PhosSTOP Phosphatase Inhibitor 
Cocktail 
Roche Applied Science, UK 
Polyoxyethylene-sorbitan monolaurate 
(Tween-20) 
Sigma-Aldrich, Dorset, UK 
Protease Inhibitor Cocktail, cOmplete, 
Mini 
Roche Applied Science, UK 
QIAshredder Qiagen, Crawley, UK 
ReBlot Plus Mild Antibody Stripping 
Solution 
Millipore, Watford, UK 
Recombinant Human Active COT R&D Systems, Europe Ltd., UK 
Recombinant Human IL-1β R&D Systems, Europe Ltd., UK 
SEK1/MKK4 Antibody Cell Signalling, Hitchin, UK 
RNA 6000 Nano LabChip kit Agilent Technologies, Workingham, UK 
RNase-Free DNase set Qiagen, Crawley, UK 
RNase Inhibitor Applied Biosystems, California, USA 
RNaseZAP Sigma-Aldrich, Dorset, UK 
Rneasy mini kit Qiagen, Crawley, UK 
Roswell Park Memorial Institute media 
(RPMI)-1640 
Sigma-Aldrich, Dorset, UK 
Platinum SYBR Green qPCR 
SuperMix-UDG 
Invitrogen, Paisley, UK 
SAPK/JNK Antibody Cell Signalling, Hitchin, UK 
SP600125 (SAPK/JNK Inhibitor) Sigma-Aldrich, Dorset, UK 
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Sterile needles BDH, Poole, Dorset, UK 
Strip Tubes and Caps Qiagen, Crawley, UK 
Syringes 3S Healthcare, London, UK 
Tissue culture dish 92mm x 17mm Fisher Scientific Ltd., UK 
Tpl2 Kinase Inhibitor Santa Cruz Biotechnology Inc., UK 
Tpl2 Kinase Inhibitor II Calbiochem, UK 
TransAM
TM
 AP-1 c-Fos kit Active Motif Europe, Rixensart, Belgium 
TransAM
TM
 AP-1 c-Jun kit Active Motif Europe, Rixensart, Belgium 
TransAM
TM
 NF-κB p65 kit Active Motif Europe, Rixensart, Belgium 
Trizma hydrochloride buffer solution, 
pH:7.4, 1M 
Sigma-Aldrich, Dorset, UK 
Trizma hydrochloride buffer solution, 
pH:8.0, 1M 
Sigma-Aldrich, Dorset, UK 
Tryphan blue Sigma-Aldrich, Dorset, UK 
U0126 (MEK1/2 Inhibitor) Cell Signalling, Hitchin, UK 
β-actin antibody with HRP Santa Cruz Biotechnology Inc., UK 
β-mercaptoethanol Sigma-Aldrich, Dorset, UK 
 
2.2 Methods 
2.2.1 Culture of Cells 
2.2.1.1 A549 Cell Lines 
    A549 human lung epithelial cells (American Type Culture Collection (ATCC)) 
were cultured in Dulbecco’s Modified Eagle’s Medium (DMEM) containing 10% 
vol/vol (v/v) FCS and 2mM L-Glutamine and were used at passage numbers 90-110. 
A549 cells were maintained in 150 cm
2
 (T150) flasks at 37
o
C with 5% CO2. The cells 
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were replenished with fresh media every 2–3 days when they had attained 
approximately 80–90% confluence. 
 
2.2.1.2 BEAS-2B Cell Lines 
    The transformed human bronchial epithelial cell line (BEAS-2B) was obtained 
from ATCC and was used at passage numbers 60–80. The BEAS-2B cells were grown 
in keratinocyte serum-free medium (K-SFM; GIBCO BRL, Gaithersburg, MD) 
supplemented with recombinant human epidermal growth factor (rhEGF) and bovine 
pituitary extract (BPE). Cells were maintained in 150 cm
2
 (T150) flasks with 5% CO2 
at 37°C. Medium was replaced every second day, and cells were passaged when 
>85% confluent. 
 
2.2.1.3 NHBE Cell Lines 
    Normal human bronchial epithelial (NHBE) cells were obtained from Lonza and 
cultured to a maximum of five passages to limit variable responses. The NHBE cells 
were grown in bronchial epithelial medium (BEGM; Lonza) containing a mixture of 
growth factors, cytokines and a variety of supplements (BulletKit; Lonza). Growth 
supplements for primary human bronchial epithelial cells included in the BulletKit 
were: bovine pituitary extract (BPE), hydrocortisone, human epidermal growth factor 
(hEGF), epinephrine, transferrin, insulin, retinoic acid, triidothyronine, GA-1000 
(Gentamicin, Amphotericin B). All the supplements were added at 0.5/500 ml growth 
medium except for BPE, which was added at 2/500 ml of medium as per the 
manufacturer’s recommendation (Lonza). 
 
2.2.1.4 Cell Passage 
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    When cells had grown to confluence, the medium was removed and the adherent 
cells were rinsed once with Dulbecco’s Phosphate Buffered Saline (DPBS) and 
covered with a solution of trypsin (0.5% wt/vol [w/v] in DPBS). The flask was then 
placed in the incubator with 5% CO2 at 37°C for approximately 2-3 minutes until the 
cells had lifted off the plastic surface this being ascertained by use of a light 
microscope. Then an equal volume of complete media was added to inactive the 
trypsin and the cells were harvested and spun at 1200rpm for 3 minutes. Cell viability 
was determined microscopically by Trypan blue (Sigma-Aldrich) exclusion, and the 
number of cells was counted by a haemocytometer. Cells that stained blue were 
counted as non-viable. The cell pellet was then resuspended in complete media and a 
total of 10
6
 cells were distributed into each 150 cm
2
 (T150) flask at 37
o
C with 5% 
CO2. At the same time and when required, cells were sub-seeded in appropriate 
culture vessels (6- or 24-well plates) and incubated at 37°C for 24 hrs prior to 
treatments. 
 
2.2.2 Cell Counts Using a Haemocytometer 
    Cells were resuspended with fresh medium and were mixed thoroughly to 
disperse clumps and produce a uniform suspension. A drop of cell suspension was 
loaded and drawn, by capillarity, into the chamber below the coverslip. The slide was 
then examined under a microscope and the cells in the four corner squares were 
counted. Since a haemocytometer is a microscope slide engraved with a 1 mm x 1mm 
grid, each square of the haemocytometer (with coverslip in place) represents a total 






.  This therefore allows calculation of the number of 




2.2.3 IL-1β Stimulation Experiments 
    For the adherent cell lines including A549, BEAS-2B and NHBE, the cells were 
first grown up in T150 flasks and after incubation with trypsin to release them from 
the flask surface, they were then seeded into appropriate tissue culture plates (6- or 
24-well plates). A total number of 4x10
5
 cells for 6-well plates and 5x10
4
 cells for 
24-well plates were seeded into each well in 2 ml and 1 ml of complete medium 
respectively. Culture plates were incubated overnight thereby allowing cells to attach 
and grow. Before the addition of the IL-1 stimulus, the cells were starved with 
serum-free media for 16 hrs to obtain cell cycle synchronization. For starvation, A549 
cells were starved with DMEM supplemented with 2mM L-Glutamine only and 
BEAS-2B cells were starved with keratinocyte serum-free medium (K-SFM). For 
NHBE cells, cells were cultured with BEGM deprived of epidermal growth factor.  
    Recombinant Human IL-1β (R&D Systems) is reconstituted with sterile 
phosphate-buffered saline containing 0.1% bovie serum albumin. Post IL-1 
stimulation at time point 0, plates were incubated at 37
 o
C with 5% CO2 for the 
appropriate length of time and then cell-free supernatants were harvested by 
centrifugation at 4,000 rpm (Mikro 22R centrifuge, Hettich, Tuttlingen, Germany) for 
5 min at 4°C for further determination of cytokines. A set of baseline experiments 
with no stimulus was completed alongside each stimulation experiment. Results were 
replicated in at least three independent experiments. 
 
2.2.4 MTT Cell Viability Assay 
    For the cell viability assay, cells were treated with 1 mg/ml 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) 
(Sigma-Aldrich) in Hanks’ balanced salt solution (HBSS) for 30 min at 37 oC. For 
adherent cells, the MTT solution was removed from the surface of the cells, and 
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dimethyl sulfoxide (DMSO) was added. The absorbance of the resultant solution was 
then measured at 550 nm, and treated cells were compared with control cells. 
2.2.5 Enzyme-Linked Immunosorbent Assay (ELISA) 
    Cell-free supernatants post-stimulation were harvested and stored at -80
o
C for 
further cytokine measurements using ELISA. All cytokines were measured using 
ELISA kits according to the manufacturer’s instructions (DuoSet; R&D Systems 
Europe; Abingdon, Oxon, UK). 
 
2.2.5.1 Measurement of IL-8 in Cell Supernatants 
    Interleukin-8 ELISA kits were purchased from R&D Systems
TM
 as DuoSets. 
Ninety six well NUNC Maxisorp
TM
 plates were coated with 4 μg/ml (100 µl/well) 
mouse anti-human IL-8 antibody (capture antibody) diluted in PBS. The plates were 
incubated at room temperature overnight. The capture antibody was removed and 
plates were then washed with 300 µl/well of wash buffer (PBS containing 0.05% (v/v) 
Tween 20) three times and blocked by incubation with 300 µl/well of block buffer 
(PBS containing 1% (w/v) BSA and 0.05% (w/v) sodium azide). Plates were 
incubated at room temperature for 1.5 h, followed by three washes with wash buffer. 
Standards of human recombinant IL-8, ranging from 31.25 pg/ml to 2000 pg/ml, were 
prepared and added to appropriate wells. At the same time, cell supernatants were 
diluted with reagent diluent (Tris-buffered Saline containing 0.1% (w/v) BSA, 0.05% 
(v/v) Tween 20) as necessary for the cytokines assays and added to the wells.  
The plates were covered and incubated for 2 hrs at room temperature. After 
incubation, the plates were washed three times with 300 µl/well of wash buffer. The 
biotinylated goat anti-human IL-8 antibody (detection antibody) was then added at a 
concentration of 20 ng/ml (diluted in reagent diluents 100 µl/well) and incubated for 2 
hrs at room temperature. After incubation, the plates were washed and 100 µl 
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streptavidin-horseradish peroxidase (HRP) were added to each well, diluted from 
stock at a 1:200 dilution with reagent diluents. The plates were covered and incubated 
in the dark for 20 min. The washing step was then repeated and 100 µl substrate 
solution was added to each well (equal volumes of Color Reagent A (H2O2) and Color 
Reagent B (Tetramethylbenzidine) mixed directly before addition to plates). The 
reaction was stopped by addition of 50 µl/well 2N H2SO4 after which plates were read 
using a SpectraMax
TM
 (Molecular Devices) spectrophotometer. 
To generate a standard curve for the determination of IL-8, all samples were 
duplicated and the duplicate readings for each standard, control and sample averaged 
and subtracted from the average blank readings. The O.D. of each well was read at 
450 nm. A subtraction reading at 570 nm from the readings at 450 nm was performed 
for the correction of optical imperfections in the plate. A standard curve was 
incorporated into a sandwich ELISA assay by making serial dilutions of a standard 
cytokine protein solution of known concentration. The data was linearized by plotting 
the log of the known concentration versus the log of the O.D. and the best fit line was 
determined by regression analysis. Figure 2.2.1 shows the standard curves of IL-8 
with an R
2
 of 0.9896 respectively showing that the regression line fits the data well. 




Figure 2.2.1 IL-8 ELISA Standard Curve. 
 
2.2.5.2 Measurement of IL-6 in Cell Supernatants 
    Interleukin-6 ELISA kits were purchased from R&D Systems
TM
 as DuoSets. All 
ELISAs were performed as directed by the manufacturer. Briefly, 96 well NUNC 
Maxisorp
TM
 plates were coated with 2 μg/ml (100 µl/well) mouse anti-human IL-6 
antibody (capture antibody) diluted in PBS. The plates were sealed and incubated at 
room temperature overnight. Excess capture antibody was removed and plates were 
then washed three times with wash buffer and were blocked by incubation with block 
buffer (see Section 2.2.5.1). Plates were incubated at room temperature for 1.5 h 
followed by three washes with wash buffer. Standards of human recombinant IL-6, 
ranging from 9.375 pg/ml to 600 pg/ml, were added to appropriate wells. At the same 
time, cell supernatants were diluted with reagent diluent (PBS containing 1% (w/v) 
BSA) as necessary for the cytokines assays. The standards and samples were 
incubated for 2 hrs at room temperature. The washing step was repeated and detection 
antibody was added to each well at a concentration of 200 ng/ml. The plates were 
incubated for 2 hrs at room temperature. After washing with wash buffer, 
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streptavidin-HRP (100 µl) was added to each well at 1:200 dilution from stock. The 
plates were incubated in the dark for 20 min at room temperature. The washing step 
was repeated and 100 µl substrate solution was added to each well. The reaction was 
stopped by the addition of 2N H2SO4 after which plates were read on a 
spectrophotometer with calculations and standard curve generation as for the IL-8 
ELISA (Section 2.2.5.1). An example of an IL-6 standard curve is shown in Figure 
2.2.2. Unknown sample concentrations were determined from extrapolation of the 
curve. 
 
Figure 2.2.2 IL-6 ELISA Standard Curve. 
 
2.2.5.3 Measurement of RANTES in Cell Supernatants 
    RANTES (regulated upon activation normal T cell expressed and secreted) 
ELISA kits were purchased from R&D Systems
TM
 as DuoSets. All ELISAs were 
performed as directed by the manufacturer. The protocol was essentially as for the 
IL-6 ELISA but with mouse anti-human RANTES antibody (capture antibody). The 
concentrations of RANTES used as standards ranged between 1000 pg/ml and 15.625 
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pg/ml. The concentration of capture and detection antibody was 1 μg/ml and 20 ng/ml 
respectively. The concentrations of reagents and assay conditions then followed those 
described for IL-6 measurement in Section 2.2.5.2. An example of a RANTES 
standard curve is shown in Figure 2.2.3. 
 
Figure 2.2.3 RANTES ELISA Standard Curve.  
 
2.2.6 Quantitative Real-time Polymerase Chain Reaction (PCR) 
2.2.6.1 RNA Isolation 
    Total RNA was isolated from harvested cells using the Qiagen RNeasy
®
 mini kit 
(Qiagen, Crawley, UK) following the manufacturer’s instructions. Cells were lysed in 
RLT buffer containing 1% (v/v) β-mercaptoethanol. The resulting lysate was then 
homogenized using a QIAshredder
TM
 column. Following centrifugation for 1 min at 
10,000 x g (Eppendorf centrifuges Models 5424, Hamburg, Germany) the effluent 
from the QIAshredder
TM
 column was mixed with an equal volume of 70% (v/v) 
ethanol and transferred to a spin column. The spin column was then centrifuged at 
10,000 x g for 1 min and washed by addition of RPE buffer followed by 
centrifugation (10,000 x g 1 min). Contaminating DNA was removed by incubation 
with RNase-free DNase for 15 min at room temperature. Samples were washed with 
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RW then RPE buffer by centrifugation at 10,000 x g for 1 min. The bound RNA was 
eluted from the column by addition of 30 µl RNase-free water and incubation for 3 
min at room temperature. The RNA was collected from the column following 
centrifugation at 10,000 x g for 2 min.  
 
2.2.6.2 RNA Quantification and Purity Analysis 
    RNA concentration was measured using the NanoDrop-1000 spectrophotometer 
(NanoDrop Technologies, Wilmington, DE, USA). One µl of RNA sample was 
analysed, following a zero reading of RNase-free water. This recorded the RNA 
concentration in ng/µl and the 260/280 ratio. The latter indicates the proportion of 
RNA to DNA with a ratio between 1.9–2.1 (A260:A280) indicating a pure RNA 
sample. The extracted RNA was stored at –80°C until further use. 
Figure 2.2.4 shows the absorbance spectrum (A) and the purity assessment (B) of 
one of the RNA samples extracted in this project. The calculations of the A260/A280 
or A260/A230 ratios are used for purity assessment. If the ratio of A260/A280 is 
appreciably lower, it may indicate the presence of protein, phenol or other 
contaminants that absorb strongly at or near 280 nm. If the ratio of A260/A230 is 
appreciably lower, this may indicate the presence of co-purified contaminants. In this 
sample, the ratio of A260/A280 and A260/A230 was 2.08 and 1.90 respectively and 
this indicates that the sample is of high-purity as the values are within the expected 




Figure 2.2.4 Absorbance Spectrum and Purity Assessment of RNA Sample.  
The absorbance spectrum (A) and the purity assessment (B) of RNA sample. The ratio 
of A260/A280 and A260/A230 is 2.08 and 1.90 respectively, indicating that this 
sample is of high-purity. 
 
2.2.6.3 Reverse Transcription 
    Reverse transcription was performed on 0.5µg of RNA and cDNA was 
synthesized using the High-Capacity cDNA Reverse Transcription Kits (Applied 
Biosystems, Warrington, UK) following manufacturer’s instructions. Briefly, a master 
mix was prepared by combining the following per reaction: RT buffer (2 µl), dNTP 
mix (0.8 µl), random primers (2 µl), MultiScribe™ reverse transcriptase (1 µl), RNase 
inhibitor (1 µl) and nuclease-free water (10 µl). Ten µl of this master mix was 
combined with 0.5 µg RNA (re-suspended in 10 µl of nuclease-free water) in 0.2 ml 
eppendorf tubes. The tubes were then loaded onto a thermal cycler (Touchgene 
Gradient, TECHNE) and heated for 10 min at 25
o
C, 120 min at 37
o
C followed by a 
denaturation at 85
 o
C for 5 min. The synthesized cDNA was stored at –20°C prior to 
use in real-time PCR experiments. 
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2.2.6.4 Polymerase Chain Reaction – Real-time PCR 
    Real-time PCR was performed using the Rotor-Gene 3000™ Real-Time PCR 
detection system (Corbett Research, Sydney, Australia). Reactions containing 7.5 µl 
of Platinum SYBR Green qPCR SuperMix-UDG (SYBR Green I, 60 U/ml Platinum 
Taq DNA polymerase, 40 mM Tris-HCl [pH 8.4], 100 mM KCl, 6mM MgCl2, 400 
µM dGTP, 400 µM dATP, 400 µM dCTP, 400 µM dUTP, 40 U/ml uracil DNA 
glycosylase [UDG], and stabilizers), 0.3 µl of 10 µM forward and reverse primers 
(200nM each, final concentration) and 3 µl cDNA template to a total final volume of 
15 µl were set up.  
PCR cycling conditions consisted of an initial activation step of 95°C for 2 min, 
followed by 40 cycles of denaturation at 95°C for 15 sec, annealing at 60°C for 30 sec 
and extension at 72°C for 30 sec. The real-time PCR system generated an 
amplification curve for each cDNA sample. A threshold cycle (Ct) was determined 
from the curve. The threshold was always set in the linear phase of the amplification 
curve, when no component was limiting. The lower the CT value, the higher the 
expression of the gene. This is an exponential relationship with a decrease of one CT 
representing a 2-fold increase in expression. Calculation of the threshold value, 
standard curve preparation and quantification of mRNA in the samples were 
performed by the Rotor-Gene 6.0 software provided by Corbett Research.  
Quantitative PCR assays routinely use housekeeping genes such as 
glyceraldehyde 3-phosphate dehydrogenase (GAPDH) as internal controls. These 
controls attempt to ensure that the same amount of starting sample is added to each 
PCR reaction. The RT-PCR products were subjected to agarose gel electrophoresis to 
identify the target band. 
Figure 2.2.5 A shows the amplification curve with slope correction obtained for 
the real-time PCR assay of GAPDH mRNA in A549 cells. A ten-fold dilution series of 
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relatively high expression of RNA sample was used to produce a standard curve. The 
quantification curve of GAPDH RNA amplification is shown in Figure 2.2.5 B. 
Relative standard curves were generated by plotting the cycle threshold (Ct) value 
versus the log of the amount of total cDNA added to the reaction. As given by the 
Rotor-Gene 6.0 software: slope =−3.957; R2 = 0.9989. DNA amplicons were analyzed 
for their specificity by melting curve analysis (Figure 2.2.5 C) and agarose gel 
electrophoresis of PCR products obtained (Figure 2.2.5 D). Agarose gel 
electrophoresis revealed a single target band of the real-time PCR product of GAPDH 
(175 bp) present in every amplification reaction. 
 
Figure 2.2.5 Representative Real-time-PCR Assay of GAPDH mRNA. 
The amplification curve with slope correction (A) and the quantification curve of 
GAPDH mRNA amplification (B) obtained for the real-time PCR assay of GAPDH 
mRNA. DNA amplicons are analyzed for their specificity by melting curve analysis 
(C) and agarose gel electrophoresis (D) of PCR products obtained. 
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    Primer pairs were designed with the Primer 3 RT-PCR program and checked for 
sequence homology against known genes using the BLAST search program
126
. Table 
2.2.1 shows the details of primers used in this project.  
 
Table 2.2.1 Primer Sequences for Target and Housekeeping Genes. 
Gene Primer Sequence PCR Product 
Size 
CCL-20 Forward: 5'-CTGCGGCGAATCAGAAGC-3' 
Reverse: 5'-GCAAGTGAAACCTCCAACCC-3' 
290 bp 
GAPDH Forward: 5'-TTCCAGGAGCGAGATCCCT-3' 
Reverse: 5'-CACCCATGACGAACATGGG-3' 
175 bp 
IL-6 Forward: 5'-CAGCCCTGAGAAAGGAGACA-3' 
Reverse: 5'-CAGGCAAGTCTCCTCATTGAA-3' 
143 bp 
IL-8 Forward: 5'-GCCAACACAGAAATTATTGTAAAGCTT-3' 
Reverse: 5'-CCTCTGCACCCAGTTTTCCTT-3' 
78 bp 
MAP3K8 Forward: 5'-TGGTGGATTTTGGCCTAAGTGTT-3' 
Reverse: 5'-CCTCTGGGCTCATGTAAATCTCTGT-3' 
90 bp 
MMP-1 Forward: 5'-CAGAGATGAAGTCCGGTTTTTC-3' 
Reverse: 5'-GGGGTATCCGTGTAGCACAT-3' 
76 bp 
MMP-12 Forward: 5'-ACACATTTCGCCTCTCTGCT-3' 
Reverse: 5'-CCTTCAGCCAGAAGAACCTG-3' 
192 bp 
MMP-3 Forward: 5'-AGCAAGGACCTCGTTTTCATT-3' 
Reverse: 5'-GTCAATCCCTGGAAAGTCTTCA-3' 
261 bp 




2.2.7 Agarose Gel Electrophoresis 
    Gels were prepared using agarose (Sigma-Aldrich) at a concentration of 2% in 
1X Tris-Borate-EDTA buffer (Sigma-Aldrich) and were solubilized with microwave 
 59 
 
heating. Ethidium bromide (10 mg/ml, Sigma-Aldrich) was then added directly to the 
gel solution at a concentration of 0.5 µg/ml. Warm gel solution was poured into the 
gel-casting platform around the comb and allowed to solidify at room temperature for 
30 min. A 100-bp DNA ladder (New England Biolabs, UK) was used as the molecular 
size marker and samples were electrophoresed in 1X Tris-Borate-EDTA buffer at 120 
V for 40 min. Gels were then exposed to an ultraviolet transilluminator (Ultra Violet 
Products Inc., BioDoc-It imaging system) to visualize appropriate bands of real-time 
PCR products and photographs were taken. 
 
2.2.8 Western Blotting 
    Analysis of specific proteins was performed using Western blotting. Protein was 
extracted from cells and separated according to size by gel electrophoresis (see 
Sections 2.2.8.1 and 2.2.8.3 below). The proteins were then transferred onto a 
nitrocellulose membrane by applying an electrical current to the gel. The membrane 
was then probed for the protein of interest using a primary antibody (see Sections 
2.2.8.4 and 2.2.8.5 below). The presence of the antibody was then detected by binding 
of a labelled secondary antibody. The relative amounts of the protein are visualized by 
chemiluminescence and exposure to a photographic film. Visualised bands can then be 
quantified using densitometry. 
 
2.2.8.1 Protein Extraction 
    The whole-cell proteins were extracted using the Active Motif Nuclear Extract 
Kit (Active Motif Europe, Rixensart, Belgium) according to the manufacturer's 
protocol. Briefly, the cells were washed with ice-cold PBS/phosphatase inhibitors and 
were removed from 6-well plates by gently scraping with cell lifter. The cells were 
transferred to fresh pre-chilled 1.5 ml eppendorf tubes and centrifuged at 4,000 rpm 
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(Mikro 22R centrifuge, Hettich, Tuttlingen, Germany) for 5 min at 4°C to remove the 
supernatants. Cells were then lysed by the addition of 40 µl radio 
immunoprecipitation assay (RIPA) lysis buffer (50 mM Tris-HCL, pH 7.4, 150 mM 
NaCl, 1% (v/v) Nonidet P-40, 0.25% (w/v) deoxycholic acid, and 1 mM EDTA) from 
Upstate Biotechnology, Inc. that also contained protease inhibitor cocktail tablets 
(Complete Mini, Roche; one tablet per 10 ml) and phosphatase inhibitors cocktail 
tablets (PhosSTOP, Roche; one tablet per 10 ml). Lysis was performed at 4 °C with 
gentle rocking for 30 min after which samples were centrifuged at 14,000 x g for 20 
min at 4 °C. The resulting supernatants were transferred to clean chilled 1.5 ml 
eppendorf tubes for measurement of protein levels using the BCA (bicinchoninic acid) 
protein assay. Purified proteins were stored at -80
o
C in aliquots until required. For 
each use, an aliquot was thawed, used and any remnants discarded after completion of 
the experiment. 
 
2.2.8.2 BCA Protein Assay 
    The BCA Protein Assay Kit (Pierce, Thermo Scientific, Cramlington, UK) was 
used according to the manufacturer’s instructions. Briefly, a set of dilutions using 2.0 
mg/ml BSA (Pierce) and a series of sample dilutions (5 μl) were incubated with the 
BCA reagents (200 μl) in a microplate well. The BCA protein assay working reagent 
consists of reagent A (which contains sodium carbonate, sodium bicarbonate, 
bicinchoninic acid and sodium tartrate in 0.1 M sodium hydroxide) and reagent B 
(which contains 4% cupric sulphate) mixed 50 parts: 1 part respectively. Samples 
were shaken thoroughly (1 min) on a plate shaker at room temperature and then 
incubated at 37°C for 30 min. The absorbance was measured at 562 nm in a 
SpectraMax
TM
 (Molecular Devices) spectrophotometer. A standard curve was 
generated by plotting the known albumin protein concentrations against the measured 
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light absorbance, and the protein content of the sample was identified by comparison 
against the standard curve (Figure 2.2.6). BSA-dilution curves were made 
accordingly and aliquots were stored to ensure an identical BSA-content for each 
experiment. 
 
Figure 2.2.6 Protein Standards Measurements for Use in Protein Quantification. 
 
2.2.8.3 Protein Gel Electrophoresis 
    For Western blots, an equal amount of 25 μg of protein for each sample was 
mixed with NuPAGE lithium dodecyl sulfate (LDS) sample buffer (Invitrogen Crop.) 
to a final volume of 24 µl. Samples were then heated for 10 min at 70 °C, in order to 
denature the proteins. Samples were then separated by sodium dodecyl sulfate 
polyacrylamide gel electrophoresis (SDS-PAGE). Ten % NuPAGE Novex Bis-Tris 
gels, 10 mm thick and 10 well capacity, were used for separation of proteins 
according to size. The gels were secured in a gel tank along with NuPAGE 
3-(N-morpholino) propanesulfonic acid (MOPS) sodium dodecyl sulfate running 
buffer (250 mM MOPS, 250 mM Tris, 5 mM EDTA, 1% (w/v) SDS). Four μl of a 
full-range rainbow molecular weight marker (GE Healthcare BioSciences Ltd) was 
added to one well of the gel. Twenty four μl of each sample was then added to the 
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individual wells using 14 mm microcapillary gel loading pipette tips (VWR 
International, UK). The gel tank was then fully assembled and connected to a power 
source and proteins resolved at 175 V for 40 min.  
 
2.2.8.4 Transfer of Proteins to Nitrocellulose 
    Briefly, the iBlot system was used (Invitrogen Crop.) to blot SDS–PAGE 
separated protein extracts onto a nitrocellulose membrane. Protein transfers to 
nitrocellulose membranes were performed using the iBlot™ DryBlotting device 




    To avoid non-specific binding by antibodies, the nitrocellulose membranes were 
blocked by incubation in 10 ml 5% (w/v) skimmed milk powder dissolved in 
Tris-buffered saline (TBS)-Tween-20 (0.01 M Tris-HCl, 0.15 M NaCl and 0.05% 
Tween-20, pH 8.0) for 1 hr at room temperature. The milk blocking solution was then 
replaced with BSA/TBS-Tween-20 containing an antibody raised against the protein 
of interest and incubated overnight at 4 °C. After the overnight incubation, the 
membrane was washed 5 min for 3 times in TBS-Tween-20 to remove unbound 
antibody and then transferred to a solution of BSA/TBS-Tween-20 containing an 
appropriate HRP-conjugated secondary antibody and incubated for 1 hr at room 
temperature.  
    After incubation, membranes were washed three times in TBS-Tween-20 to 
remove unbound antibody after which they were incubated with 2 ml of enhanced 
chemi-luminescence (GE Healthcare ECL/ECL Plus [Amersham]) detection solution 
(according to manufacturer’s instructions) for 2 min at room temperature. The blot 
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was wrapped in clingfilm and exposed to a sheet of X-ray film (Super RX, Fuji) for 
1-5 min. Films were developed using an AFP Imaging (New York, USA) developer. 
For quantitative analysis, the bands were scanned in a UVP GelDoc-It imaging system 
and the densities of the bands were quantitated by using Labworks 4.6 software 
(Bio-Rad Lab. Hercules, CA).  
    In order to detect alternative proteins on the same membranes, membranes were 
stripped of antibodies by incubation with 10 ml 1 x mild stripping buffer (ReBlot Plus 
Mild Antibody Stripping Solution; Millipore) for 30 min. The membranes were then 
washed with TBS-Tween-20. Repeat blocking and incubation with specific antibodies 
could then be performed (as described above). Membranes were reused a maximum of 
3 times.  
 
2.2.9 RNA Interference 
    RNA interference (RNAi) was carried out using ON-TARGETplus SMARTpool 
against target gene (Dharmacon Research Inc., Lafayette, CO). ON-TARGETplus 
Non-targeting Pool negative control (Dharmacon Research Inc., Lafayette, CO) were 
used as controls in the experiments. RNAi transfection of A549 cells was carried out 
with using Lipofectamine RNAiMAX (Invitrogen Corp.). Briefly cells were seeded 
into 24-well plates (Corning Costar Corp.) at 4x10
4
 cells/well to reach 40–60% 
confluence on the day of transfection. RNAi-Lipofectamine RNAiMAX
 
complexes 
were formed in a 1.5 ml eppendorf tube by adding 2 µl/ml of Lipofectamine 
RNAiMAX and 50nM of RNAi in serum free medium (Sigma-Aldrich)
 
followed by 
incubation for 15 min at room temperature. RNAi-Lipofectamine RNAiMAX
 
complexes were then added to each well of plate simultaneously and the cells were 
placed in a
 
CO2 incubator at 37°C for 24 hrs. After transfection for 24 hrs, RNAi 
transfection of A549 cells was performed again with incubation at 37°C for another 
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24 hrs. After double transfection, cells were starved in serum free medium for 16 hrs 
and then stimulated with 1 ng/ml of IL-1. Cells were collected and proteins extracted 
for Western blot analysis (Section 2.2.8). At the same time, supernatants were 
harvested for cytokine release measurements (Section 2.2.5) at different time points. 
 
2.2.10 Immunoprecipitation 
    Immunoprecipitation (IP) is a method that uses the antigen-antibody reaction 
principle to identify a protein from a mixture of proteins that reacts specifically with 
an antibody so that the target protein’s quantity or physical characteristics can be 
examined. A typical immunoprecipitation experiment contains the following steps:1) 
The proteins from the cell or tissue homogenate are precipitated in an appropriate 
lysis buffer containing an immune complex which includes the protein of interest (the 
antigen), primary antibody and Protein A- or G- (Protein A or G binds to the antibody, 
which is bound to its antigen) or a secondary antibody-agarose conjugate. 2) The 
immune complex is then captured on a solid support to which either Protein A or 
Protein G has been immobilized. Proteins that bind to the antibody are precipitated 
and proteins that do not are washed away. 3) Components of the bound immune 
complex (both antigen and antibody) are eluted from the support. 4) 
Immunoprecipitated proteins are further analyzed by SDS-PAGE and 
immuno-blotting to determine their molecular weights, to study their interactions with 
other proteins, to determine specific enzymatic activity, to monitor protein 
post-translational modifications and to determine the presence and quantity of 




Figure 2.2.7 Schematic Diagram of Immunoprecipitation Process. Picture taken 
from website: http://www.komabiotech.co.kr/www/techniques/immunodection/ 
imm_precipitation.html  
 
2.2.10.1 MAP3K8 Immunoprecipitation 
    Cells were lysed using RIPA lysis buffer from Upstate Biotechnology, Inc. (50 
mM Tris-HCL, pH 7.4, 150 mM NaCl, 1% (v/v) Nonidet P-40, 0.25% (w/v) 
deoxycholic acid, and 1 mM EDTA) supplemented with protease and phosphatase 
inhibitors (Roche Applied Science). Four hundred and fifty μg of whole cell lysate 
was used for the immunoprecipitation process. Briefly, cell lysate was diluted in 300 
μl modified RIPA buffer (50 mM Tris-HCL, pH 7.4, 150 mM NaCl, and 1% (v/v) 
Nonidet P-40) and incubated with 30 μl of a rabbit polyclonal antibody against 
MAP3K8 (Santa Cruz Biotechnology Inc.) for 3 h at 4 °C. Fifty μl of TrueBlot 
anti-Rabbit Ig IP beads (eBioscience, Ltd.) was then added and rocked on a rocker 
platform for 2 hrs at 4 °C to form an immune complex. The sample was then 
centrifuged at 4,000 rpm for 2 min, and collected pellets were washed 2 times with 
modified RIPA lysis buffer. Following washing, protein complexes bound to the beads 
were denatured by adding sample buffer and boiling for 5 minutes at 95 °C in order to 
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dissociate the immunocomplexes from the beads. The beads were collected by 
centrifugation and SDS-PAGE was performed with the supernatant. The supernatants 
were electrophoresed in 10% SDS-PAGE (Section 2.2.8.3), transferred to 
nitrocellulose membranes (Section 2.2.8.4), and probed with the MAP3K8 antibody 
(Santa Cruz Biotechnology Inc.). MAP3K8 protein was detected using Protein A-HRP 
as the secondary antibody to avoid non-specific binding of denatured heavy chain. 
 
2.2.10.2 In Vitro Kinase Assay 
    To establish an in vitro kinase assay for MAP3K8, 0.1 µg of recombinant human 
active MAP3K8 (R&D Systems Europe Ltd., Abingdon, Oxford, UK) was purchased 
and incubated with 0.2 µg of the purified substrate MEK1 (Abcam, Cambridge, UK) 
and cold ATP (0.5 mM, final concentration) in kinase buffer (25 mM Tris-HCl (pH 
7.5), 5 mM -glycerophosphate, 2 mM dithiothreitol (DTT), 0.1 mM Na3VO4, 10 
mM MgCl2) at 30 °C for 30 min. The reaction was terminated by adding sample 
loading buffer. The protein complexes bound to the beads were denatured by boiling 
for 5 min at 95 °C to dissociate the immunocomplexes from the beads. The 
supernatants were then electrophoresed in 10% SDS-PAGE gels, transferred to 
nitrocellulous membranes, and probed with the phospho-MEK1/2 (Ser217/221) 
antibody (Cell Signalling Technology) to identify the effectiveness of this MAP3K8 
specific in vitro kinase assay.  
    A time series analysis of in vitro catalytic activity of immunoprecipitated 
MAP3K8 after IL-1β (1 ng/ml) stimulation was then assessed. After protein extraction 
from A549 cells, the MAP3K8 protein was precipitated in lysis buffer by means of an 
immune complex including the MAP3K8 protein, primary antibody and TrueBlot 
anti-Rabbit Ig IP beads (eBioscience, Ltd.). Beads were washed 2 times with the lysis 
buffer, and once with the kinase assay buffer (25 mM Tris-HCl (pH 7.5), 5 mM 
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-glycerophosphate, 2 mM dithiothreitol (DTT), 0.1 mM Na3VO4, 10 mM MgCl2). 
Bead-bound kinase was then incubated in the kinase buffer with 0.2 µg of the purified 
substrate MEK1 (Abcam, Cambridge, UK) and cold ATP (0.5 mM, final 
concentration) at 30 °C for 30 min. The reaction was terminated by adding sample 
loading buffer. The protein complexes bound to the beads were denatured by boiling 
for 5 minutes at 95 °C to dissociate the immunocomplexes from the beads. The 
supernatants were then electrophoresed in 10% SDS-PAGE gels, transferred to 
nitrocellulose membranes and then probed with the phospho-MEK1/2 (Ser217/221) 
antibody (Cell Signalling Technology). 
 
2.2.11 Gene Expression Profiling 
    Global gene expression was determined using the Affymetrix microarrays. The 
Affymetrix
®
 Human Gene 1.1 ST Array Plate enables high-throughput expression 
profiling of 16 samples at a time. The Human Gene 1.1 ST Array Plate interrogates 
more than 28,000 well-annotated genes with more than 750,000 distinct probes. The 
design is based on the March 2006 human genome sequence assembly (UCSC HG18, 
NCBI Build 36), with comprehensive coverage of RefSeq, Ensembl, and putative 
complete CDS GenBank®  transcripts. The Human Gene 1.1 ST Array Plate has 
greater than 99 percent coverage of sequences in the RefSeq database. Figure 2.2.8 
depicts the workflow for the complete WT assay. Using the Affymetrix GeneChip
®
 
WT Terminal Labeling Kit in conjunction with the Ambion
®
 WT Expression Kit 




Figure 2.2.8 Assay Schematic for Global Gene Expression Profiling Using the 




2.2.11.1 RNA Isolation 
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    Total RNA was isolated from using the Qiagen RNeasy
®
 mini kit (Qiagen, 
Crawley, UK) (see Section 2.2.6.1). RNA concentration was measured using the 
NanoDrop-1000 spectrophotometer (NanoDrop Technologies, Wilmington, DE, USA) 
(see Section 2.2.6.2). 
 
2.2.11.2 RNA Analysis 
    The quality of the RNA samples was quantified using the RNA 6000 Nano 
Assay
TM
 kit with the Agilent 2100 Bioanalyser
TM
. Briefly, running gel was prepared 
by combining gel mix and dye. The microchannels were filled by pipetting 9 μl of the 
gel–dye mixture into the appropriate well and then transferring the mixture into the 
microchannels by applying pressure to the well via a 1 ml syringe (chip priming 
station). The ladder well and sample wells were subsequently loaded with 5 μl of the 
RNA size marker mixture. 1 μl of RNA ladder and samples were denatured at 70 °C 
for 2 min and then added to the wells of the chip. After mixing by vortex at 2,400 rpm 
for 1 min, the chips were immediately inserted into the bioanalyser and processed 
according to the manufacturer’s instructions. A RNA integrity number (RIN) was 
generated for each Bioanalyzer trace using 2100 Expert Software (Agilent 
Technologies). The maximum RIN score possible is 10. The resulting profile was then 
used to determine RNA quality, where a RIN value greater than 8 and an 18S:28S 





Figure 2.2.9 Assessment of RNA Integrity Using the Agilent Bioanalyser. RNA 
isolated from cells was analyzed using a Bioanalyser. Panels A and B represent an 
electropherogram and gel image (respectively) of an RNA size reference ladder. 
Panels C and D are examples of electropherogram and gel image respectively of an 
RNA sample. In Panels C and D the characteristic 18S and 28S ribosomal RNA bands 
present in total RNA are observed. [FU], fluorescence unit; [S], second. 
 
2.2.11.3 cRNA Amplification 
    Total RNA was converted to labelled cDNA for hybridization onto the gene 
expression chips using the Ambion
®
 WT Expression Kit following the manufacturer’s 
protocol. The Affymetrix Poly-A RNA control kit and eukaryotic hybridization 
control kit were used to ensure the efficiency of cRNA amplification and 
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hybridization during the entire experimental process. Figure 2.2.8 depicts the 
workflow for the complete WT assay. 
The first step involved synthesis of first strand cDNA from 125 ng total RNA 
re-suspended in 3 μl nuclease-free water with 2 μl of Poly A RNA control. One μl of 
first-strand enzyme mix (oligo (T7) primer) mixed with 4 μl of first-strand buffer mix 
was added to each sample. The reaction was carried out in a Peltier Thermal 
Cycler–PTC225 DNA Engine Tetrad (MJ Research, Reno, NV, USA) with incubation 
for 1 hr at 25 °C then 1 hr at 42 °C followed by a final incubation of at least 2 min at 4 
°C. 
    The second-strand cDNA synthesis was then performed by the addition of 
second-strand master mix containing 5 μl of second-strand enzyme mix (DNA 
polymerase and RNase H) mixed with 12.5 μl of second-strand buffer mix and 
re-suspended in nuclease-free water to achieve  a final total volume of 50µl. The 
samples were then incubated in a thermal cycler for 1 hr at 16 °C then 10 min at 65 °C 
followed by a final incubation of at least 2 min at 4 °C. Antisense cRNA was 
synthesized by In Vitro Transcription (IVT). Thirty μl of the IVT master mix 
containing 6 μl of IVT enzyme mix (T7 RNA polymerase) mixed with 24 μl of IVT 
buffer mix was added to each sample and followed by incubation in a thermal cycler 
for 16 hrs at 40 °C. 
    The cRNA was then purified by isopropanol precipitation using nucleic acid 
binding beads. Sixty μl of cRNA binding mix was added to each sample and cRNA 
was precipitated from the aqueous phase by the addition of 60 μl of 100% 
isopropanol. The cRNA was then eluted from the nucleic acid binding beads by the 
addition of 35 μl of preheated (56 °C) elution solution. cRNA concentrations and 
quality were then analyzed using the RNA 6000 Nano Assay
TM
 kit with the Agilent 
2100 Bioanalyser
TM
 and the NanoDrop-1000 spectrophotometer (NanoDrop 
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Technologies, Wilmington, DE, USA) (see Section 2.2.6.2). Based on the data from 
an RNA size reference ladder, the fluorescence of 4000 nucleotides (nt) is detected at 
50 second. The expected cRNA profile is a distribution of sizes from 50 to 4500 nt 
with most of the cRNA sizes in the 200 to 2000 nt range (Figure 2.2.10).   
 
Figure 2.2.10 Example of Bioanalyser Electropherogram (A) and Gel Image (B) 
of cRNA. Based on the data from an RNA size reference ladder, the cRNA profile is a 
distribution of sizes from 50 to 4500 nt with most of the cRNA sizes in the 200 to 
2000 nt range shown most of cRNA at 35 second. [FU], fluorescence unit; [S], 
second. 
 
2.2.11.4 cDNA Amplification 
    Ten μl of cRNA was re-suspended in 22 μl nuclease-free water with 2 μl of 
random primers. The samples were then denatured in a thermal cycler for 5 min at 70 
°C, 5 min at 25 °C with a final 2 min at 4 °C. After the incubation, the second cycle of 
synthesis was then performed by the addition of second-cycle master mix containing 8 
μl of second-cycle enzyme mix (dUTP/dNTP mix) mixed with 8 μl of second-cycle 
buffer mix. The samples were then incubated in a thermal cycler for 10 min at 25 °C, 
then 90 min at 42 °C followed by a final incubation of at least 2 min at 4 °C. The 
second-cycle cDNA was hydrolyzed by the addition of 2 μl of RNase H and then 
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incubated in a thermal cycler for 45 min at 37 °C, 5 min at 95 °C, then for a minimum 
of 2 min at 4 °C.  
The cDNA was then purified by ethanol precipitation using nucleic acid binding 
beads. Sixty μl of cDNA binding mix was added to each sample and cDNA was 
precipitated from the aqueous phase by the addition of 120 μl of 100% ethanol. The 
cDNA was eluted from the nucleic acid binding beads by addition of 30 μl of 
pre-heated (56 °C) elution solution. cDNA concentrations and quality were analyzed 
using the RNA 6000 Nano Assay
TM
 kit with the Agilent 2100 Bioanalyser
TM
 and the 
NanoDrop-1000 spectrophotometer (NanoDrop Technologies, Wilmington, DE, USA) 
(see Section 2.2.6.2). The expected cDNA profile is a distribution of sizes 
approximately 400 nt. An example of the molecular weight distribution of cDNA is 
shown in Figure 2.2.11.   
 
Figure 2.2.11 Example of Bioanalyser Electropherogram (A) and Gel Image (B) 
of cDNA. Based on the data from an RNA size reference ladder, the expected cDNA 
profile is a distribution of sizes approximately 400 nt shown most of cDNA at 30 





    For the fragmentation reaction, 5.5 μg of single-stranded DNA was re-suspended 
in 31.2 μl nuclease-free water. Fragmentation master mix containing 1 μl of UDG (10 
U/μl), 1 μl of APE 1 (1,000 U/μl) and 4.8 μl of 10X cDNA fragmentation buffer was 
added to each sample and the samples then denatured in a thermal cycler for 60 min at 
37 °C, followed by 2 min at 93 °C with a final incubation of 2 min at 4 °C. To ensure 
fragmentation was successful an aliquot of each sample was analyzed using the RNA 
6000 Nano Assay
TM
 kit with the Agilent 2100 Bioanalyser
TM
. The expected range in 
peak size of the fragmented samples should be approximately 40 to 70 nt. An example 
of the molecular weight distribution after fragmentation is shown in Figure 2.2.12.  
 
Figure 2.2.12 Example of Bioanalyser Electropherogram (A) and Gel Image (B) 
of cDNA after Fragmentation. Based on the data from an RNA size reference ladder, 
the fragmented sample is approximately 40 to 70 nt shown most of fragmented sample 
at 25 second. [FU], fluorescence unit; [S], second. 
 
2.2.11.6 Labelling and Hybridization 
    For labelling of fragmented single-stranded DNA, a master mix using 2 μl of 
TdT, 1 μl of DNA labelling reagent (5mM) and 12 μl of 5X TdT buffer was added to 
each sample. The samples were incubated in a thermal cycler for 60 min at 37 °C, 10 
min at 70 °C and then 4 °C for at least 2 min.  
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    The GeneChips were hybridized using the Eukaryotic Hybridization Control Kit 
purchased from Affymetrix (Santa Clara, CA). All GeneChip
®
 Eukaryotic Expression 
Arrays contain probe sets for several prokaryotic genes that serve as hybridization 
controls. The genes present on the arrays are bioB, bioC and bioD from biotin 
synthesis of Escherichia coli, and cre from P1 bacteriophage. In addition, the kit also 
contains control Oligo B2 which is used to provide alignment signals for the 
Affymetrix Microarray Suite software. Hybridization cocktails were set up and 
contained 5.5 μg of the fragmented, end-labelled cDNA. The cocktails were denatured 
in a thermal cycler for 5 min at 95 °C, followed by 45 °C for 5 min after which they 
were applied to the GeneChip Human Gene 1.1ST arrays. Hybridization was 
performed for 16 hrs on the GeneTitan
TM
 Instrument. The GeneTitan
TM
 Instrument is 
a fully integrated instrument that maximizes data reproducibility and laboratory 
productivity by minimizing user intervention. By combining a hybridization oven, 
fluidics processing and state-of-the art imaging device into a single bench-top 
instrument, the GeneTitan
TM
 Instrument automates array processing from target 
hybridization to data generation. 
 
2.2.11.7 Microarray Data Analysis 
2.2.11.7.1 Quality Assessment Metrics 
    Raw intensity measurements of all probe sets were corrected for the background, 
normalized and converted into expression measurements by using the Affymetrix 
expression console (EC) (Version 1.1). The CEL files of microarrays were loaded up 
into an EC study to allow a multi-chip analysis of the CEL files. In EC, random 
multiple access (RMA)-Sketch was selected as the probe set summarization method 
for running a gene level core analysis. A variety of quality assessment metrics 
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including probeset signals and probeset summarization are calculated by EC during 
probe set summarization. 
 
2.2.11.7.2 Gene Expression and Clustering analysis 
    The Partek Genomic Suite (Version 6.5) was used to identify differentially 
expressed genes between each pair of sample groups. Raw expression data were 
background adjusted, quantile normalized and median polished using the random 
multiple access (RMA) program. Principal Components Analysis (PCA) was applied 
to the data for the identification of latent batch effects. P-values were adjusted for 
multiple testing using the Benjamini & Hochberg method for the control of the 
expected false discovery rate (FDR)
127
. Genes with significantly differential 
expressions were selected by use of a cut-off of a FDR-adjusted P value and fold 
change in the level of expression. These significant genes were clustered using 
Hierarchical Clustering within the Partek Genomic Suite.  
    For c-means clustering, data summarized at the level of transcript clusters were 
then imported into R software (Version 2.11.0). C-means clustering was used to group 
the significantly differential transcripts into discrete and stable clusters of time series 
data using the Mfuzz package. Factors found to yield sample clustering were 
incorporated into all subsequent differential expression analyses using the R package 
Limma (Linear Models for Microarray Data)
128
. Differential expression was assessed 
through linear modelling, applying a single contrast between samples at different time 
points and the zero time point. The genes in each cluster were analyzed using 
Database for Annotation, Visualization and Integrated Discovery (DAVID) Version 
6.7 (http://david.abcc.ncifcrf.gov) to provide Gene Ontology (GO) term enrichment 
analysis, functional annotation clustering as well as details of the gene families found 
within the gene clusters. 
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2.2.11.7.3 Functional Network Mapping and Molecular Pathway Analysis 
    Additional filtering using a cut-off of a FDR-adjusted P value was applied to 
extract significantly differential genes by using Ingenuity Pathway Analysis (IPA) 
software (Ingenuity Systems, Redwood City, CA). Those genes with known gene 
symbols (Human Genome Organisation; HUGO) and their corresponding expression 
values were uploaded into the software. Each gene symbol was mapped to its 
corresponding gene object in the Ingenuity Pathways Knowledge Base. Networks of 
these genes were algorithmically generated based on their connectivity and assigned a 
score. The score is a numerical value used to rank networks according to how relevant 
they are to the genes in the input dataset but may not be an indication of the quality or 
significance of the network. The score takes into account the number of focus genes in 
the network and the size of the network to approximate how relevant this network is 
to the original list of focus genes. The network identified is then presented as a graph 
indicating the molecular relationships between genes/gene products. Genes are 
represented as nodes and the biological relationship between two nodes is represented 




Figure 2.2.13 Ingenuity Pathway Analysis Node and Edge Types. Picture taken 
from Hinkelbein, J., Kalenka, A., Schubert, C., Peterka, A. & Feldmann, R.E., Jr. 
Protein Pept Lett 17, 18-31 (2010)
129
.   
 
    The intensity of the node colour indicates the degree of up- (red) or down- 
(green) regulation. Genes in uncoloured nodes were not identified as differentially 
expressed in the experiment and were integrated into the computationally generated 
networks on the basis of the evidence stored in the IPA knowledge memory indicating 
their relevance to the network. Canonical pathways analysis identified the pathways, 
from the IPA library of canonical pathways, which were most significant to the input 
data set. The significance of the association between the data set and the canonical 
pathway was determined based on two parameters: (1) A ratio of the number of genes 
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from the data set that map to the pathway divided by the total number of genes that 
map to the canonical pathway and (2) a P value calculated using B-H multiple testing 
determining the probability that the association between the genes in the data set and 
the canonical pathway is due to chance alone. 
 
2.2.12 Signalling Pathways Inhibitor Studies 
    In order to conduct functional analysis of signalling pathways, after starvation to 
obtain cell cycle synchronization, cells were pre-treated for 1 hr with specific 
inhibitors before the addition of the IL-1 stimulus. Post IL-1 stimulation at time 
point 0, plates were incubated at 37
 o
C with 5% CO2 for the appropriate length of time 
and then cell-free supernatants were harvested by centrifugation at 4,000 rpm (Mikro 
22R centrifuge, Hettich, Tuttlingen, Germany) for 5 min at 4°C after which cytokine 
levels were determined. The MEK1/2 inhibitor U0126 was purchased from Cell 
Signalling. The c-Jun NH2-terminal kinase (JNK) inhibitor, SP 6001125 was 
purchased from Sigma-Aldrich (Dorset, UK). Both inhibitors, U0126 
(1,4-diamino-2,3-dicyano-1,4-bis[2-aminophenylthio] butadiene) and  SP600125 
(anthra[1,9-cd]pyrazole-6 (2H)-one) were dissolved in dimethyl sulfoxide (DMSO; 
Sigma-Aldrich) leading to a 10
-2
 M stock solutions of each. For experiments, U0126 
or SP600125 were used either at 1, 5 or 10 µM concentrations in serum-free medium. 
A set of baseline experiments with control cells treated with DMSO alone was 
completed alongside each stimulation experiment.  
 
2.2.13 Determination of Transcription Factor Activation by ELISA 
2.2.13.1 Extraction of Nuclear Proteins 
    The preparation of nuclear extracts was performed using the Nuclear Extract kit 
(Active Motif) according to manufacturer’s instructions. Briefly, cells were washed, 
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collected in 2 ml ice-cold PBS in the presence of phosphatase inhibitors and then 
centrifuged at 5,000 rpm (Mikro 22R centrifuge, Hettich, Tuttlingen, Germany) for 3 
min at 4°C to remove the supernatants. The cell pellets were re-suspended in 1 ml of 
hypotonic buffer containing 20 mM Hepes pH 7.5, 5 mM NaF, 10 μM Na2MoO4 and 
0.1 mM EDTA for 15 min on ice. Fifty μl of 10% Nonidet P-40 (0.5 % final) was 
added and the tubes vortexed vigorously for 30 seconds then centrifuged at 5,000 rpm 
(Mikro 22R centrifuge, Hettich, Tuttlingen, Germany) for 1 min at 4°C to remove the 
supernatants (cytoplasmic fraction). After removing the cytoplasmic fraction, the 
nuclei were lysed and nuclear proteins solubilized in 60 µl of complete lysis buffer 
containing 5 μl of 1 M Dithiothreitol (DTT) and 10 μl Protease Inhibitor Cocktail per 
ml of Lysis Buffer AM2. After rocking the tubes gently on ice for 30 min on a shaking 
platform, the samples were centrifuged at 14,000 x g (Mikro 22R centrifuge, Hettich, 
Tuttlingen, Germany) for 10 min at 4°C. The supernatant (nuclear extract) was then 
collected and stored at -80°C until use. Protein concentrations were determined using 
the Bradford protein assay. 
 
2.2.13.2 Bradford Protein Assay 
    The protein concentrations of all samples were determined by using a 
Bradford-based assay. Briefly, 2 μl of the protein extract was added to 200 μl of the 
Bradford Reagent (Sigma-Aldrich) and mixed. A serial dilution of Bovine Serum 
Albumin (BSA) by adding 1 µl, 2 µl, 4 µl, 6 µl, 8 µl and 10 µl of BSA (1mg/1ml) was 
prepared and assayed along with the samples to be tested. The assay is based on the 
observation that the absorbance maximum for an acidic solution of Coomassie 
Brilliant Blue G-250 shifts when binding to protein occurs. Both hydrophobic and 
ionic interactions stabilize the anionic form of the dye causing a visible color change. 





(Molecular Devices) spectrophotometer. A standard curve was generated by plotting 
the known albumin protein concentrations against the measured light absorbance, and 
the protein content of the sample was identified by comparison against the standard 
curve (Figure 2.2.14). 
 
Figure 2.2.14 Protein Standard Measurements for Use in Protein Quantification. 
 
2.2.13.3 NF-κB DNA Binding Activity Assay 
    TransAM
TM
 NF-κB Kit (Active Motif Europe, Belgium) contains a 96-well plate 
on which oligonucleotides containing the NF-κB consensus site 
(5 -´GGGACTTTCC-3 )´ have been immobilized. The active NF-κB subunits in 
nuclear extracts specifically bind to the oligonucleotides. The primary antibody used 
for detection of NF-κB recognizes an epitope common to all NF-κB subunits (p50, 
p52, p65, c-Rel or RelB), which is accessible only when NF-κB is activated and is 
bound to the target DNA. An HRP conjugated secondary antibody provides a sensitive 
colorimetric readout that is quantified using a spectrophotometer. As this assay is 
performed in 96-well plates, a number of samples can be handled simultaneously. 
    Nuclear extracts were evaluated for the presence of NF-κB p65 subunits using 
TransAM NF-κB p65 Transcription Factor Assay kits according to the manufacturer’s 
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instructions. Briefly 30 µl of complete binding buffer containing Dithiothreitol (DTT), 
Herring sperm DNA and Binding Buffer AM3 was added to each well to be used. 
Nuclear protein extracts (5 µg) were diluted in complete lysis buffer containing DTT, 
protease inhibitor cocktail and Lysis Buffer AM2. Incubation was performed for 1 hr 
at room temperature with mild agitation (100 rpm on a rocking platform). After 
incubation wells were washed 3 times with 200 µl washing buffer.  
    Next the diluted NF-κB p65 antibodies (1:1,000 dilution in antibody binding 
buffer) were applied to each well (100 µl/well). The plate was incubated for 1 hr at 
room temperature without agitation. Wells were then washed 3 times with 200 µl 
washing buffer. HRP-conjugated antibody (1:1,000 dilution in antibody binding 
buffer) was applied to the wells (100 µl/well). The plate was incubated for 1 hr at 
room temperature without agitation. After incubation, wells were then washed 4 times 
with 200 µl washing buffer. The developing solution (100 µl/well) was then added. 
The colour reaction was monitored until the developing solution turned blue and 
incubation was performed at room temperature for 2.5 min. At the end, 100 µl/well 
stop solution were added turning any blue colour present to yellow. The product of 
this chromogenic reaction was then measured at 450 nm in a SpectraMax
TM
 
(Molecular Devices) spectrophotometer. 
 
2.2.13.4 AP-1 DNA Binding Activity Assay 
    The preparation of nuclear extracts was performed using the Nuclear Extract kit 
(Active Motif) according to manufacturer’s instructions and as described in Section 
2.2.13.1. For the AP-1 DNA binding activity assay, after removing the cytoplasmic 
fraction, the nuclei were lysed and the nuclear proteins solubilized in 60 µl complete 
lysis buffer containing DTT, protease inhibitor cocktail and Lysis Buffer AM1 which 
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contains phosphatase inhibitors to prevent de-phosphorylation of AP-1 during the 
extract preparation and the assay.  
    TransAM
TM
 AP-1 Kit (Active Motif Europe, Belgium) contains a 96-well plate 
on which has been immobilized an oligonucleotide that contains a TPA-response 
element (TRE) (5 -´TGAGTCA-3 )´. AP-1 contained in nuclear extracts specifically 
binds to this oligonucleotide. The primary antibodies used for detection of AP-1 
activity recognize epitopes on c-Fos, FosB, c-Jun or JunD proteins upon DNA 
binding. An HRP conjugated secondary antibody provides a sensitive colorimetric 
readout that is quantified using spectrophotometer.  
    Nuclear extracts were evaluated for the DNA binding activity of AP-1 c-Fos or 
c-Jun according to the manufacturer’s instructions. Briefly, 30 µl of complete binding 
buffer including DTT and Poly [d(I-C)] in Binding Buffer AM2 was added to each 
well to be used. Nuclear protein extracts (5 µg) were diluted in complete lysis buffer 
containing DTT, protease inhibitor cocktail and Lysis Buffer AM1. Incubation was 
performed for 1 hr at room temperature with mild agitation (100 rpm on a rocking 
platform). After incubation, wells were washed 3 times with 200 µl washing buffer.  
    After discarding the last washing buffer, the diluted AP-1 c-Fos antibodies 
(1:1,000 dilution) or AP-1 c-Jun antibodies (1:500 dilution in antibody binding buffer) 
were applied to each well (100 µl/well). The plate was incubated for 1 hr at room 
temperature without agitation. Wells were then washed 3 times with 200 µl washing 
buffer. HRP-conjugated antibody (1:1,000 dilution in antibody binding buffer) was 
applied to the wells (100 µl/well). The plate was incubated for 1 hr at room 
temperature without agitation. After incubation, wells were washed 4 times with 200 
µl washing buffer. The developing solution (100 µl/well) was then added. The colour 
reaction was monitored until the developing solution turned blue approximately 10 
min at room temperature incubation. One hundred µl/well stop solution was then 
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added resulting in a colour change of blue to yellow. The chromogenic reaction was 
then measured at 450 nm using a SpectraMax
TM
 (Molecular Devices) 
spectrophotometer. 
 
2.2.14 Statistical Analysis 
    Statistical comparisons between treatments were carried out using 
Mann-Whitney U tests for nonparametric data, comparing medians of samples to 
controls. Means were compared by Student’s t-test. Comparisons between more than 
two groups were carried out using Kruskall-Wallis (ANOVA) tests. A P value of < 
0.05 was considered significant. All statistical analyses were performed using the 
Statistical Program for Social Sciences (SPSS 17.0 for windows, SPSS Inc., Chicago, 
IL, USA) and graphs were drawn using GraphPad Prism Version 5.01 software 







Expression of MAP3K8 in IL-1β-Induced Response in Respiratory 
Epithelial Cells  
 
3.1 Introduction 
Airway inflammation is a hallmark of chronic airway diseases, including 
bronchial asthma and chronic obstructive pulmonary disease (COPD). The importance 
of airway inflammation in the pathogenesis of airway diseases has been clearly 
established. COPD is characterized by chronic inflammation throughout the airways, 
lung parenchyma and pulmonary vasculature
130
. Destruction of the lung parenchyma 
by inflammatory processes leads to emphysema which decreases lung elastic recoil 
and results in airflow limitation. Similarly inflammation is also a cornerstone of 
asthma. The main pathological features of asthma include mucus metaplasia, 
sub-epithelial fibrosis, airway wall thickening and smooth muscle cell 
hypertrophy
131,132
. In asthma and COPD, chronic inflammation in the bronchi causes 
remodelling of the airway wall and narrowing of the small airways
132
. When airway 
inflammation is not adequately treated, it can result in permanent structural changes in 
the airways. Airway remodelling is characterized by an alteration in the size, mass or 
number of tissue components which occur in and around the trachea, bronchi and 
bronchioles in the airways in response to injury and/or inflammation
133
. It has been 
shown to occur during chronic inflammation, even in very young asthma patients
131
.  
    IL-1β is an important mediator of the inflammatory response and it is well 
established that it is involved in the initiation and persistence of inflammation
45
. IL-1β 
partakes in a variety of cellular activities including cell proliferation, differentiation 
and apoptosis. It can also induce the activation of IκB/NF-κB. Released NF-κB 
dimmers, a key transcription factor in inflammation, translocate to the nucleus 
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resulting in the transcription of inflammatory genes and causing the subsequent 
inflammatory response
72
. Asthma patients have been shown to have an increased level 
of IL-1β in their bronchial alveolar lavage (BAL) fluid compared to patients with 
asymptomatic asthma
46
. Increased expression of IL-1β in asthmatic airway epithelium 
has also been reported, together with an increased number of macrophages expressing 




    In airway diseases, chronic inflammation is the prominent feature and 
broncho-constriction and airway hyper-reactivity appear to be secondary to the release 
of inflammatory mediators
25
. Multiple cytokines play a role in the inflammation of 
airway diseases. In COPD, many studies have shown that COPD is associated with 
increased levels of several pro-inflammatory cytokines such as TNF-α, IL-6, IL-8 and 
acute phase reactants
135
. Among them, IL-6 appears to amplify the inflammatory 
process and may contribute to some of the systemic effects of COPD. In asthma, 
pro-inflammatory cytokines such as IL-1, TNF-α, IL-6, IL-11, 
granulocyte–macrophage colony stimulating factor (GM-CSF) and stem cell factor 
(SCF) are important in disease severity and resistance to anti-inflammatory therapy
136
. 
Furthermore asthma is viewed as an eosinophilic disease, with increased numbers of 
activated eosinophils in the airway mucosa and in sputum as a result of the release of 
eosinophil chemotatic factors, such as RANTES (CCL5), from airway epithelial cells. 
Neutrophils are prominent inflammatory cells in the airways of patients with COPD 
and there is increasing evidence that neutrophilic inflammation, which is poorly 
responsive to corticosteroids, plays a major role in the pathogenesis of asthma 
exacerbations
14
. Neutrophilic recruitment into airways is partially as a result of 
chemo-attraction by neutrophil chemokines such as IL-8 (cysteine-X-cysteine 
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chemokine ligand [CXCL] 8). Recently it has been reported that there is an increase in 
IL-8 in the airway epithelium of severe asthma patients
137
.  
An understanding of the regulation of genes involved in the inflammatory 
process has the potential to result in the identification of novel therapeutic targets for 
airway diseases. In the Molecular Genetics and Genomics Group, a prior pilot study 
of global gene expression in human airway epithelial cell lines under IL-1 
stimulation identified a number of genes which may play major roles in response to 
inflammation. One of the genes, MAP3K8, was found to be highly associated with 
inflammatory gene expression and its gene expression was elevated 60-fold in the 
acute response of A549 and BEAS-2B cells to inflammatory stimuli. MAP3K8 is a 
member of the serine/threonine protein kinase family and has been shown to be 
involved in the mitogen activated protein kinase (MAPK) pathway. The MAP kinase 
signal transduction pathway plays a crucial role in many aspects of the immune 
mediated inflammatory response
56
. In macrophages, an essential role of MAP3K8 is 
in the regulation of responses to lipopolysaccharide (LPS) 
117
. The role of MAP3K8 in 
inflammatory response however has not been fully evaluated in airway epithelial 
cells. 
MAP3K8 is hypothesized to be expressed in airway epithelial cells and play an 
important role in inflammatory response. The major goal of this study is to establish 
an in vitro cytokine-induced inflammation model. Inflammatory mediators related to 
airway inflammation including IL-6, IL-8 and RANTES were selected and assessed in 
an IL-1β-induced inflammation model. The response of MAP3K8 was also 




3.2 Materials and Methods 
3.2.1 Culture of Cell Lines 
    A549 and BEAS-2B cells were obtained from the American Type Culture 
Collection (ATCC) and NHBE from Lonza. They were cultured as described in 
Chapter 2, Section 2.2.1. A549 cells were used at passage numbers 90-110 and the 
BEAS-2B cells were used at passage numbers 60–80. Cell viability was determined 
microscopically by trypan blue (Sigma-Aldrich) exclusion and the number of cells 
counted by a haemocytometer (see Section 2.2.2). Cells were sub-seeded in 
appropriate culture vessels (6- or 24-well plates) and incubated at 37°C for 24 hrs 
prior to all treatments if necessary. 
 
3.2.2 IL-1β Stimulation – Concentration Response of IL-1β 
    Adherent cells of A549 and BEAS-2B were selected for concentration response 
of IL-1β stimulation. The cells were first grown up in T150 flasks and after incubation 
with trypsin to release them from the flask surface, they were then seeded into tissue 
culture plates (24-well plates). A total number of 5x10
4
 A549 or BEAS-2B cells for 
24-well plates were seeded into each well in 1 ml of complete medium overnight for 
cells to attach and grow. Before the addition of the IL-1 stimulus, the cells were 
starved with serum-free media for 16 hrs to obtain cell cycle synchronization. A549 or 
BEAS-2B cells were stimulated with 0.001ng/ml, 0.01ng/ml, 0.1ng/ml, 1ng/ml and 
10ng/ml of IL-1β (R&D Systems Europe Ltd., Abingdon, Oxford, UK) respectively 
and cell-free supernatants were harvested at 24 hrs after IL-1 stimulation. Cytokines 
including IL-6, IL-8, and RANTES were then determined and concentration-response 
analyses were performed simultaneously as described in Chapter 2 Section 2.2.5. The 




3.2.3 IL-6, IL-8 and RANTES Measurement by ELISA 
Cell-free supernatants post-stimulation were harvested and stored at -80
o
C for 
further cytokine measurements using enzyme-linked immunosorbent assays (ELISA). 
IL-6, IL-8, and RANTES were measured using ELISA kits according to the 
manufacturer’s instructions (DuoSet; R&D Systems Europe; Abingdon, Oxon, UK) as 
described in Chapter 2, Section 2.2.5. 
 
3.2.4 MTT Cell Viability Assay 
    For the cell viability assay, A549 or BEAS-2B cells were treated with 1 mg/ml 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) 
(Sigma-Aldrich) in Hanks’ balanced salt solution (HBSS) for 30 min at 37 oC. After 
incubation, the MTT solution was removed from the surface of the cells and dimethyl 
sulfoxide (DMSO) was added. The absorbance of the resultant solution was then 
measured at 550 nm and treated cells were compared with control cells. 
 
3.2.5 IL-1β Stimulation – Times Series Experiments 
A549 cell lines were used for the time series experiments. The response of IL-1 
stimulation was measured at 0, 2, 4, 6, 8, 16 and 24 hrs with each time point being 
done in triplicate. Post IL-1 stimulation at time point 0, plates were incubated at 37 
o
C with 5% CO2 for the appropriate length of time (2, 4, 6, 8, 16 and 24 hrs) and then 
RNA was isolated from A549 cells using the Qiagen RNeasy mini kit (Qiagen, 
Crawley, UK) according to the manufacturer’s instructions and as described in 
Chapter 2, Section 2.2.6. BEAS-2B and NHBE cell lines were used for confirming 
significant findings in A549 cells.   
 
3.2.6 Quantitative Real-time Polymerase Chain Reaction (PCR) 
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    Total RNA was isolated from A549, BEAS-2B and NHBE cells using the Qiagen 
RNeasy
®
 mini kit (Qiagen, Crawley, UK) (Chapter 2, Section 2.2.6.1). RNA 
concentration and the A260/A280 ratio were determined using the NanoDrop-1000 
spectrophotometer (Chapter 2, Section 2.2.6.2). Reverse transcription was performed 
using 0.5µg of RNA and cDNA was synthesized using High-Capacity cDNA Reverse 
Transcription Kits (Chatper 2, Section 2.2.6.3). The synthesized cDNA was stored at 
–20°C prior to use in real-time PCR. 
    Real-time PCR was then performed (Chapter 2, Section 2.2.6.4) using primer 
pairs designed with the Primer 3 RT-PCR program and checked for sequence 
homology against known genes using the BLAST search program
126
. Specific primers 
for MAP3K8 real-time PCR were designed to give a PCR product of 90 bp. Real-time 
PCR of glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was performed to act 
as an internal control with primers designed to give a PCR product of 175 bp. The 
forward primer for MAP3K8 was 5'-TGGTGGATTTTGGCCTAAGTGTT-3', and the 
reverse primer was 5'-CCTCTGGGCTCATGTAAATCTCTGT-3'. The forward primer 
for GAPDH was 5'-TTCCAGGAGCGAGATCCCT-3', and the reverse primer was 
5'-CACCCATGACGAACATGGG-3'. Amplification conditions for the MAP3K8 and 
GAPDH are described in Chapter 2, Section 2.2.6.4. Calculation of the threshold 
value, standard curve preparation and quantification of mRNA in the samples were 
performed by the Rotor-Gene 6.0 software provided by Corbett Research. 
 
3.2.7 Western Blotting 
    Western blot analysis was performed for the protein of the selected significant 
gene. Whole-cell protein extracts were prepared by using the Active Motif Nuclear 
Extract Kit (Chapter 2, Section 2.2.8.1). Protein concentrations were determined using 
the BCA with bovine serum albumin (BSA; Pierce) used as the standard control 
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(Chapter 2, Section 2.2.8.2). For Western blots, an equal amount of 25 μg of protein 
for each sample was separated by electrophoresis on 10% sodium dodecyl sulfate 
polyacrylamide gels and transferred to nitrocellulose membranes using the iBlot™ 
DryBlotting device and iBlot™ Transfer stacks as described in Chapter 2, Sections 
2.2.8.3 and 2.2.8.4. The blots were incubated with the rabbit polyclonal anti-human 
IgG primary antibodies against MAP3K8 at 1:400 (Santa Cruz Biotechnology Inc.) 
and phospho-MAP3K8 at 1:200 (T290, Invitrogen
 
Corp.) overnight at 4°C. Labelling 
of the first antibodies was detected using relevant secondary antibodies conjugated to 
horseradish peroxidase (HRP) (1:4,000; DAKO Cytomation, Glostrup, Denmark) and 
detected using enhanced chemi-luminescence (GE Healthcare ECL/ECL Plus 
(Amersham)) detection solutions. For quantitative analysis, the bands were scanned in 
a UVP GelDoc-It imaging system and the densities of the bands were quantitated by 
using Labworks 4.6 software (Bio-Rad Lab. Hercules, CA). 
 
3.2.8 Statistical Analysis 




3.3.1 Cell Viability after IL-1β Stimulation 
    Investigation of cell viability at the various concentrations of IL1-β was done in 
the absence of fetal bovine serum (FBS) in the culture media. Serum free culture 
media was used to ensure cell cycle synchronization prior to IL-1 stimulation. The 
MTT assay was performed to establish the viability of the A549 and BEAS-2B cells 
in the presence of IL-1 at different concentrations, from 0.001 ng/ml to 10 ng/ml, for 
24 hrs. As shown in Figure 3.3.1, the stimulation with IL-1 at different 
concentrations did not have any significant impact on A549 (Figure 3.3.1 A) or 
BEAS-2B (Figure 3.3.1 B) cell viability.  
            
Figure 3.3.1 Cell Viability of A549 (A) and BEAS-2B (B) Cells after IL-1 
Stimulation. MTT assay was performed to establish the viability of the A549 and 
BEAS-2B cells in the presence of IL-1. No significant differences were found at 
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different concentrations of IL-1β stimulation. Experiments were performed in 
triplicate and data shown are mean  SEM of three separate experiments. NT, 
non-treat. 
3.3.2 Effect of IL-1β on IL-6, IL-8 and RANTES Release 
A concentration-dependent increase in IL-6 (Figure 3.3.2 A and B) and IL-8 
(Figure 3.3.2 C and D) expression was found in A549 cells with differing 
concentrations of IL-1. There was a significant difference in IL-6 release from 
baseline at an IL-1 concentration of 1 and 10 ng/ml. Similar results were obtained 
with IL-8 release.  
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Figure 3.3.2 Concentrations of IL-6 and IL-8 in Response to IL-1 Stimulation in 
A549 Cells. A concentration-dependent increase in IL-6 (A and B) and IL-8 (C and D) 
expression was found. A significant difference in IL-6 and IL-8 release from baseline 
was found at an IL-1 concentration of 1 and 10 ng/ml. Data shown are mean  SEM 
of four separate experiments. ***P<0.0001 as compared to result for NT. NT, 
non-treat. 
  Similar results were obtained with IL-6 (Figure 3.3.3 A and B) and IL-8 (Figure 
3.3.3 C and D) expression in BEAS-2B cells. There was a significant difference in 
IL-6 and IL-8 release from baseline at an IL-1 concentration of 1 and 10 ng/ml.  
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Figure 3.3.3 Concentrations of IL-6 and IL-8 in Response to IL-1 Stimulation in 
BEAS-2B Cells. A concentration-dependent increase in IL-6 (A and B) and IL-8 (C 
and D) expression was found. A significant difference in IL-6 and IL-8 release from 
baseline was found at an IL-1 concentration of 1 and 10 ng/ml. Data shown are mean 
 SEM of four separate experiments. ***P<0.0001 as compared to result for NT. NT, 
non-treat. 
 
    A concentration-dependent increase in RANTES (Figure 3.3.4) expression was 
found in A549 cells with differing concentrations of IL-1. There was also a 
significant difference in RANTES release from baseline at IL-1 concentrations of 1 
and 10 ng/ml respectively. There was however no appreciable RANTES release after 
IL-1 stimulation in BEAS-2B cells.  
 
Figure 3.3.4 Concentrations of RANTES in Response to IL-1 Stimulation in 
A549 Cells. A concentration-dependent increase in RANTES (A and B) expression 
was found in A549 cells. A significant difference in RANTES release from baseline 
was found at an IL-1 concentration of 1 and 10 ng/ml. Data shown are mean  SEM 
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of four separate experiments. ***P<0.0001 as compared to result for NT. NT, 
non-treat. 
 
    As shown in Figure 3.3.2, Figure 3.3.3 and Figure 3.3.4, the IL-1 
concentration of 1 ng/ml represented an approximate 80% increase in IL-6, IL-8 and 
RANTES expression. The sub-maximal dose of 1 ng/ml of IL-1 was therefore 
selected for future experiments. 
 
3.3.3 MAP3K8 Gene Expression in A549 and BEAS-2B Cells 
A549 cells were cultured in the presence of IL-1 (1 ng/ml) and cells were 
harvested at 0, 2, 4, 6, 8, 16 and 24 hrs time points. RNA was extracted from these 
cells and the fold difference in MAP3K8/GAPDH mRNA expression from IL-1 
stimulated epithelial cells was compared to non-stimulated cells at different time 
points using quantitative real-time PCR (Figure 3.3.5). The real-time PCR assay of 
MAP3K8 mRNA in A549 cells is shown in Figure 3.3.6. 
    As shown in Figure 3.3.5, comparing with the non-stimulation control, a 
significant 20-fold rise in MAP3K8/GAPDH mRNA expression was identified at 2 
hrs after IL-1 stimulation (1 ng/ml), suggesting that MAP3K8 may play a crucial 




Figure 3.3.5 Fold Difference in MAP3K8/GAPDH mRNA Expression after 1 
ng/ml of IL-1 Stimulation in A549 Cells. The experiments were performed in 
triplicate and data are shown as mean  SEM of three separate experiments. *P<0.05 
as compared to result for 0 hr. 
 
Figure 3.3.6 Representative Real-time-PCR Assay of MAP3K8 mRNA in A549 
Cells. The amplification curve with slope correction (A) and the quantification curve 
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of MAP3K8 mRNA amplification (B) obtained for the real-time PCR assay of 
MAP3K8 mRNA. DNA amplicons are analyzed for their specificity by melting curve 
analysis (C) and agarose gel electrophoresis (D) of PCR products obtained. 
 
To ensure that the finding of MAP3K8 gene expression was not restricted to the 
lung A549 epithelial cell line, an optimal time point with highest expression of 
MAP3K8 at 2 hrs was selected and MAP3K8/GAPDH mRNA expression after IL-1 
stimulation (1 ng/ml) was examined in primary bronchial epithelial cells (NHBE) and 
BEAS-2B cells. As shown in Figure 3.3.7, a similar rise in MAP3K8 gene expression 
was found at 2 hrs after IL-1 stimulation in NHBE cells. 
 
Figure 3.3.7 Fold Difference in MAP3K8/GAPDH mRNA Expression in A549, 
BEAS-2B and NHBE Cells. A549, BEAS-2B and NHBE cells were cultured in the 
presence of IL-1 (1 ng/ml). Cells were harvested and RNA extracted after 2 hrs of 1 
ng/ml IL-1 stimulation. Data are expressed as the mean  SEM of three separate 




3.3.4 MAP3K8 Protein Expression and Phosphorylation Regulated by IL-1β 
After IL-1 stimulation, the A549 cells were harvested and MAP3K8 protein 
measured at 5, 10, 20, 30, 45 and 60 min. As shown in Figure 3.3.8, MAP3K8 
showed significantly to be degraded at 30 minutes and reproduced at 2 hrs after IL-1β 
stimulation. A time series analysis of MAP3K8 phosphorylation was conducted and 
phosphorylated MAP3K8 was detected by phospho-specific antibody (T290, 
Invitrogen
 
Corp.) using Western blot (Figure 3.3.9). The phosphorylation of MAP3K8 
showed significantly to occur at 20 minutes after IL-1β stimulation. In A549 cells, the 




Figure 3.3.8 MAP3K8 Protein Expression in IL-1-treated A549 Cells. MAP3K8 
protein was measured at 5, 10, 20, 30, 45 and 60 min (A) and 30, 60, 120, 240 360 
and 480 min (B). Data are expressed as the mean  SEM of three separate 




Figure 3.3.9 MAP3K8 Phosphorylation in IL-1-treated A549 Cells. Data are 
expressed as the mean  SEM of three separate experiments. *P<0.05 as compared to 





Chronic airway inflammation is the prominent feature of airway diseases and 
airway epithelial cells are key participants in the inflammatory response. Human 
airway epithelial cells can be induced to express pro-inflammatory cytokines and 
chemokines that may directly contribute to the development of respiratory symptoms. 
In particular, chemokines produced in the epithelium are powerful recruiters of 
inflammatory cells and resulting in the pathologic changes associated with airway 
diseases
138
. CXC chemokines such as IL-8 attract neutrophils, whereas CC 
chemokines such as RANTES recruit eosinophils, basophils, monocytes and CD4 T 
cells
139
. The bronchial epithelial cell line, BEAS-2B, has been documented to produce 
IL-6, IL-8 and RANTES in response to TNF-α or interferon (IFN)-γ140,141. The human 
alveolar epithelial cell line A549 has previously been extensively studied and has been 
shown to release inflammatory mediators such as MCP-1, IL-8, TNF-, and IL-6 all 
of which are involved in inflammation.  
In this study, an in vitro IL-1β-induced inflammatory response in BEAS-2B and 
A549 cells has been established. A concentration of 1 ng/ml of IL-1 stimulation 
resulted in approximately 80-90% of IL-6, IL-8 and RANTES release in response to 
inflammatory stimuli in A549 cells. It has been reported that bronchial cell lines, 
BEAS-2B, express RANTES in response to TNF-α and that this is enhanced by 
INF-γ141. In this study however, there was no appreciable RANTES release after 
IL-1 stimulation in BEAS-2B cells. This is consistent with the finding for IL-1β 
stimulation in NCI-H292 cells
142
, a bronchial epithelial cell line from human lung 
mucoepidermoid carcinoma. The mechanism of RANTES expression may therefore 
differ between airway epithelial cell lines; however, the present study has 
demonstrated that the A549 cell line can express RANTES in response to IL-1β 
stimulation. Similar MAP3K8 gene expression in response to IL-1β was also found in 
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primary human bronchial epithelial cells. An in vitro cytokine-induced inflammation 
model developed in A549 cells with IL-1β stimulation is therefore more likely to be 
suitable for further investigation of the effects of airway inflammation. 
    MAP3K8 has been shown to be involved in the mitogen activated protein kinase 
(MAPK) pathways, the latter playing a crucial role in many aspects of immune 
mediated inflammatory response
56
. A specific defect in LPS-stimulated TNF release 
has been documented in MAP3K8-deficient macrophages
117
. Elevated levels of 
TNF-α have been clinically implicated as a mediator of a number of autoimmune 
diseases such as rheumatoid arthritis
143
. MAP3K8 may therefore be an appropriate 
therapeutic target for rheumatoid arthritis. MAPK pathways have however also been 
identified as therapeutic targets in airway inflammation
144
. MAP3K8 may therefore 
also provide a new therapeutic strategy for airway diseases such as COPD and 
asthma. In this study, the role of MAP3K8 in airway inflammation was investigated 
using an in vitro IL-1β-induced inflammation response in A549 cells. The gene 
expression of MAP3K8 was found to exhibit a high level of expression with a 20-fold 
rise at 2 hrs after IL-1 stimulation (1ng/ml) suggesting that this kinase may play a 
crucial role in the early stages of airway inflammation.  
The activation of MAP3K8 was also investigated in this study. It has been well 
established that MAP3K8 binds to nuclear factor kappa-light-chain-enhancer of 
activated B cells (NF-κB-1)/p105, a precursor of p50118. In un-stimulated 
macrophages, the interaction of MAP3K8 with NF-κB-1/p105 resulted in MAP3K8 
being maintained in an inactive form. Stimulation with pro-inflammatory mediators 
such as TNF or LPS has been shown to induce NF-κB-1/p105 degradation and 
release/activation of MAP3K8. Although MAP3K8 activity has been shown to 
regulate TNF-induced NF-κB-1/p105 degradation118, NF-κB-1/p105 degradation is 
believed to be mainly regulated by the IκB kinase (IKK) complex through 
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phosphorylation of p105 serines 927 and 932
120,145
. In this study, MAP3K8 appeared 
to be phosphorylated at 20 minutes and degraded at 30 minutes after IL-1β 
stimulation, indicating activated MAP3K8 phosphorylates and activates its 
downstream substrate prior to being degraded by the proteasome. In A549 cells, the 
degradation of MAP3K8 seems to coincide with the increase in MAP3K8 activation, 
which is consistent with the findings from LPS stimulations of macrophages
145
. 
Furthermore, MAP3K8 protein appeared to be re-expressed at 2 hrs and reached 
maximum level at 4 hrs after IL-1β stimulation. This is compatible with the finding 
that MAP3K8 had a high level of mRNA expression at 2 hrs after IL-1 stimulation in 
this study. 
Nuclear factor (NF)-kB transcription factor regulates expression of numerous 
components of the immune system
72
. The classic NF-κB pathway can be induced by 
various inflammatory stimuli, including tumor necrosis factor-, IL-1 and bacterial 
products (e.g., LPS) through IKK/IKK/IKK complex75. This pathway is classified 
by rapid phosphorylation and subsequent degradation of IκB, an inhibitory protein 
that retains the NF-κB complex in the cytoplasm, by IKK, which leads to the nuclear 
translocation of NF-kappa-B heterodimeric p65-p50 and the transcription of 
inflammatory genes including IL-6, IL-8 and RANTES
146
.  
In this in vitro IL-1β-induced inflammation response in A549 cells, MAP3K8 is 
shown to be expressed in airway epithelial cells and may play an important role in 
acute inflammatory response. In A549 cells, the degradation of MAP3K8 seems to 
coincide with the increase in MAP3K8 activation. It is believed that the activation of 
IKK induced by IL-1β in A549 cells leads to the phosphorylation of NF-κB-1/p105 
and its degradation, which releases MAP3K8 from a complex with NF-κB-1/p105 and 




The Role of MAP3K8 in Regulation of IL-1β-Induced Inflammatory 
Response in Respiratory Epithelial Cells 
  
4.1 Introduction 
    The mitogen activated protein (MAP) kinase signal transduction pathway plays a 
crucial role in many aspects of immune mediated inflammatory responses
56
. MAP 
kinases, a large family of serine/threonine kinases, constitute major inflammatory 
signalling from the initiation phase of innate immunity, to activation of adaptive 
immunity and to cell death
147
. Activation of MAP kinases results in the 
phosphorylation and subsequent activation of transcription factors such as activating 
protein 1 (AP-1) and NF-κB, producing altered gene transcription148. Products of 
inflammatory genes, cytokines and chemokines, recruit immune-competent cells from 
the circulation to the affected site resulting in an inflammatory response. 
In mammals, three major MAPK pathways have been identified: MAPK/ERK, 
SAPK/JNK, and p38 MAPK. The ERK1/2 signalling module is a vital mediator of 
cellular fates including growth, proliferation and survival. The ERK1/2 cascade is 
known to be activated by a variety of stimuli including growth factors, mitogens and 
oxidative stress. In this cascade, MEK1/2 functions as upstream MAPKK and the Raf 
proteins as MAPKKK. The most important role of ERK1/2 signalling is to regulate 
the activation of the AP-1 family of transcription factors such as c-Jun, c-Fos and 
activating transcription factor 2 (ATF-2)
149
. ERK1/2 has been shown to be involved in 
many of the inflammatory processes associated with asthma and COPD. The role of 
ERK1/2 in proliferation of airway smooth muscle cells has been proved to be 
inappropriately enhanced in asthmatic airways
150
. ERK1/2 signalling is also involved 






The SAPK/JNK signalling pathway is a cell stress activated pathway and is 
involved in the regulation of cell proliferation and apoptosis. Two MAPKK proteins, 
MKK4 and MKK7, act as upstream JNK activators and are activated by multiple 
upstream MAPKKK kinases including MEKK and the mixed lineage kinases (MLKs) 
groups. The SAPK/JNK cascade appears to be essential for AP-1 c-Jun activation 
caused by inflammatory cytokine stimulation
152
. In patients with severe asthma, 
increased expression of AP-1 and enhanced JNK activity have been reported
106
. In 
addition, a SAPK/JNK inhibitor has also been shown to reduce arthritis inflammatory 
symptoms
153
 and several inflammatory mediators of lipopolysaccharide-induced lung 
injury in animal models
154
. These findings indicate that the inhibition of the 
SAPK/JNK cascade may be effective in airway inflammatory diseases such as asthma 
and COPD. 
The p38 MAPK signalling pathway is associated with cell growth, cell 
differentiation, cell death and inflammation. The activation of p38 MAPK occurs 
through two upstream MAPKKs, MKK3 and MKK6. In contrast, there is a large 
group of proteins acting as MAPKKK, which are activated by a wide variety of 
stimuli including inflammatory cytokines, growth factors and oxidative stress
56
. 
Increased p38 MAPK activation has been found in the epithelial cells of patients with 
severe asthma and it is also a feature of macrophages from patients with COPD
103,155
. 
In immune-based asthma models, the inhibition of p38 MAPK has been shown to 
inhibit bronchial hyper-responsiveness, allergic inflammation and airway 
remodeling
156
. Thus p38 MAPK probably plays a crucial role in the regulation of 
inflammatory response in airway diseases. 
    MAP3K8 is a member of serine/threonine protein kinase family and has been 
demonstrated to involve mitogen activated protein kinase (MAPK) pathway. The 
 107 
 
interaction of MAP3K8 with the NF-kB1/p105 prevents MAP3K8 from accessing its 
substrate MAPK/ERK kinase (MEK) and greatly inhibits the phosphorylation and 
activation of MEK (upstream kinase of ERK)
118
. MAP3K8 has been shown to activate 
not only ERK1/2 and SAPK/JNK pathways but also the NF-κB pathway in a cell-type 
and stimulus-specific manner
125
 (Chapter 1, Sections 1.5). RNA interference (RNAi) 
is a powerful technique that has been used for applications in biotechnology, 
particularly in the study of functional genomics and potential as therapeutics
157
.  
MAP3K8 is hypothesized to play an important role in the regulation of 
inflammatory response in airway inflammation. In order to explore the effect of 
MAP3K8 on inflammatory response, a MAP3K8 gene knockdown experiment was 
carried out to clarify the relationship between MAP3K8 and the inflammatory 
mediators including IL-6, IL-8 and RANTES. The regulation of MAP3K8 and 




4.2 Material and Methods 
4.2.1 Culture of Cell Lines 
    A549 cells were obtained from the American Type Culture Collection (ATCC). 
They were cultured as described in Chapter 2, Section 2.2.1. A549 cells were used at 
passage numbers 90-110. Cell viability was determined microscopically by trypan 
blue (Sigma-Aldrich) exclusion and the number of cells counted using a 
haemocytometer (see Section 2.2.2). Cells were sub-seeded in appropriate culture 
vessels (6- or 24-well plates) and incubated at 37°C for 24 hrs prior to all treatments if 
necessary. 
 
4.2.2 RNA Interference 
    RNA interference (RNAi) was carried using ON-TARGETplus SMARTpool, 
against MAP3K8 (Dharmacon Research Inc., Lafayette, CO). ON-TARGETplus 
Non-targeting Pool negative control (Dharmacon Research Inc., Lafayette, CO) were 
used as controls in the experiments. RNAi transfection of A549 cells was carried out 
using Lipofectamine RNAiMAX (Invitrogen Corp.) as described in Chapter 2, 
Section 2.2.9. Knockdown efficiency of MAP3K8 was then confirmed on RNA and 
protein level using quantitative real-time PCR and protein blot analysis, respectively. 
 
4.2.3 IL-1β Stimulation – Times Series Experiments 
After double transfection, cells were starved in serum free medium for 16 hrs and 
then stimulated with 1 ng/ml of IL-1. The response of IL-1 stimulation was 
measured at 0, 2, 4, 6, 8 and 24 hrs with each time point being done in triplicate. Post 
IL-1 stimulation at time point 0, plates were incubated at 37 oC with 5% CO2 for the 
appropriate length of time (2, 4, 6, 8 and 24 hrs). The supernatants were harvested for 
IL-6, IL-8 and RANTES release measurement at 8 and 24 hrs. The cell-free 
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supernatants post-stimulation were then stored at -80
o
C for further cytokine 
measurements using enzyme-linked immune-sorbent assays (ELISA). IL-6, IL-8 and 
RANTES were measured using ELISA kits according to the manufacturer’s 
instructions (DuoSet; R&D Systems Europe; Abingdon, Oxon, UK) as described in 
Chapter 2, Section 2.2.5. At the same time, cells were collected at 2, 4 and 6 hrs and 
RNA was then extracted from these cells for IL-6, IL-8 and RANTES mRNA 
expression measurement. Cell viability was also assessed at each time point using 
MTT as described in Chapter 2, Section 2.2.4.  
 
4.2.4 Quantitative Real-time Polymerase Chain Reaction (PCR)  
    Total RNA was isolated from A549 cells using the Qiagen RNeasy
®
 mini kit 
(Chapter 2, Section 2.2.6.1). Reverse transcription was performed using 0.5µg of 
RNA and cDNA was synthesized using the High-Capacity cDNA Reverse 
Transcription Kits (Chapter 2, Section 2.2.6.3). Real-time PCR was performed using 
the Rotor-Gene 3000™ Real-Time PCR detection system (Corbett Research, Sydney, 
Australia) as previously described in Section 2.2.6.4. Gene-specific primers for IL-6, 
IL-8, MAP3K8 and RANTES were used. Real-time PCR of GAPDH was performed 
to act as an internal control. Gene sequences of the primers used are given in Chapter 
2, Section 2.2.6.4, Table 2.2.1. Amplification conditions for these primers are 
described in Chapter 2, Section 2.2.6.4. The RT-PCR products were subjected to 
agarose gel electrophoresis to identify the target band. Calculation of the threshold 
value, standard curve preparation and quantification of mRNA in the samples were 
performed by the Rotor-Gene 6.0 software provided by Corbett Research.  
 
4.2.5 Western Blotting  
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    Western blot analysis was performed for the protein of the selected significant 
gene. Whole-cell protein extracts were prepared by using the Active Motif Nuclear 
Extract (Chapter 2, Section 2.2.8.1). Protein concentrations were determined using the 
BCA protein assay kit with bovine serum albumin as the standard control (Chapter 2, 
Section 2.2.8.2). Purified proteins were stored at -80
o
C in aliquots until required.  
For each use, an aliquot was thawed, used and any reminants remaining 
discarded after completion of the experiment. For Western blots, an equal amount of 
25 μg of protein for each sample was separated by sodium dodecyl sulfate 
polyacrylamide gel electrophoresis (SDS-PAGE), under reducing conditions, on a 
10% NuPAGE Novex Bis-Tris gel using the NuPAGE MOPS running buffer (Chapter 
2, Secion 2.2.8.3). After electrophoresis, protein transfers to nitrocellulose membranes 
were performed using the iBlot™ DryBlotting device and iBlot™ Transfer stacks as 
described in Chapter 2, Section 2.2.8.3 and 2.2.8.4. Primary antibodies against 
MEK1/2, p-MEK-1/2 (Santa Cruz) and p44/42 MAPK, phospho-p44/42 MAPK; 
SAPK/JNK, phospho-SAPK/JNK; p38 MAPK, phospho-p38 MAPK (Cell Signalling 
Technology) were used for immuno-detection as described in Chapter 2, Section 
2.2.8.5. For detecting alternative proteins on the same membranes, membranes were 
stripped of antibodies by incubation with 10 ml 1 x mild stripping buffer as described 
in Chapter 2, Section 2.2.8.5.  
 
4.2.6 Statistical Analysis  




4.3.1 Knockdown Efficiency of MAP3K8 in A549 Cells  
To establish the relationship between MAP3K8 and inflammatory mediators, 
RNAi-mediated knockdown of MAP3K8 gene was performed. The small interfering 
RNA (siRNA) effects on MAP3K8 gene silencing were assessed by performing a 
real-time PCR assay and Western Blot. 
Lipofectamine RNAiMAX reagent was used for the transfection of A549 cells. 
Cell viability of A549 cells at different concentrations of Lipofectamine RNAiMAX 
reagent was established by the MTT assay. RNA interference assays were done in 
96-well plates with 10 nM non-targeting siRNA at different concentrations of 
Lipofectamine RNAiMAX reagent from 0.5-3 μg/ml for 48 hrs (double transfection, 
Chapter 2, Section 2.2.9). As shown in Figure 4.3.1, Lipofectamine RNAiMAX 
reagent showed low cell toxicity (>80% viability). Two µg/ml of Lipofectamine 
RNAiMAX was therefore selected for further experiments (> 90% viability). 
    
Figure 4.3.1 Cell Viability of A549 Cells at Different Concentrations of 
Lipofectamine RNAiMAX Reagents. MTT assay was performed to establish the 
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viability of the A549 cells in the presence of Lipofectamine RANiMAX. Experiments 
were performed in triplicate and data shown are mean  SEM of three separate 
experiments. *P<0.05 as compared to result for NT. NT, non-treat.  
 
Transfections of A549 cells with Lipofectamine RNAiMAX with MAP3K8 
siRNA or a non-targeting siRNA were performed. A non-targeting siRNA control is 
designed to have no gene targets in human, mouse and rat cells. RNA interference 
assays were done in 24-well plates (4x10
4
 cells/well) with 2 µg/ml of Lipofectamine 
RNAiMAX in the presence of MAP3K8 siRNA or a non-targeting siRNA at 50, 75 
and 100 nM. As shown in Figure 4.3.2, after 48 hrs transfection there was an 
approximate 50% reduction in MAP3K8 gene expression at 50 nM of siRNA. 
        
Figure 4.3.2 Knockdown Efficiency of MAP3K8 Gene at Different 
Concentrations of siRNA. MAP3K8/GAPDH expression was performed at 50, 75 
and 100 nM of siRNA in the presence of 2 µg/ml of Lipofectamine RANiMAX. 
Experiments were performed in triplicate and data shown are mean  SEM of three 
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separate experiments. *P<0.05 as compared to result for NT. NT, non-targeting 
siRNA. 
 
To validate the knockdown efficiency was caused by MAP3K8 targeting siRNA 
rather than Lipofectamine RNAiMAX delivery, the MAP3K8 gene expression was 
compared between control, Lipofectamine RNAiMAX only and non-targeting siRNA 
using real-time PCR. As shown in Figure 4.3.3 A, there was no significant difference 
in MAP3K8 gene expression between control, Lipofectamine RNAiMAX only and 
the non-targeting siRNA. At the same time, there was an approximate 85% 
knockdown efficiency at 48 hr transfection in GAPDH (Figure 4.3.3 B), indicating 
that the transfection efficiency was successful and efficient using 50 nM siRNA. 
 
Figure 4.3.3 Comparison of MAP3K8 (A) and GAPDH (B) Gene Expression 
between Control, Lipofectamine RNAiMAX only and Non-targeting siRNA in 
A549 Cells. No significant difference in MAP3K8 gene expression was found 
between control, Lipofectamine RNAiMAX only and the non-targeting siRNA. An 
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approximately 85% knockdown efficiency was found at 48 hr transfection in 
GAPDH. Data shown are mean  SEM of four separate experiments. *P<0.05 as 
compared to NT. NS, non-stimulated; NT, non-targeting siRNA.  
 
MAP3K8 expression at 48 hr after gene knockdown was examined by real-time 
PCR and Western blot. As shown in Figure 4.3.4 A, compared with non-targeting 
siRNA, approximately 40% reduction in MAP3K8 gene expression was found in the 
presence of 50 nM MAP3K8 siRNA (Dharmacon). For MAP3K8 protein expression 
analysis, whole cell proteins were extracted from A549 cells transfected with 
transfection reagent alone (Mock), non-targeting control siRNA or MAP3K8 targeting 
siRNA. Beta actin protein levels were used as a control for protein loading. As shown 
in Figure 4.3.4 B, two isoforms of MAP3K8 were identified and MAP3K8 proteins 
remained unchanged in the mock treated and control siRNA-treated cells. Compared 
with non-targeting siRNA, an approximately 40% reduction in MAP3K8 protein 





Figure 4.3.4 MAP3K8 mRNA Expression (A) and Protein (B) after Gene 
Silencing in A549 Cells. An approximately 40% knockdown efficiency was 
significantly found at 48 hr transfection in MAP3K8. Data are shown as mean  SEM 
of six separate experiments. *P<0.05 as compared to NT. NT, non-targeting siRNA. 
 
4.3.2 Effect of MAP3K8 Gene Silencing on IL-6, IL-8 and RANTES mRNA 
Expression and Protein Release  
 
To establish the effect of MAP3K8 gene silencing on inflammation-associated 
cytokines, the mRNA expression and protein release of IL-6, IL-8 and RANTES after 
IL-1β stimulation were determined by real-time PCR and ELISA respectively. The 
IL-1 stimulation experiments were conducted on A549 cells after MAP3K8 gene 
silencing. First, the MTT assay was performed to establish the viability of the A549 
cells at 8 and 24 hrs after 1 ng/ml IL-1 stimulation. As shown in Figure 4.3.5, 
compared with non-targeting siRNA control, the MAP3K8 gene silencing does not 
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appear to influence A549 cell viability significantly therefore subsequent experiments 
are valid and results seen are not due to problems in cell viability. 
 
Figure 4.3.5 Cell Viability Assay of A549 Cells with IL-1β Stimulation after 
MAP3K8 Gene Silencing. No significant difference in cell viability was found 
between MAP3K8 gene silencing and non-targeting siRNA groups (P>0.05). 
Experiments were performed in triplicate and data shown are mean  SEM of three 
separate experiments. 
 
    For real-time PCR analysis, RNA extracted from A549 cells was collected at 
time points 2, 4 and 6 hrs. For ELISA analysis, the supernatants were collected at time 
points 8 and 24 hrs. All experiments were replicated with at least three independent 
cell passages. A significant reduction in IL-6 (Figure 4.3.6 A), IL-8 (Figure 4.3.7 A) 
and RANTES (Figure 4.3.8 A) mRNA expression was found at 4 hrs after IL-1 
stimulation. Furthermore, a significant reduction in IL-6 (Figure 4.3.6 B), IL-8 
(Figure 4.3.7 B) and RANTES (Figure 4.3.8 B) protein release was found at both 8 




Figure 4.3.6 Effect of MAP3K8 Gene Silencing on IL-6 mRNA Expression (A) 
and Protein Release (B) in A549 Cells. A significant reduction in IL-6 mRNA 
expression and protein release was found after MAP3K8 gene silencing. Data shown 
are mean  SEM of four separate experiments. *P<0.05 versus Non-targeting siRNA. 
 
Figure 4.3.7 Effect of MAP3K8 Gene Silencing on IL-8 mRNA Expression (A) 
and Protein Release (B) in A549 Cells. A significant reduction in IL-8 mRNA 
expression and protein release was found after MAP3K8 gene silencing. Data shown 




Figure 4.3.8 Effect of MAP3K8 Gene Silencing on RANTES mRNA Expression 
(A) and Protein Release (B) in A549 Cells. A significant reduction in RANTES 
mRNA expression and protein release was found after MAP3K8 gene silencing. Data 
shown are mean  SEM of four separate experiments. *P<0.05 versus Non-targeting 
siRNA. 
 
4.3.3 Effect of MAP3K8 on MAPK Signalling Pathway 
4.3.3.1 MAPK Phosphorylation Regulated by IL-1β 
A time series analysis of MAPK phosphorylation after IL-1β stimulation was 
assessed. After IL-1β stimulation, the A549 cells were harvested and proteins were 
extracted at 5, 10, 20, 30, 45 and 60 min. As shown in the graphs below, both the 
phosphorylation of ERK1/2 (Figure 4.3.9) and SAPK/JNK (Figure 4.3.10) increased 
significantly after 10 min of IL-1β stimulation. p38 MAPK phosphorylation (Figure 




Figure 4.3.9 ERK1/2 Phosphorylation in IL-1β-treated A549 Cells. 
Phosphorylation of ERK1/2 increased significantly after 10 min of IL-1β stimulation. 
Data shown are mean  SEM of three separate experiments. *P<0.05 as compared to 
0 min. 
 
Figure 4.3.10 SAPK/JNK Phosphorylation in IL-1β-treated A549 Cells. 
Phosphorylation of SAPK/JNK increased significantly after 10 min of IL-1β 
stimulation. Data shown are mean  SEM of three separate experiments. *P<0.05 as 





Figure 4.3.11 p38 MAPK Phosphorylation in IL-1β-treated A549 Cells. 
Phosphorylation of p38 MAPK increased significantly after 5 min of IL-1β 
stimulation. Data shown are mean  SEM of three separate experiments. *P<0.05 as 
compared to 0 min. 
 
    Since the phosphorylation of MAPK seems to occur gradually after 10 min of 
IL-1β stimulation, a comparison of P-MAPK between MAP3K8 gene silencing and 
controls was assessed at time points 20 and 30 min. 
 
4.3.3.2 Effect of MAP3K8 Gene Silencing on MAPK Phosphorylation 
    RNAi-mediated knockdown of MAP3K8 gene in A549 cells was performed and 
MAP3K8 protein expression at 20 and 30 min after IL-1β stimulation was assessed 
using Western blots to ensure there had been successful gene knockdown. As shown 
in Figure 4.3.12, siRNA against MAP3K8 resulted in ~50% reduction of MAP3K8 




Figure 4.3.12 MAP3K8 Protein Expression at Different Time Points following 
IL-1β Stimulation after MAP3K8 Gene Silencing in A549 Cells. MAP3K8 protein 
expression shown at different time points is compared with non-targeting siRNA at 0 
min. MAP3K8 gene silencing resulted in significant reduction of MAP3K8 protein 
expression at different time point. Data shown are mean  SEM of three separate 
experiments. *P<0.05 as compared to non-targeting siRNA. 
 
    A comparison of MAPK between MAP3K8 gene silencing and controls was 
conducted. Compared with non-targeting siRNA, a significant (20%) decrease in 
phosphorylation of ERK1/2 was found in A549 cells with MAP3K8 gene silencing at 
30 min after IL-1β stimulation (Figure 4.3.13). Similar results were obtained with 
SAPK/JNK phosphorylation (Figure 4.3.14). There was however no significant 
difference in P-p38 MAPK between MAP3K8 gene silencing and controls at 20 and 




Figure 4.3.13 Comparison of P-ERK1/2 between MAP3K8 Gene Silencing and 
Controls at Varying Time Points after IL-1β Stimulation. A significant decrease in 
phosphorylation of ERK1/2 was found in A549 cells with MAP3K8 gene silencing. 





Figure 4.3.14 Comparison of P-SAPK/JNK between MAP3K8 Gene Silencing 
and Controls at Varying Time Points after IL-1β Stimulation. A significant 
decrease in phosphorylation of SAPK/JNK was found in A549 cells with MAP3K8 
gene silencing. Data shown are mean  SEM of eight separate experiments. *P<0.05 




Figure 4.3.15 Comparison of P-p38 MAPK between MAP3K8 Gene Silencing 
and Controls at Varying Time Points after IL-1β Stimulation. No significant 
decrease in phosphorylation of p38 MAPK was found in A549 cells with MAP3K8 
gene silencing. Data shown are mean  SEM of nine separate experiments. 
 
4.3.3.3 MEK1/2 and MKK4/7 Phosphorylation Regulated by IL-1β 
A time series analysis of MEK1/2 and MKK4 phosphorylation after IL-1β 
stimulation was conducted. After IL-1β stimulation, the A549 cells were harvested 
and proteins extracted at 5, 10, 20, 30, 45 and 60 min. As shown in Figure 4.3.16, the 
phosphorylation of MEK1/2 increased significantly after 20 min of IL-1β stimulation. 
Similar results were obtained with MKK4 phosphorylation. The phosphorylation of 





Figure 4.3.16 MEK1/2 Phosphorylation in IL-1β-treated A549 Cells. 
Phosphorylation of MEK1/2 increased significantly after 20 min of IL-1β stimulation. 
Data shown are mean  SEM of three separate experiments. *P<0.05 as compared to 
0 min.  
 
 
Figure 4.3.17 MKK4 Phosphorylation in IL-1β-treated A549 Cells. 
Phosphorylation of MKK4 increased significantly after 20 min of IL-1β stimulation. 





Figure 4.3.18 MKK7 Phosphorylation in IL-1β-treated A549 Cells. 
Phosphorylation of MKK7 increased significantly after 20 min of IL-1β stimulation. 
Data shown are mean  SEM of three separate experiments. *P<0.05 as compared to 
5 min. 
 
    As the phosphorylation of MEK1/2 and MKK4/7 occurs significantly after 20 
min of IL-1β stimulation, a comparison of P-MEK1/2 and P-MKK4/7 between 
MAP3K8 gene silencing and controls was done at time points of 20 and 30 min. 
 
4.3.3.4 Effect of MAP3K8 Gene Silencing on MEK1/2 and MKK4/7 
    Next a comparison of P-MEK1/2 and P-MKK4/7 between MAP3K8 gene 
silencing and controls was conducted. Compared with non-targeting siRNA, there was 
a significant (30%) decrease in phosphorylation of MEK1/2 (Figure 4.3.19) and a 
60% decrease in phosphorylation of MKK4 (Figure 4.3.20) at 30 min after IL-1β 
stimulation in A549 cells with MAP3K8 gene silencing. There was however no 
significant difference in phosphorylation of P-MKK7 between MAP3K8 gene 




Figure 4.3.19 Comparison of P-MEK1/2 between MAP3K8 Gene Silencing and 
Controls at Variable Time Points after IL-1β Stimulation. A significant decrease in 
phosphorylation of MEK1/2 was found in A549 cells with MAP3K8 gene silencing. 





Figure 4.3.20 Comparison of P-MKK4 between MAP3K8 Gene Silencing and 
Controls at Variable Time Points after IL-1β Stimulation. A significant decrease in 
phosphorylation of MKK4 was found in A549 cells with MAP3K8 gene silencing. 





Figure 4.3.21 Comparison of P-MKK7 between MAP3K8 Gene Silencing and 
Controls at Variable Time Points after IL-1β Stimulation. No significant decrease 
in phosphorylation of MKK7 was found in A549 cells with MAP3K8 gene silencing. 




    RNAi using siRNA mediated gene silencing provides a new reliable method to 
investigate gene function and is currently the most widely used gene-silencing 
technique in functional genomics
157
. Gene knockdown of 70% or greater is usually 
necessary for functional analysis. Several reports however indicate that siRNA 
concentrations of 100 nM or higher in mammalian cultured cells can lead to 
non-specific changes in gene expression
158
. Using the lowest possible siRNA 
concentration appears to minimize non-specific effects and further reduce the chance 
of eliciting off-target effects
159
. A series of varying siRNA concentrations was carried 
out in this study and 50 nM of MAP3K8 siRNA showed the best knockdown 
efficiency. Double transfection, the initial siRNA transfection of cell suspensions 
followed by re-transfection of adherent cells on the following day, showed more 
consistent knockdown in A549 cells. 
    It has previously been reported that knockdown of MAP3K8 in B cells is 
unsuccessful
160
, whilst only 50% of knockdown efficiency was found in T cells by 
electroporation
161
. In this study, only approximately 40% MAP3K8 knockdown 
efficiency was achieved in A549 cells despite having 80% siRNA delivery efficiency 
assessed by monitoring of GAPDH gene expression. In adherent cells, lipid-mediated 
transfection is believed to have good delivery efficiency as in this study. The low 
MAP3K8 knockdown efficiency in A549 cells may be because MAP3K8 eludes the 
knockdown by the siRNA through other unknown mechanisms. 
    The inhibition of MAP3K8 in primary human cell types has been shown to 
decrease the production of TNF-α and other pro-inflammatory mediators such as IL-6 
and IL-8 during inflammatory events
162
. Among these mediators, IL-6 has been shown 
to amplify the inflammatory process of COPD
19
. Furthermore, neutrophils 
chemo-attracted mainly by IL-8 have been found in the airways of patients with 
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COPD and severe asthma patients
137
. In this present study (Chapter 4), 
RNAi-mediated knockdown of the MAP3K8 gene in A549 cells was found to result in 
a significant reduction in IL-6, IL-8 and RANTES release (protein) and mRNA 
expression after IL-1 stimulation. Despite the limitations of a modest 40% reduction 
in MAP3K8 gene expression and protein levels, there were still significant decreases 
in IL-6, IL-8 and RANTES expression and release. These results indicate that 
MAP3K8 may play an important role in the regulation of airway epithelial cells in 
response to inflammation. The inhibition of MAP3K8 may potentially be a new 
therapeutic strategy for airway inflammation. 
    The SAPK/JNK signalling pathway is strongly activated in response to 
cytokines, UV irradiation and growth factors. Like the SAPK/JNK, the mammalian 
p38 MAPK signalling pathway is also activated by environmental stresses and 
inflammatory cytokines such as IL-1β and TNF-α. Nevertheless, the activation of 
ERK1/2 mediates cell proliferation in response to mitogens and growth factors
163
. 
IL-1β, a pro-inflammatory cytokine, has been shown to activate all of these MAPK 
pathways in many cell types
164,165
. In this study, the activation of MAPK was found 
when A549 cells were stimulated with IL-1β which is consistent with other 
reports
59,166
. Furthermore, after MAP3K8 gene silencing, there was only a noticeable 
decrease in the phosphorylation of MEK1/2-ERK1/2 and MKK4-SAPK/JNK 
observed, indicating that MAP3K8 appears to regulate the inflammatory response by 
ERK1/2 and SAPK/JNK pathways but not the p38 MAPK pathway. Although the 
signalling role of MAP3K8 has been shown to depend on the cell type and to be also 
stimulus-specific, the findings obtained in A549 cells in this study (Chapter 4) are 
compatible with the results of the study in the MAP3K8-deficient mouse embryo 
fibroblasts stimulated with TNF-α125. The biological functions of the MAP kinase 





. This provides a clue that the suppression of ERK1/2 and SAPK/JNK 
signalling pathways caused by MAP3K8 inhibition may also be an alternative in 
treating airway inflammation. 
In this study, MAP3K8 shows to play an important role in the regulation of 
airway epithelial cells in response to inflammation. Furthermore, MAP3K8 regulates 
the inflammatory response by ERK1/2 and SAPK/JNK pathways but not the p38 
MAPK pathway. The overview of the activation of MAPK signalling pathways 
regulated by MAP3K8 in IL-1β-induced A549 cells based on the results of this 
current study is shown in Figure 4.4.1. 
 
 
Figure 4.4.1 Overview of the Activation of MAPK Signalling Pathways Regulated 
by MAP3K8 in IL-1β-Stimulateded A549 Cells. Stimulation with IL-1β induces the 
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phosphorylation of MAP3K8, which regulates the release of inflammatory cytokines 
including IL-6, IL-8 and RANTES through the activation of MEK1/2-ERK1/2 and 




The Effect of MAP3K8 Inhibition on Corticosteroid Suppression of 
the Inflammatory Response 
 
5.1 Introduction 
Airway inflammation, integral and intimately linked to the process of epithelial 
injury, is the prominent feature in both asthma and COPD. Corticosteroids are the 
cornerstone of current treatments of airway inflammation. They are however 
ineffective in suppressing pulmonary inflammation in COPD. Although 
corticosteroids are by far the most effective controllers for the treatment of asthma, 
they may not provide adequate asthma control in patients with severe persistent 
asthma
169
. In addition, there is increasing evidence that neutrophilic inflammation, 
which is poorly responsive to corticosteroids, plays a major role in the pathogenesis of 
asthma exacerbations
170
. In these cases, a certain degree of airway inflammation is 
always present. On the other hand, kinases are believed to play a crucial role in the 
expression and activation of inflammatory mediators in the airway. Selective MAP 




Inhaled corticosteroids are currently the most effective anti-inflammatory 
medication for asthma treatment. Inhaled corticosteroids may suppress the 
transcription of several activated inflammatory genes in airway epithelial cells and 
thus reduce inflammation in the airway wall. Multiple inflammatory genes that 
encode for cytokines, chemokines, adhesion molecules, inflammatory enzymes and 
receptors, are primarily switched off by the inhibition of transcriptional factors such 
as nuclear factor-κB (NF-κB) and activating protein-1 (AP-1) (Chapter 1, Section 
1.3.4). Corticosteroids also have potent inhibitory effects on MAPK signalling 
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pathways through the induction of mitogen-activated protein kinase phosphatase 
(MKP)-1
86
. MKP-1 plays a critical role in the regulation of pro-inflammatory 
cytokines synthesis via the inhibition of all MAP kinases (Chapter 1, Section 1.3.5). 
MKP-1 has been shown to have specificity toward p38 and c-Jun N-terminal kinase 
(JNK) over extracellular-signal-regulated kinase (ERK), indicating that the selectivity 
of MKP-1 for different MAP kinases appears to vary from cell to cell
92
. In A549 cells, 
repression of ERK1/2 and p38 MAPK phosphorylation by MKP-1 has been 
confirmed by using adenoviral-mediated overexpression
171
. 
In this study (Chapter 4), MAP3K8 gene silencing has been shown to result in a 
significant reduction in the release of inflammatory mediators such as IL-6, IL-8 and 
RANTES by ERK1/2 and SAPK/JNK signalling pathways in IL-1-induced A549 
cells. Dexamethasone (Dex), a potent synthetic glucocorticoid, has been widely used 
in inflammatory, allergic, and autoimmune diseases. MAP3K8 inhibition is 
hypothesized to provide additive therapeutic effect of corticosteroid on airway 
inflammation. In this chapter in order to explore the effect of MAP3K8 inhibition on 
corticosteroid suppression of the inflammatory response, a combination of MAP3K8 
gene silencing and dexamethasone administration is assessed in an IL-1β-induced 
inflammatory response in respiratory epithelial cells. In addition, the interaction of 
MAP3K8 with corticosteroid suppression of the inflammatory response via MKP-1 




5.2 Material and Methods 
5.2.1 IL-1β Stimulation – Concentration Response of Dexamethasone  
    A total number of 4x10
5
 for 6-well plates and 5x10
4
 for 24-well plates A549 cells 
were seeded into each well in 2 ml and 1 ml of complete medium respectively 
overnight for cells to attach and grow. Before the addition of the IL-1 stimulus, the 
cells were starved with serum-free media for 24 hrs to obtain cell cycle 











 M and 10
-5
 M of dexamethasone (Sigma-Aldrich) for one hour 
respectively followed by 1ng/ml IL-1 stimulation. Cell-free supernatants were 
harvested at 24 hrs after IL-1β stimulation. Cytokine levels including IL-8 and 
RANTES were determined and concentration-response analyses performed 
simultaneously. 
 
5.2.2 IL-8 and RANTES Measurement by ELISA 
Cell-free supernatants post-stimulation were harvested and stored at -80
o
C for 
further cytokine measurements using enzyme-linked immunosorbent assays (ELISA). 
IL-8 and RANTES were measured using ELISA kits as described (Chapter 2, Section 
2.2.5). Cell viability was also assessed at each time point using MTT as described in 
Chapter 2, Section 2.2.4.  
 
5.2.3 RNA Interference 







 M of dexamethasone pre-treatment were performed and cell-free supernatants 
were harvested at 24 hrs after 1ng/ml IL-1 stimulation for IL-8 and RANTES 
determination. RNAi transfection of A549 cells was carried out with using 
Lipofectamine RNAiMAX (Invitrogen Corp.) as described in Chapter 2, Section 
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2.2.9. After double transfection, cells were starved in serum free medium for 16 hrs 
and then stimulated with 1 ng/ml of IL-1. Cells were collected and proteins were 
extracted for Western blot analysis. At the same time, supernatants were harvested for 
IL-8 and RANTES release measurement. 
 
5.2.4 Western Blotting 
    Whole-cell protein extracts were prepared by using the Active Motif Nuclear 
Extract (Chapter 2, Section 2.2.8.1). Protein concentrations were determined using the 
BCA protein assay kit with bovine serum albumin as the standard control (Chapter 2, 
Section 2.2.8.2). For Western blots, an equal amount of 25 μg of protein for each 
sample was separated by sodium dodecyl sulfate polyacrylamide gel electrophoresis 
(SDS-PAGE), under reducing conditions, on a 10% NuPAGE Novex Bis-Tris gel 
using the NuPAGE MOPS running buffer (Chapter 2, Secion 2.2.8.3). After 
electrophoresis, protein transfer to nitrocellulose membranes was performed using the 
iBlot™ DryBlotting device and iBlot™ Transfer stacks as described in Chapter 2, 
Section 2.2.8.3 and 2.2.8.4. Primary antibodies against MKP-1, MEK1/2, p-MEK-1/2 
(Santa Cruz) and p44/42 MAPK, phospho-p44/42 MAPK (Erk1/2) (Cell Signalling 
Technology) were used for immuno-detection as described in Chapter 2, Section 
2.2.8.5. For detecting alternative proteins on the same membranes, membranes were 
stripped of antibodies by incubation with 10 ml 1 x mild stripping buffer as described 
in Chapter 2, Section 2.2.8.5.  
 
5.2.5 Statistical Analysis 




5.3.1 Cell Viability after a Combination of Dexamethasone and IL-1β Stimulation 










 M and 
10
-5
 M of dexamethasone (Sigma-Aldrich) for one hour respectively followed by 
1ng/ml IL-1 stimulation. MTT assay was performed to establish the viability of the 
A549 cells at 24 hrs after IL-1 stimulation (Figure 5.3.1).  
 
Figure 5.3.1 Cell Viability of A549 Cells after Stimulation by a Combination of 
Dexamethasone and IL-1β Stimulation. MTT assay was performed to establish the 
viability of the A549 cells in the presence of different concentration of dexamethasone 
pre-treatment. Experiments were performed in triplicate and data shown are mean  
SEM of three separate experiments. NS, non-stimulated; NT, non-treat. 
 
As shown in Figure 5.3.1, the pre-treatment with dexamethasone does not 
appear to influence A549 cell viability significantly therefore subsequent experiments 
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are valid and results seen are not due to problems in cell viability. All experiments 
were replicated at a minimum three times with independent cell passages. 
 
5.3.2 Effect of Dexamethasone on IL-1β-induced IL-8 and RANTES Release 
    A concentration-dependent decrease in IL-8 expression was found in A549 cells 
with differing concentrations of dexamethasone (Figure 5.3.2 A and B). There was a 





 M.  
         
Figure 5.3.2 Effect of Dexamethasone on Concentration (A) and Percent (B) of 
IL-8 Release in A549 Cells. A significant difference in IL-8 release from baseline at 
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 M. The half maximal 





 M respectively. Data shown are mean  SEM of four separate experiments. 
***P<0.0001 as compared to treatment without Dex. 
 
    Similar results were obtained with RANTES release. A concentration-dependent 
decrease in RANTES expression was found in A549 cells with differing 
concentrations of dexamethasone (Figure 5.3.3 A and B). There was a significant 





 M.  
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Figure 5.3.3 Effect of Dexamethasone on Concentration (A) and Percent (B) of 
RANTES Release in A549 Cells. A significant difference in RANTES release from 




 M. The half 
maximal inhibitory concentration (IC50) and maximal inhibitory concentration is 
1.14x10
-8
 M and 10
-6
 M respectively. Data shown are mean  SEM of four separate 




As shown in Figure 5.3.2 and Figure 5.3.3, the inhibition of IL-1-induced 
inflammatory cytokine release from A549 cells by dexamethasone was found to result 
in a significant reduction in both IL-8 and RANTES release. The decrease in IL-8 and 





5.3.3 Effect of a Combination of Dexamethasone and MAP3K8 Gene Silencing on 
IL-1β-induced IL-8 and RANTES Release 
    In order to investigate the effect of MAP3K8 inhibition on corticosteroid 
suppression of the inflammatory response, the release of IL-1-induced IL-8 and 
RANTES was assessed by using a combination of dexamethasone and MAP3K8 gene 




 M and 
10
-6
 M) were combined with MAP3K8 gene silencing.  





 M and 10
-6
 M of dexamethasone (Sigma-Aldrich) for one hour 
respectively and cell-free supernatants were harvested at 24 hrs after 1 ng/ml IL-1 
stimulation. A similar concentration-dependent decrease in IL-8 expression was found 
at different concentrations of dexamethasone in both non-targeting siRNA and 
MAP3K8 siRNA group (Figure 5.3.4 A). Compared with the non-targeting siRNA 
group at different concentrations of dexamethasone pre-treatment, there was a 
consistent decrease in IL-8 release in A549 cells with MAP3K8 gene silencing 




         
Figure 5.3.4 Effect of the Combination of Dexamethasone and MAP3K8 Gene 
Silencing on Percent (A) and Concentration (B) of IL-1β-induced IL-8 Release in 
Non-targeting siRNA and MAP3K8 siRNA. A549 cells were transfected by either 
non-targeting siRNA (■) or MAP3K8 siRNA (▼) for 48 hrs. Cells were then 
pre-treated with different concentrations of dexamethasone for one hour. Cell-free 
supernatants were harvested at 24 hrs after 1 ng/ml IL-1 stimulation. The IC50 value 
of dexamethasone for IL-8 reduction in combination with non-targeting siRNA or 
MAP3K8 siRNA is similar (3.4x10
-9
 M and 1.5x10
-9
 M, respectively). Data shown are 
mean  SEM of four separate experiments. *P<0.05 versus Non-targeting siRNA. 
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    A similar concentration-dependent decrease in RANTES expression was also 
found at different concentrations of dexamethasone in both non-targeting siRNA and 
MAP3K8 siRNA group (Figure 5.3.5 A). Compared with the non-targeting siRNA 
group at different concentrations of dexamethasone pre-treatment, there was a 
consistent decrease in RANTES release in A549 cells with MAP3K8 gene silencing 
(Figure 5.3.5 B).  
         
Figure 5.3.5 Effect of a Combination of Dexamethasone and MAP3K8 Gene 
Silencing on Percent (A) and Concentration (B) of IL-1β-induced RANTES 
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Release in Non-targeting siRNA and MAP3K8 siRNA Group. A549 cells were 
transfected either by non-targeting siRNA (■) or MAP3K8 siRNA (▼) for 48 hrs. 
Cells were then pre-treated with different concentrations of dexamethasone for one 
hour. Cell-free supernatants were harvested at 24 hrs after 1 ng/ml IL-1 stimulation. 
The IC50 value of dexamethasone for RANTES reduction in combination with 
non-targeting siRNA or MAP3K8 siRNA is similar (1.48x10
-8
 M and 1.54x10
-8
 M, 
respectively). Data shown are mean  SEM of four separate experiments. *P<0.05 
versus Non-targeting siRNA. 
 
    As shown in Figure 5.3.3 and Figure 5.3.5, the results show that partial gene 
silencing of MAP3K8 resulted in a significant decrease in IL-8 and RANTES release 
at different concentrations of dexamethasone pre-treatment. A similar IC50 value of 
dexamethasone for IL-8 or RANTES reduction was found in combination with 
non-targeting siRNA or MAP3K8 siRNA. These findings indicate that the suppression 
of MAP3K8 enhances the anti-inflammation effect of dexamethasone. It is likely that 
this is via a different mechanism to that of dexamathasone itself.  
 
5.3.4 MKP-1 Protein Expression Regulated by Dexamethasone and/or IL-1β 
Stimulation 
    Dexamethasone has been shown to induce MKP-1. In A549 cells, repression of 
ERK and p38 phosphorylation by MKP-1 was found using adenoviral-mediated 
over-expression. In order to explore the effect of MAP3K8 inhibition on 
corticosteroid suppression of the inflammatory response, a time series analysis of 
MKP-1 expression in A549 cells stimulated with dexamethasone (1 µM) alone, IL-1β 
(1 ng/ml) alone or a combination of both was assessed. For a combination of 
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dexamethasone and IL-1β, cells were pre-treated with dexamethasone for one hour 
directly followed by IL-1β stimulation. Whole cell proteins were collected at 0, 30, 60 
and 120 min after IL-1β stimulation.  
    The results show that in the presence of dexamethasone (Figure 5.3.6 A), IL-1 
(Figure 5.3.6 B) or both (Figure 5.3.6 C), MKP-1 expression was induced transiently 
peaking at 1 hr. With a combination of dexamethasone and IL-1, MKP-1 expression 
was enhanced relative to each treatment alone at 1 hr (Figure 5.3.7). 
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Figure 5.3.6 MKP-1 Expression in A549 Cells Stimulated with Dex (1 µM), IL-1 
(1 ng/ml) or a Combination of Both. MKP-1 expression was induced transiently 
peaking at 1 hr and was enhanced relative to each treatment alone (A and B) in 
comparison with a combination of dexamethasone and IL-1 (C). Data shown are 
mean  SEM of three separate experiments. *P<0.05 as compared to 0 min. 
 
        
Figure 5.3.7 MKP-1 Expression in A549 Cells Stimulated with Dex (1 µM), IL-1 
(1 ng/ml) or a Combination of Both at 60 min. MKP-1 expression was enhanced 
relative to each treatment alone at 1 hr in comparison with a combination of 
dexamethasone and IL-1. Data shown are mean  SEM of three separate 
experiments. *P<0.05 as compared to NS. NS, non-stimulated. 
 
5.3.5 Effect of Dexamethasone on IL-1β-induced MEK1/2-ERK1/2 and 
MKK4-SAPK/JNK Pathway Phosphorylation 
    A549 cells were pre-treated with dexamethasone (1 µM) for one hour and whole 
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cell proteins were collected at 0, 30 and 60 min after IL-1β (1 ng/ml) stimulation. The 
results show that although dexamethasone had no effect on MEK 1/2 (Figure 5.3.8 A) 
it did reduce the appearance of phosphorylated ERK1/2 (Figure 5.3.8 B) at 30 min 
and 1 hr after IL-1 stimulation. Similar results were obtained for the 
MKK4-SAPK/JNK pathway. Dexamethasone had no effect on MKK4 (Figure 5.3.9 
A) at 30min and 1 hr after IL-1 stimulation but it did reduce the appearance of 
phosphorylated SAPK/JNK (Figure 5.3.9 B) at 30 min. 
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Figure 5.3.8 Effect of Dex and IL-1 on MEK1/2-ERK1/2 Pathway 
Phosphorylation. Dexamethasone showed no effect on the phosphorylation of MEK 
1/2 (A) in the presence of IL-1β. However, dexamethasone significantly reduced the 
appearance of phosphorylated ERK1/2 (B) at 30 min and 1 hr after IL-1 stimulation. 
Data shown are mean  SEM of three separate experiments. *P<0.05 as compared to 
IL-1β stimulation alone. 
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Figure 5.3.9 Effect of Dex and IL-1 on MKK4-SAPK/JNK Pathway 
Phosphorylation. Dexamethasone showed no effect on the phosphorylation of 
MKK4 (A) in the presence of IL-1β. However, dexamethasone significantly reduced 
the appearance of phosphorylated SAPK/JNK (B) at 30 min after IL-1 stimulation. 
Data shown are mean  SEM of three separate experiments. *P<0.05 as compared to 
IL-1β stimulation alone.  
 
5.3.6 Comparison of the Effect of Dexamethasone on MAPK Phosphorylation 
between MAP3K8 Gene Silencing and Controls 
    A549 cells were pre-treated with dexamethasone (1 µM) for one hour and whole 
cell proteins were collected at 0 and 30 min after IL-1β (1 ng/ml) stimulation. The 
results show that dexamethasone reduced the phosphorylation of MAPK including 
ERK1/2, SAPK/JNK and p38 MAPK at 30 min after IL-1 stimulation. Furthermore, 
compared with Dex alone, a combination of Dex and MAP3K8 gene silencing in 
A549 cells was found to result in a greater inhibition of phosphorylated ERK1/2 
(Figure 5.3.10) and SAPK/JNK (Figure 5.3.11) but not p38 MAPK (Figure 5.3.12) 




Figure 5.3.10 Effect of the Combination of Dex and MAP3K8 Gene Silencing on 
ERK1/2 Phosphorylation. A combination of Dex and MAP3K8 siRNA significantly 
reduced the appearance of phosphorylated ERK1/2 at 30 min after IL-1 stimulation. 
Data shown are mean  SEM of four separate experiments. *P<0.05 as compared to 





Figure 5.3.11 Effect of the Combination of Dex and MAP3K8 Gene Silencing on 
SAPK/JNK Phosphorylation. A combination of Dex and MAP3K8 siRNA 
significantly reduced the appearance of phosphorylated SAPK/JNK at 30 min after 
IL-1 stimulation. Data shown are mean  SEM of four separate experiments. 





Figure 5.3.12 Effect of the Combination of Dex and MAP3K8 Gene Silencing on 
p38 MAPK Phosphorylation. A combination of Dex and MAP3K8 siRNA showed 
no significant effect on the phosphorylation of p38 MAPK at 30 min after IL-1 
stimulation in comparison with Dex with non-targeting siRNA. Data shown are mean 




Inflammatory mediators play a critical role in the pathogenesis of chronic airway 
diseases and facilitate the recruitment, activation and trafficking of inflammatory cells 
in the airways
136
. Airway epithelial cells are the major cellular target for inflammation 
in response to external stimuli. IL-8 is likely to be derived from airway epithelial cells 
and may be induced by viral infection, cigarette smoke, allergens and air pollutants. 
IL-8 is a potent chemokine that plays a key role in the recruitment and activation of 
neutrophils during inflammation
172
. Increased neutrophils are a feature of airway 
inflammation in COPD and severe asthma especially in patients during exacerbations, 
which appear to lead to resistance or poor response to corticosteroids
170,173
. For 
example, in severe exacerbations of asthma the number of neutrophils are 
significantly increased in both sputum and bronchial biopsies compared with those 
from individuals with stable disease
31,132
. A further study has also shown that the 
incidence of asthma exacerbations after inhaled corticosteroids withdrawal is 
associated with increased IL-8 and neutrophil levels
174
.  
Eosinophils may play quite an active role in the development of allergic airway 
inflammation
175
. Eosinophils accumulate in the airway under the influence of IL-5, 
GM-CSF, IL-8, RANTES, and eotaxin
176
. Among them, CCL5 (RANTES) is an 
important chemokine for eosinophils and makes a significant contribution to the 
movement of eosinophils from the peripheral blood to the sites of inflammation. 
RANTES is also expressed in airways of COPD patients during exacerbations
17
.  
    At a cellular level, corticosteroids reduce the numbers of inflammatory cells in 
the airways including eosinophils, T-lymphocytes and mast cells by inhibition of the 
recruitment of inflammatory cells by suppression of the production of chemotactic 
mediators such as IL-8 and RANTES. In this study of A549 cells, dexamethasone 
effectively inhibits IL-1β-induced IL-8 and RANTES expression consistent with 
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previous reports in human airway epithelial cells and smooth muscle cells
177,178
. More 
importantly, the suppression of MAP3K8 resulted in a greater reduction in 
dexamethasone down-regulated IL-8 and RANTES without influencing the effect of 
dexamethasone on the suppression of their release, suggesting that MAP3K8 
inhibition might be an alternative to poor response of corticosteroids in the treatment 
of airway inflammation. 
    Corticosteroids have been shown to reduce airway inflammation through 
inhibiting the MAPK signalling pathways by the induction of MKP-1. In A549 cells, 
repression of MAPK phosphorylation by MKP-1 has been well established
171
. In this 
current study, MKP-1 expression was induced by dexamethasone with a peak at 1 hr. 
Furthermore, MKP-1 expression was additive relative to each treatment alone at 1 hr 
with a combination of dexamethasone and IL-1 which is consistent with the previous 
findings that MAP kinases phosphorylation appears to clear at 1 hr after IL-1β 
stimulation (Chapter 4, Section 4.3.3.1). In this current study, dexamethasone reduced 
the IL-1β-induced phosphorylation of MAP kinases including ERK1/2 and 
SAPK/JNK. There was however no obvious change in phosphorylation of the 
upstream kinases of ERK1/2 and SAPK/JNK, MEK1/2 and MKK4. These findings 
suggest dexamethasone induced MKP-1 appears to inhibit MAP kinases only, rather 
than their upstream kinases. 
    In addition, after IL-1 stimulation, a combination of dexamethasone and 
MAP3K8 gene silencing resulted in a greater inhibition of phosphorylated ERK1/2 
and SAPK/JNK but not p38MAPK, compared to dexamethasone alone. These results 
are not only consistent with the previous findings that MAP3K8 regulates 
inflammatory response by ERK1/2 and SAPK/JNK but not the p38 MAPK pathways 
(Chapter 4) but they also indicate that the suppression of MAP3K8 enhances the 
anti-inflammation effect of dexamethasone via enhancement of the inhibition of 
 156 
 
MAPK signalling pathways through inhibition of their upstream kinases. 
In this study, MAP3K8 inhibition shows to provide additive therapeutic effect of 
corticosteroid on airway inflammation via additive inhibition of MAPK signalling 
pathways through inhibition of the upstream kinases of MAP kinases. The overview 
of the regulation of MAP3K8 inhibition on corticosteroid suppression of the 
inflammatory response in IL-1β-induced A549 cells based on the findings of this 
current study is shown in Figure 5.4.1.  
 
Figure 5.4.1 Regulation of MAP3K8 Inhibition on Corticosteroid Suppression of 
the Inflammatory Response. Glucocorticoids enter the cell to bind to glucocorticoid 
receptors (GR) in the cytoplasm that translocate to the nucleus. GR homodimers bind 
to glucocorticoid-response elements (GRE) in the promoter region of steroid-sensitive 
genes, which encodes anti-inflammatory protein of mitogen-activated protein (MAP) 
kinase phosphatase-1 (MKP-1). Glucocorticoid-induced MKP-1 regulates the 
phosphorylation of MAP kinases only, rather than their upstream kinases which are 
regulated by MAP3K8. Both dexamethasone and MAP3K8 invlove the regulation of 
 157 
 





Gene Expression Profiling and Network Analysis of MAP3K8 on 




    Microarray technologies have become a robust and widely accepted tool in 
inflammation research. The advantage of high-throughput microarray technologies is 
that they offer a new opportunity to gain insight into the global gene expression in 
inflammatory diseases, leading to the identification of new inflammatory 
disease-related genes and pathways
179
. Microarray analyses now allow the 
simultaneous examination of the expression of all known human genes from particular 
cells or tissues
180
. Microarray measurements at multiple time points can be used for 
the systematic identification of altered gene expression in response to particular 
stimuli. Furthermore, statistical analyses with clustering algorithms permit the 
identification of genes that are co-regulated in response to the stimulus
181,182
. 
Reference to known genes and to gene ontology databases also allows inference of the 
function of unknown genes within each gene cluster. To understand the molecular 
pathogenesis of airway diseases, a previous pilot time series study of global gene 
expression analysis following IL-1β-induced inflammation of human airway epithelial 
cell lines was carried out in the Molecular Genetics and Genomics group and a 
number of genes which may play major roles in the inflammatory response were 
identified, including MAP3K8. 
    In the previous experiments of this current project (Chapters 3 to 5 inclusive), 
MAP3K8 has been shown to play a key role in the inflammatory cytokine response 
post IL-1β stimulation. MAP3K8 gene silencing appears to result in a significant 
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reduction in inflammatory mediators via the ERK1/2 and SAPK/JNK signalling 
pathways in IL-1-induced A549 cells. The inhibition of MAP3K8 gene expression 
not only suppresses these key inflammatory cytokines but also appears to enhance the 
therapeutic effect of steroids. More details however about the molecular mechanism 
of MAP3K8 in airway inflammation are required. A better understanding of the gene 
networks of MAP3K8 that regulate airway inflammation could therefore enhance its 
therapeutic potential for airway diseases. 
    MAP3K8 is hypothesized to regulate the inflammatory response of airway 
inflammation via a series of genes and their signalling networks involved 
inflammation. The objectives of this chapter are to characterize changes in gene 
expression associated with airway inflammation in response to IL-1β stimulation and 
to evaluate the effects of MAP3K8 on this gene expression profile after gene 
silencing. The pathways and networks of those genes which are regulated by 
MAP3K8 will be investigated to elucidate their roles in the pathogenesis of airway 
inflammation. It is also anticipated that the genes differentially expressed between 
MAP3K8 gene silencing and controls may provide more information about the 




6.2 Materials and Methods 
6.2.1 Culture of Cell Lines 
    A549 cells were obtained from the American Type Culture Collection (ATCC). 
They were cultured as described in Chapter 2, Section 2.2.1. A549 cells were used at 
passage numbers 90-110. Cell viability was determined microscopically by trypan 
blue (Sigma-Aldrich) exclusion, and the number of cells was counted using a 
haemocytometer (see Section 2.2.2). Cells were sub-seeded in appropriate culture 
vessels (6- or 24-well plates) and incubated at 37°C for 24 hrs prior to all treatments 
as required. 
 
6.2.2 RNA Interference 
    RNA interference (RNAi) was carried using ON-TARGETplus SMARTpool, 
against MAP3K8 (Dharmacon Research Inc., Lafayette, CO). ON-TARGETplus 
Non-targeting Pool negative control (Dharmacon Research Inc., Lafayette, CO) were 
used as controls in the experiments. RNAi transfection of A549 cells was carried out 
with using Lipofectamine RNAiMAX (Invitrogen Corp.) as described in Chapter 2, 
Section 2.2.9.  
 
6.2.3 Immunoprecipitation 
    Cells were lysed using RIPA lysis buffer as described in Chapter 2, Section 
2.2.8.1. Four hundred and fifty μg of whole cell lysate was used for the 
immunoprecipitation process as previously described in Chapter 2, Section 2.2.10.1. 
To confirm the effectiveness of MAP3K8 immunoprecipitation, the supernatants were 
electrophoresed in 10% SDS-PAGE, transferred to nitrocellulous membranes and 
probed with the MAP3K8 antibody (Santa Cruz Biotechnology Inc.) as described in 
Section 2.2.8.  
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    After MAP3K8 immunoprecipitation, beads were washed 2 times with the lysis 
buffer, and one time with the kinase assay buffer. A time series analysis of in vitro 
catalytic activity (Chapter 2, Section 2.2.10.2) of immunoprecipitated MAP3K8 after 
IL-1β (1 ng/ml) stimulation was then assessed. To confirm the effectiveness of 
MAP3K8 activity, the supernatants were then electrophoresed in 10% SDS-PAGE, 
transferred to nitrocellulous membranes and probed with the phospho-MEK1/2 
(Ser217/221) antibody (Cell Signalling Technology) as described in Section 2.2.8. A 
suitable time point was then selected for subsequent comparison of activity assay of 
immunoprecipitated MAP3K8 between MAP3K8 gene silencing and controls. 
 
6.2.4 Gene Expression Profiling 
6.2.4.1 IL-1β Stimulation – Times Series Experiments 
    A total number of 4x10
4
 cells for 24-well plates were seeded into each well in 1 
ml of complete medium overnight for cells to attach and grow. After double 
transfection (Chapter 2, Section 2.2.9), cells were starved in serum free medium for 
16 hrs and then stimulated with 1 ng/ml of IL-1. The response to IL-1 stimulation 
was measured at 0, 1, 2, 4, 6, 8 and 12 hrs. Post IL-1 stimulation at time point 0, 
plates were incubated at 37
 o
C with 5% CO2 for the appropriate length of time (1, 2, 4, 
6, 8 and 12 hrs). Cells were collected at different time points and RNA extracted from 
the cells for microarray analysis. 
 
6.2.4.2 RNA Extraction and Quality Analysis 
    Total RNA was isolated using the Qiagen RNeasy
®
 mini kit (Qiagen, Crawley, 
UK) as indicated in Chapter 2, Section 2.2.6.1. RNA concentration was measured 
using the NanoDrop-1000 spectrophotometer (Chapter 2, Section 2.2.6.2). The quality 
of the RNA samples was assessed using the RNA 6000 Nano Assay
TM





 as described in Chapter 2, Section 2.2.11.2. A RNA 
integrity number (RIN) was generated for each Bioanalyzer trace using 2100 Expert 
Software (Agilent Technologies).  
 
6.2.4.3 Microarray Profiling 
    Global gene expression was determined using the Affymetrix microarrays. The 
Affymetrix GeneChip
®
 WT Terminal Labeling Kit in conjunction with the Ambion
®
 
WT Expression Kit was used to generate sense-strand target for hybridization onto 
GeneChip ST Arrays (Chapter 2, Section 2.2.11). By combining a hybridization oven, 
fluidics processing and state-of-the art imaging device into a single bench-top 
instrument, the GeneTitan
TM
 Instrument automates array processing from target 
hybridization to data generation. The levels of a number of mRNAs, selection based 
on the results from the microarray studies, were validated using the SYBR-based 
quantitative RT-PCR method.  
 
6.2.4.4 Microarray Data Analysis 
    For microarray data quality control, raw intensity measurements of all probe sets 
were corrected for background, normalized and converted into expression 
measurements by using the Affymetrix expression console (EC) (Version 1.1). The 
Partek Genomic Suite (Version 6.5) was used to identify differentially expressed 
genes between each pair of sample groups as described in Chapter 2, Section 2.2.11.7. 
Genes with significantly differential expressions were then selected by use of a cutoff 
of a FDR-adjusted P value and fold change in the level of expression. The significant 
genes were also clustered in the Partek Genomic Suite for Hierarchical Clustering. 
C-means clustering was used to group the significantly differential transcripts into 
discrete and stable clustering of time series data using the Mfuzz package of R 
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software (Version 2.11.0). The genes in each cluster were analyzed using Database for 
Annotation, Visualization and Integrated Discovery (DAVID) Version 6.7 
(http://david.abcc.ncifcrf.gov) to provide Gene Ontology (GO) term enrichment 
analysis, functional annotation clustering, and details of the gene families found 
within the gene clusters. For functional network mapping and molecular pathway 
analysis, additional filtering using a cut-off of a FDR-adjusted P value was applied to 
extract significantly differential genes by using Ingenuity Pathway Analysis (IPA) 
software as described in Chapter 2, Section 2.2.11.7.3.  
 
6.2.5 Quantitative Real-time Polymerase Chain Reaction (PCR) 
    Total RNA was isolated from A549 cells using the Qiagen RNeasy
®
 mini kit 
(Chapter 2, Section 2.2.6.1). Reverse transcription was performed using 0.5µg of 
RNA and cDNA was synthesized using the High-Capacity cDNA Reverse 
Transcription Kits (Chapter 2, Section 2.2.6.3). Real-time PCR was performed using 
the Rotor-Gene 3000™ Real-Time PCR detection system (Corbett Research, Sydney, 
Australia) as previously described in Section 2.2.6.4. Inflammation-related genes 
regulated by MAP3K8 including CCL20, MMP-1, MMP-3 and MMP12 were selected 
for microarray data validation. Gene-specific primers for these genes were used and 
GAPDH was used as an internal control. Gene sequences of the primers used are 
given in Chapter 2, Section 2.2.6.4, Table 2.2.1. The RT-PCR products were subjected 
to agarose gel electrophoresis to identify the target band. Calculation of the threshold 
value, standard curve preparation and quantification of mRNA in the samples were 
performed by the Rotor-Gene 6.0 software provided by Corbett Research. 
 
6.2.6 Statistical Analysis 




6.3.1 In Vitro Catalytic Activity of MAP3K8 Regulated by IL-1β 
    The effectiveness of the in vitro kinase assay of MAP3K8 was assessed. 
Recombinant human active MAP3K8 (R&D Systems Europe Ltd., Abingdon, Oxford, 
UK) was incubated with 0.2 μg of the purified substrate MEK1 (Abcam, Cambridge, 
UK) and cold ATP (0.5 mM, final concentration) in kinase buffer at 30 °C for 30 min. 
The reaction was terminated by adding sample loading buffer. The samples were 
electrophoresed in 10% SDS-PAGE, transferred to nitrocellulous membranes and 
probed with the phospho-MEK1/2 (Ser217/221) antibody (Cell Signalling 
Technology). As shown in Figure 6.3.1, substrate MEK1 was phosphorylated by 
active MAP3K8 with ATP, indicating that the in vitro kinase assay of MAP3K8 was 
robust. 
 
Figure 6.3.1 The In Vitro MAP3K8 Kinase Assay. Active MAP3K8 shows to 
phosphorylate the purified substrate MEK1 under the incubation with cold ATP. 
 
A time series analysis of in vitro catalytic activity of immunoprecipitated 
MAP3K8 after IL-1β (1 ng/ml) stimulation was then assessed. After protein extraction 
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from A549 cells, the MAP3K8 protein was precipitated in lysis buffer by means of an 
immune complex including the MAP3K8 protein, primary antibody and TrueBlot 
anti-Rabbit Ig IP beads (eBioscience, Ltd.). Following washing, protein complexes 
bound to the beads were denatured by adding sample buffer and boiled for 5 minutes 
to dissociate the immunocomplexes from the beads. The beads were collected by 
centrifugation and SDS-PAGE was performed with the supernatant.  
As shown in Figure 6.3.2, MAP3K8 protein was precipitated using 
immunoprecipitation and was detected using Protein A-HRP as secondary antibody. 
After MAP3K8 immunoprecipitation, MAP3K8 protein expression appeared to 
decrease at 30 min after IL-1 stimulation. Furthermore, a similar 2-fold rise in 
phosphorylatin of MEK1 was found at 20 and 30 min after IL-1 stimulation in the in 
vitro MAP3K8 kinase assay. Therefore, the 30 min time point of having high 
efficiency of MAP3K8 was selected for the subsequent activity assay of MAP3K8. 
 
Figure 6.3.2 In Vitro Catalytic Activity of MAP3K8 after Immunoprecipitation at 
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Different Time Points after IL-1 Stimulation. MAP3K8 protein expression 
appeared to decrease at 30 min after IL-1 stimulation after MAP3K8 
immunoprecipitation. A significant (2-fold) rise in phosphorylatin of MEK1 was 
found at 20 and 30 min after IL-1 stimulation. Data shown are mean  SEM of three 
separate experiments. *P<0.05 as compared to 0 min. 
 
    A comparison of the activity assay of immunoprecipitated MAP3K8 between 
MAP3K8 gene silencing and controls at 30 min after IL-1 stimulation was then 
conducted. First, immunoprecipitated MAP3K8 protein at 30 min after IL-1 
stimulation was compared between MAP3K8 gene silencing and controls to confirm 
the efficiency of MAP3K8 gene silencing. A comparison of MEK1 phosphorylation 
between MAP3K8 gene silencing and controls was then performed at 30 min after 
IL-1 stimulation. As shown in Figure 6.3.3, there was an approximately 30% 
decrease in MAP3K8 protein in A549 cells with MAP3K8 gene silencing. In addition, 
in the in vitro kinase assay of MAP3K8, an approximately 30% decrease in MEK1 




Figure 6.3.3 Comparison of Immunoprecipitated MAP3K8 Protein between 
MAP3K8 Gene Silencing and Controls at 30 min after IL-1 Stimulation. A 
significant decrease in MAP3K8 protein was found in A549 cells with MAP3K8 gene 
silencing. Data shown are mean  SEM of three separate experiments. *P<0.05 as 




Figure 6.3.4 Comparison of MEK1 Phosphorylation between MAP3K8 Gene 
Silencing and Controls at 30 min after IL-1 Stimulation. A significant decrease in 
MEK1 phosphorylation was found in A549 cells with MAP3K8 gene silencing. Data 
shown are mean  SEM of three separate experiments. *P<0.05 as compared to NT 
siRNA. NT siRNA, non-targeting siRNA. 
 
6.3.2 Analysis of Global Gene Expression 
    First, the quality assessment of all samples was examined using Affymetrix 
expression console (EC). In EC, random multiple access (RMA)-Sketch was selected 
as the probe set summarization method for running a gene level core analysis. Three 
probeset summarizations, Pos_vs_neg_auc, X_mad_residual_mean and X_rle_mean, 
were used for excluding outliers from further analysis. Next global gene expression of 
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A549 cells with non-targeting siRNA in response to IL-1β was examined to confirm 
the role of MAP3K8 in the inflammatory response. The comparison of gene 
expression profiling between MAP3K8 gene silencing and controls was then 
examined. Functional networks, canonical pathways and inflammation-related genes 
regulated by MAP3K8 were investigated to elucidate the regulation of MAP3K8 in 
the inflammatory response. 
 
6.3.2.1  Quality Assessment Metrics 
    In the Affymetrix Expression Console (EC), random multiple access 
(RMA)-Sketch was selected as the probeset summarization method for running a gene 
level core analysis on Exon Arrays. A variety of quality assessment metrics are 
calculated by EC during probeset summarization. Box plots for the relative log 
expression (RLE) values of all probesets were generated in EC (Figure 6.3.5). The 
middle bar in each box is the median RLE and should be zero. No deviations from 
zero were found in the total dataset of 48 samples, indicating no skewness in the raw 
intensities for the chip that was properly corrected by normalization. 
 
Figure 6.3.5 Box Plots of the Relative Log Expression for all Probesets Analyzed. 
Each column represents a sample. The mean absolute relative log expression (RLE) 
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will be proportional to the width of the box plots, or the inter-quartile range of RLE 
values. The middle bar in each box is the median RLE. These should be zero in most 
applications and deviations from zero typically indicate a skewness in the raw 
intensities for the chip that was not properly corrected by normalization. No 
deviations from zero were found in the total dataset of 48 samples. 
 
6.3.2.1.1 Probeset Signals 
    Individual probeset signal values including the bacterial spike and polyA spike 
probesets were used as controls. Bacterial spike is the set of probesets which 
hybridize to the pre-labeled bacterial spike controls (BioB, BioC, BioD and Cre) and 
it is useful in identifying problems with the hybridization and/or chip. PolyA spike is 
the set of polyadenylated RNA spikes (Lys, Phe, Thr and Dap) and it is useful in 
identifying problems with the target preparation. The signal values for bacterial spikes 
and polyA spikes are shown in Figure 6.3.6 and Figure 6.3.7 respectively. The 
bacterial spikes showed a similar pattern to that of the polyA spikes. The expected 
rank orders of these spikes were also observed. 
 
Figure 6.3.6 Signal Values for the Bacterial Spikes. Each sample is shown on the 
x-axis and signal value of each bacterial spike control is shown on y-axis. The 
bacterial spikes display the expected rank order (BioB (green) < BioC (pink) < BioD 
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(blue) < Cre (red)), which means there are no problems with the hybridization and/or 
chip.   
 
 
Figure 6.3.7 Signal Values for the polyA Spikes. Each sample is shown on the 
x-axis and signal value of each polyA spike control is shown on y-axis. The polyA 
spikes display the expected rank order (lys (blue) < phe (pink) < dap (green) < thr 
(red)), which means there are no problems with the the RNA sample or the target 
preparation. 
 
6.3.2.1.2 Probeset Summarization 
    Three probeset summarizations were used for excluding outliers from further 
analysis. Pos_vs_neg_auc is the area under the curve (AUC) for a receiver operating 
characteristic (ROC) plot comparing signal values for the positive controls to the 
negative controls. X_mad_residual_mean is the mean of the absolute deviation of the 
residuals from the median. X_rle_mean is the mean absolute relative log expression 
(RLE) for all the probesets analyzed from category X which calculates the difference 
in log base 2 from the median signal value of that probeset over all the chips. As 
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shown in Figure 6.3.8, all three of these metrics suggest no chip was an outlier in this 
study.  
 
Figure 6.3.8 Signal Values for Pos_vs_neg_auc, X_mad_residual_mean and 
X_rle_mean. Each sample is shown on the x-axis and y-axis shows the difference in 
log base 2 from the median signal value of that probeset over all the chips. The area 
under the receiver operator curve for signal discrimination of the positive and 
negative controls (Pos_vs_neg_auc, red), mean absolute deviation of residuals 
(X_mad_residual_mean, blue) and mean absolute relative log expression 
(X_rel_mean, green) all show no chip is an outlier. 
 
6.3.2.2  Response of A549 Cells to IL-1β 
    The Partek Genomic Suite (Version 6.5) was used to identify differentially 
expressed genes and raw expression data were background adjusted, quantile 
normalized and median polished using the random multiple access (RMA) algorithm 
as implemented in the Partek Genomic Suite. Principal Components Analysis (PCA) 
was applied to the data for the identification of latent batch. PCA involves a 
mathematical procedure that transforms a number of possibly correlated variables into 
a smaller number of uncorrelated variables called principal components. As shown in 
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Figure 6.3.9, 24 samples of IL-1β-stimulated A549 cells were clustered by time 
points and separated fairly well in the PCA map. This indicates that the quality control 
and normalization of microarray data was robust. 
 
Figure 6.3.9 The PCA Map of 24 Samples at the Various Time Points after IL-1β 
Stimulation. Principal components analysis (PCA) mapping of the samples showed in 
three dimensions for interactive visualization. Samples are colored by time points and 
ellipsoids are drawn around time points. Samples clustered by time points are 
separated fairly well in the PCA map. 
 
6.3.2.2.1 Cluster Analysis 
    The response of the A549 cells to IL-1β (24 samples) was examined using 
differentially expressed genes analysis. One thousand 487 transcripts varied 
significantly during the time-course of the experiment, 1357 of which corresponded to 
known genes (10
-6
 FDR). These significant genes were clustered using Hierarchical 
Clustering in the Partek Genomic Suite. Figure 6.3.10 shows the result of the 
hierarchical clustering. The differentially expressed genes clustered the samples into 
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different subgroups which in general clustered with the samples at different time 
points.   
    
Figure 6.3.10 Hierarchical clustering with 1357 Differentially Expressed Genes 
after IL-1β Stimulation. Each row represents the expression profile of a gene across 
24 samples and each column represents a sample. The time points are listed below the 
heatmap. Red or blue colours indicate higher and lower expression levels respectively 
of the genes correlating into a smaller number of uncorrelated variables called 
principal components.  
 
    C-means clustering was performed using R software and package Mfuzz and this 
resulted in 6 modules of genes that showed distinctive temporal patterns characterised 
by their initial levels of abundance and variation in expression during the time-course 
(Figure 6.3.11). Cluster 4 (outlined in blue in Figure 6.3.11) contained numerous 
known modulators of inflammation, including CCL2, CCL20, CSF1, CXCL2, CXCL3, 
ICAM1, IL1A, IL6, IL8, NFKB1, NFKBIZ, REL, VDR and MAP3K8. This cluster 
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contained many genes known to be associated with the inflammatory response and 
was up-regulated 2 hrs after IL-1β stimulation and remained activated until 4 hrs after 
which levels decreased to those seen at the initial state (time 0). The full set of 160 
genes up-regulated by IL-1β in Cluster 4 is given in Appendix A. 
 
Figure 6.3.11 Clustering of Genes Differentially Regulated by IL-1β in A549 Cells. 
The time course of the experiment is shown on the x-axis. Expression levels on the 
y-axis are the ratio of each transcript to the global mean expression of all genes on the 
chip. Expression is shown on a log2 scale. 
 
    One hundred and fifty five over-expressed genes in Cluster 4 were input into the 
DAVID Bioinformatics tool for functional annotation clustering. Fourteen functional 
clusters were identified with many of the enriched biologic terms being related to 
cytokine, chemokine activity, inflammatory response and transcription factor activity. 
The top two clusters and their Protein Information Resource (SP_PIR) and GO 


























1 5.14 SP_PIR_KEYWORDS: cytokine 13 2.20E-08 5.10E-06 
  GO:0005125: cytokine activity 14 5.10E-08 1.40E-05 
  
SP_PIR_KEYWORDS: inflammatory 
response 9 1.70E-07 2.00E-05 
































     
Returning to the expression clusters, Cluster 2 unlike Cluster 4 was 
down-regulated after 2 hrs post IL-1β stimulation and remained so until 4 hrs after 
which levels of expression increased to that seen at the initial state. Cluster 2 
contained numerous known modulators of transcription regulation including nuclear 
receptor coactivator 3, nuclear receptor subfamily 1 and inhibitor of DNA binding 1, 2 
and 3. Seventy nine down-regulated genes in Cluster 2 were input into the DAVID 
Bioinformatics tool for functional annotation clustering. Eight functional clusters 
were identified with many of the enriched biologic terms relating to transcription 
co-factor and co-repressor activity. The top two sample clusters and their SP_PIR and 













































































  SP_PIR_KEYWORDS: repressor 10 5.90E-05 7.50E-03 











6.3.2.2.2 Functional Network Mapping  
    Additional filtering using a stringent threshold false discovery rate (FDR) of 10
-6
 
was applied to extract the genes most significantly differentially expressed during the 
time course. The genes identified were then analyzed using the Ingenuity Pathway 
Analysis (IPA) software (Ingenuity Systems, Redwood City, CA) in order to 
investigate biological functions regulated by IL-1β. The top biofunctions associated 








Table 6.3.3 Functions of Top 5 Networks after IL-1β Stimulation. 
ID Associated Network Functions Score 
1 Cell Death, Organ Morphology, Gene Expression 30 
2 Cell Cycle, Cellular Growth and Proliferation, Cell Death 30 
3 
Cell-To-Cell Signalling and Interaction, Cellular Compromise, 
Reproductive System Development and Function 28 
4 
Inflammatory Response, Gene Expression, Cell-To-Cell Signalling 
and Interaction 24 
5 Cellular Movement, Cell Morphology, Cellular Development 23 
     
    The most significant gene network functions included cell death, organ 
morphology. Gene expression contained many genes known to be regulated by TNF 




Figure 6.3.12 The Most Significant Gene Network of Genes. Focus genes are 
represented as nodes and the gene relationship between two nodes is represented as a 
line. The shapes of nodes symbolize the functional class of genes (Chapter 2, Section 
2.2.11.7). 
 
    The associated network functions, including inflammatory response, gene 
expression and cell-to-cell signalling and interaction, contained many genes known to 
be predominantly regulated by IL-1β (Figure 6.3.13). This inflammatory response 
associated gene network was also focused around RELA and NF-κB1 genes which 




Figure 6.3.13 Inflammatory Response Associated Gene Network of Genes. Focus 
genes are represented as nodes and the direct interaction of gene relationship between 
two nodes is represented as a solid line. The intensity of the node colour indicates the 
degree of regulation of expression. Non-coloured nodes represent genes that were not 
identified as differentially expressed and were integrated into computationally 
generated networks on the basis of the evidence stored in the IPA knowledge memory 
indicating a relevance to this network. The shapes of nodes symbolize the functional 





6.3.2.2.3 Canonical Pathway Analysis 
    For the analysis of canonical pathways at different time points, two-fold changes 
and above were analyzed by filtering the dataset using a FDR-adjusted P value ≤ 1%. 
 
Table 6.3.4 shows the number of significant genes expressed in comparison with the 0 
time point. 
 
Table 6.3.4 Number of Significant Genes Expressed in Comparison with Time 0. 
Time 1hr vs 0hr 2hr vs 0hr 4hr vs 0hr 6hr vs 0hr 8hr vs 0hr 12hr vs 0hr 
No. of 
Genes 
44 256 585 543 318 297 
 
    Inflammatory response associated canonical pathways including NF-κB 
signalling, p38 MAPK signalling, ERK/MAPK signalling and SAPK/JNK signalling 
were analyzed using IPA. Figure 6.3.14 shows the changes of NF-κB and MAPK 
signalling regulated by IL-1β at different time points. Induced inflammatory response 
after IL-1β stimulation in A549 cells was significantly involved in both NF-κB and 
p38 MAPK pathways. SAPK/JNK and ERK/MAPK pathways seemed to be activated 




Figure 6.3.14 The Expression Pattern of Inflammatory Response Associated 
Canonical Pathways Regulated by IL-1β. The time course of the experiment is 
shown on the x-axis. Level on the y-axis is the ratio of the number of genes from the 
data set that map to the pathway divided by the total number of genes that map to the 
canonical pathway. IL-β-induced inflammatory response shows to activate NF-κB 
(A), p38 MAPK (B), ERK/MAPK (C) and SAPK/JNK (D) pathways. 
 
6.3.2.3 Comparison of Gene Expression Profiling between MAP3K8 Gene Silencing 
and Controls 
    The Partek Genomic Suite (Version 6.5) was also used to identify differentially 
expressed genes between MAP3K8 gene silencing and controls. Figure 6.3.15 shows 
the PCA map of all 48 samples (including the controls) of the time series of MAP3K8 
gene silencing. The samples were well separated and clustered by their time points in 





Figure 6.3.15 The PCA Map of the 48 Samples at the Various Time Points after 
IL-1β Stimulation. Principal components analysis (PCA) mapping of the samples 
showed in three dimensions for interactive visualization. Samples are colored by time 
points and ellipsoids are drawn around time points. Samples clustered by time points 
are separated fairly well in the PCA map. 
     
First the expression of the MAP3K8 gene during time series stimulation with 
IL-1β (1ng/ml) was examined. MAP3K8 gene expression plotted from the microarray 
data is shown in Figure 6.3.16 A. Highest MAP3K8 gene expression was found at 2 
hrs after IL-1β stimulation as was observed previously by RT-PCR (Chapter 3, Figure 
3.3.5). The expression fold change of MAP3K8 is shown in Figure 6.3.16 B. 
Compared with non-targeting siRNA, there was an approximately 40% decrease in 
MAP3K8 gene expression after RNA interference. The approximately 2.5-fold 




     
Figure 6.3.16 MAP3K8 Gene Expression in Microarray Data. The expression of 
MAP3K8 and fold change is represented in dot plots (A) and column (B) respectively. 
The time course of the experiment is shown on the x-axis. Expression levels on the 
y-axis are the ratio of each transcript to the global mean expression of all genes on the 
chip. Expression is shown on a log2 scale. The difference of MAP3K8 gene expression 
between MAP3K8 siRNA (red) and non-targeting siRNA (blue) is shown in the 






6.3.2.3.1 Functional Network Mapping 
    For the analysis of functional networks and canonical pathways at different time 
points, a number of combinations of fold changes and P value were examined. Table 
6.3.5 shows the number of genes significantly differentially expressed between 
MAP3K8 gene silencing and controls.  
 
Table 6.3.5 Number of Significant Differentially Expressed Genes between 
MAP3K8 Gene Silencing and Controls. 
Time 
Fold change / 




1hr 2hr 4hr 6hr 8hr 
 
12hr 
2/0.05  15 12 9 14 13 18 3 
2/0.01  7 10 7 10 9 13 2 
1.4/0.05  127 131 159 196 253 192 80 
1.4/0.01  98 114 136 172 218 147 59 
    
1.4-fold changes were analyzed by filtering the dataset using P value with 1% 
FDR. Genes with significant differential expression were selected by using the cutoff 
of fold change ≥ 1.4 and FDR-adjusted P value < 0.01 in the level of expression and 
were analyzed using Ingenuity Pathway Analysis (IPA) software. Biofunctions of 
significant networks between MAP3K8 gene silencing and controls at different time 








Table 6.3.6 Functions of Significant Networks between MAP3K8 Gene Silencing 
and Controls. 
ID Associated Network Functions Score 
0 hr  
1 Cell Cycle, Reproductive System Disease, Cell Death 14 
2 Inflammatory Response, Cell-To-Cell Signalling and Interaction, 
Hematological System Development and Function 
7 
1 hr 
1 Cell Cycle, Cardiovascular System Development and Function, 
Organismal Development 
21 
2 Inflammatory Disease, Cell Death, Gene Expression 10 
2 hr 
1 Inflammatory Response, Organismal Functions, Cell Cycle 30 
2 Cell Cycle, Cellular Movement, Cellular Growth and Proliferation 14 
4 hr 
1 Hematological System Development and Function, Inflammatory 
Response, Lymphoid Tissue Structure and Development 
37 
2 Cellular Movement, Gene Expression, Cell Cycle 28 
3 Cellular Movement, Hematological System Development and 
Function, Immune Cell Trafficking 
12 
6 hr 
1 Cell-To-Cell Signalling and Interaction, Tissue Morphology, Lipid 
Metabolism 
35 
2 Gene Expression, Cell-To-Cell Signalling and Interaction, Cellular 
Growth and Proliferation 
26 
3 Cellular Movement, Hematological System Development and 
Function, Immune Cell Trafficking 
17 
8 hr 
1 Cellular Growth and Proliferation, Cellular Movement, 34 
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Dermatological Diseases and Conditions 
2 Cell Death, Reproductive System Disease, Cell Cycle 19 
12 hr 
1 Inflammatory Disease, Cancer, Cell-To-Cell Signalling and 
Interaction 
32 
     
    The inflammatory response associated functions of significant differentially 
networks were mainly found at 2 and 4 hrs in comparison with non-targeting siRNA 
controls. Figure 6.3.17 shows the Ingenuity network analysis of differentially 
expressed genes between MAP3K8 gene silencing and controls at 4 hrs after IL-1β 




Figure 6.3.17 Ingenuity Network Analysis of Differentially Expressed Genes 
between MAP3K8 Gene Silencing and Controls at 4 hrs after IL-1β Stimulation. 
Focus genes are represented as nodes and the direct interaction of gene relationship 
between two nodes is represented as a solid line. The intensity of the node colour 
indicated the degree of up-(red) or down-(green) regulation. Non-coloured nodes 
represent genes that were not identified as differentially expressed and were integrated 
into computationally generated networks on the basis of the evidence stored in the IPA 
knowledge memory indicating a relevance to this network. The shapes of nodes 
symbolize the functional class of genes (Chapter 2, Section 2.2.11.7). 
 
    The inflammation-related genes (N=101) regulated by MAP3K8 at 4 hrs after 
IL-1β stimulation are detailed in Appendix B. Table 6.3.7 shows the 
inflammation-related genes which have been linked with airway diseases including 
COPD and asthma. 







Fold-change Gene Assignment 
4 hr 
7951271 MMP1 1.65E-08 -2.64646 matrix metallopeptidase 1  
8054722 IL1B 3.64E-09 -2.45465 interleukin 1, beta 
7951284 MMP3 1.31E-08 -2.32029 matrix metallopeptidase 3 
8054712 IL1A 8.14E-06 -1.82905 interleukin 1, alpha 
8131803 IL6 5.27E-06 -1.80396 interleukin 6  
8048864 CCL20 1.43E-03 -1.4414 chemokine (C-C motif) ligand 20 
8 hr 
7951297  MMP12  8.80E-04  -1.98877  matrix metallopeptidase 12 
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6.3.2.3.2 Canonical Pathway Analysis 
    For the analysis of canonical pathways at different time points, 1.4-fold changes 
were also analyzed by filtering the dataset using a P value with 1% FDR. Genes with 
significantly differential expressions were selected and were analyzed using Ingenuity 
Pathway Analysis (IPA) software.  
Table 6.3.8 shows the number of significant gene expressions in MAP3K8 gene 
silencing (MAP3K8 siRNA) and controls (Non-targeting siRNA) in comparison with 
the 0 time point. 
 
Table 6.3.8 Number of Significant Differentially Expressed Genes in MAP3K8 
Gene Silencing and Controls Compared to 0 hr Time Point. 
Time 1hr vs 0hr 2hr vs 0hr 4hr vs 0hr 6hr vs 0hr 8hr vs 0hr 12hr vs 0hr 
NT siRNA 44 256 585 543 318 297 
MAP3K8 siRNA 50  198  448  421  251  223  
     
    Compared with non-targeting siRNA, inflammatory response associated 
canonical pathways after MAP3K8 gene silencing included NF-kB signalling, p38 
MAPK signalling, ERK/MAPK signalling and SAPK/JNK signalling. Figure 6.3.18 
shows the changes of NF-kB and MAPK signalling regulated by IL-1β in MAP3K8 
gene silencing and controls at the various time points. MAP3K8 regulated 
inflammatory response after IL-1β stimulation was mainly found to be involved in 




Figure 6.3.18 The Expression Pattern of Inflammatory Response Associated 
Canonical Pathways Regulated by IL-1β in MAP3K8 Gene Silencing (Green) 
and Controls (Red). The time course of the experiment is shown on the x-axis. Level 
on the y-axis is the ratio of the number of genes from the data set that map to the 
pathway divided by the total number of genes that map to the canonical pathway. 
MAP3K8 regulated IL-1β-induced inflammatory response associated canonical 
pathways are mainly involved in NF-kB (A), ERK/MAPK (C) and SAPK/JNK (D) 
pathways rather than the p38 MAPK (B) pathway.  
 
6.3.2.4  Microarray Data Validation 
    The mRNA levels of selected genes from the microarray studies were validated 
using the SYBR-based quantitative RT-PCR method. For real-time PCR analysis, 
extracted RNA for microarray was examined at time points of 2, 4, 6 and 8 hrs. 
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Inflammation-related genes regulated by MAP3K8 and that have also been previously 
reported to be involved in airway diseases were selected for validation and included 
MMP-1, MMP-3, MMP-12 and CCL20. For all four genes, a significant reduction in 
mRNA expression was found at 2, 4, 6 and 8 hrs after IL-1 stimulation: MMP-1 
(Figure 6.3.19 A), MMP-3 (Figure 6.3.19 B), MMP-12 (Figure 6.3.19 C) and CCL20 
(Figure 6.3.19 D).  
 
Figure 6.3.19 Effect of MAP3K8 Gene Silencing on MMP-1, MMP-3, MMP-12 
and CCL20 mRNA Expression in A549 Cells. A significant reduction in MMP-1 
(A), MMP-3 (B), MMP-12 (C) and CCL20 (D) mRNA expression after MAP3K8 
gene silencing was found at 2, 4, 6 and 8 hrs after IL-1 stimulation. Data shown are 




    Airway inflammation is the prominent pathophysiological feature and well 
recognized as the primary characteristic of asthma and COPD. Molecular biological 
methods including microarray analysis and quantitative real-time PCR determinations 
have been used in the search to determine the mechanism of the development of 
airway diseases with the hope of finding new diagnostic and prognostic markers
183,184
. 
An improved understanding in the molecular pathogenesis of airway inflammation 
has the potential to result in the identification of molecular targets for clinical 
treatments. Comparative gene expression profiles of lung tissues at different stages 
using a serial analysis of microarrays have revealed a number of 
differentially-regulated genes associated with the progress of airway diseases
185-187
. 
Although these studies have shed new light on the molecular mechanisms of airway 
diseases, small sample numbers of lung tissue and the cellular composition of the 
tissues make certain results not truly representative.  
A microarray gene expression analysis at different time points of the 
IL-1β-induced inflammation process of human airway epithelial cell lines, as 
conducted in this present study, may provide more consistent and reproducible 
patterns characterizing airway inflammation. In addition, a systems biology approach 
for studying airway inflammation by integrating data from microarray experiments, 
functional annotations and comparative genomics has been shown to greatly eliminate 
background noise contained in samples
188
.  
By analyzing mRNA spectra using differentially expressed genes analysis, 1357 
known genes were identified in the progression of IL-1β-induced inflammation. This 
study has demonstrated new genetic networks and biological pathways in both up- 
and down-regulated gene expression levels. One important gene network was 
identified around the IL-1β gene (Figure 6.3.13). This gene has been reported to be a 
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potent modulator of cellular differentiation and a suitable target for anti-inflammation. 
In this study, the genes of a group of chemokines (CCL2, CCL20, CXCL1, CXCL2, 
CXCL3, CXCL5 and CXCL10) were up-regulated as a result of IL-1β stimulation. 
Chemokines are small heparin-binding proteins that direct the movement of 
circulating leukocytes to sites of inflammation or injury and their ligands are 
considered to have a significant role in inflammation
26
. Among them, CXCL2 and 
CXCL3 have been shown to be involved in inflammatory lung disease. In particular, 
CCL20 is the most potent known chemoattractant for dendritic cells and is enriched in 
the airways of patients with COPD
189
. In addition, the inflammatory response 
associated gene network was also focused around RELA (p65) and NF-κB1 (p50) 
genes, the most common and best-characterized form of NF-κB (p65/p50 
heterodimer). These findings suggest that most of the inducible chemokines during 
IL-1β-induced inflammation are regulated by NF-κB transcription factors, a family of 
expression regulators of inflammatory and immune responses.   
Microarray clustering analysis allows one to minimize a set of data points into 
self-similar groups such that the points that belong to the same group are more similar 
than the points belonging to different groups. Clustering reveals similar expression 
patterns, in particular in time-series expression data
190
. In this study, c-means 
clustering was used to group transcripts into discrete and stable clusters which 
partially represent modules of genes with shared regulatory sequences and functions. 
A number of differentially-regulated genes associated with inflammation, including 
genes involved in the regulation of cytokines, chemokine activity and transcription 
factor activity, were identified and clustered in the same cluster with MAP3K8, 
indicating MAP3K8 may take part in the regulation of inflammation in airway 
epithelial cells. 
In this study, an opposite down-regulated gene expression pattern to the 
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inflammation-related cluster was also identified. Clustering analysis of this cluster has 
revealed numerous genes, mainly involved in transcription regulation, including 
transcription co-repressor and co-activator activity. A co-repressor is a protein that 
binds to transcription factors and inhibits the expression of genes. In contrast, a 
co-activator is a protein that increases gene expression by binding to an activator (or 
transcription factor) which contains a DNA binding domain. Co-repressors and 
co-activators compete for the same binding sites in transcription factors
191
. For 
example, the gene transactivation by the transcription factor NF-κB has been shown to 
be subject to the regulation of a dynamic balance between the co-activators and 
co-repressors
192
. Based on these findings of gene cluster analysis, IL-1β-induced 
inflammatory gene expression in airway epithelial cell seems to be mainly regulated 
by the NF-κB transcription factor followed by a negative regulation of transcriptional 
inhibition.  
Another gene network function related to cell death, organ morphology and gene 
expression was identified around the TNF gene (Figure 6.3.12), which is compatible 
to the findings of pathway level analysis. In this study, canonical pathway analysis 
revealed that activation of interferon regulatory factor (IRF), tumor necrosis factor 
receptor (TNFR) 2 and TNFR1 signalling were the most significant signalling 
pathways modulated by the differentially-regulated genes in the inflammatory model 
induced by IL-1β. Tumor Necrosis Factor (TNF) family members play important roles 
in various physiological and pathological processes including cell proliferation, 
differentiation, apoptosis, modulation of immune responses and induction of 
inflammation
193
. TNF family members act through two receptors, TNFR1 and TNFR2. 
TNFR1 is expressed by all human tissues and is the major signalling receptor for 
TNF-α. TNFR2 is mostly expressed in immune cells and mediates limited biological 
responses. TNF-α not only has been shown to be one of the most pleiotropic cytokines 
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in mediating inflammatory and immune response in chronic lung diseases but it also 
cooperates with the family of interferons (IFN) to synergistically regulate the 




    In the present study, for identifying differentially expressed genes between 
MAP3K8 gene silencing and controls because of the somewhat limited (approximately 
40%) knockdown efficiency of MAP3K8, a slightly lower threshold of a 1.4-fold 
change of gene expression was selected for further data analysis. Genes with 
significantly differential expression were defined to be differentially expressed if they 
were up or down-regulated with a fold change above 1.4 and P-value with 1% FDR. 
Using these criteria, it was found that MAP3K8 regulates gene networks including 
gene expression, cell cycle, cell death, cell growth and cell proliferation. This is in 
agreement with the recognised cellular activity functions of the MAPK signalling 
system activated by MAP3K8 such as gene expression, mitosis, differentiation, 
proliferation and cell survival/apoptosis
54
.  
    IL-1β-induced inflammation has been shown to activate MAPK pathways 
including ERK/MAPK, SAPK/JNK and p38 MAPK in different cell types
59,166
. 
Among them, the p38 MAPK plays a central role in the regulation of a wide range of 
immunological responses and the main biological response of p38 activation involves 
the production and activation of inflammatory mediators to initiate leucocyte 
recruitment and activation
56
. In this study, canonical pathway analysis revealed that 
the p38 MAPK pathway was significantly involved in the IL-1β-induced 
inflammatory response in A549 cells. The MAP3K8 regulated inflammatory response 
however seems mainly involved in ERK/MAPK and SAPK/JNK rather than the p38 




    In this present study, MAP3K8 has also been shown to regulate the inflammatory 
response induced by IL-1β. Inflammatory diseases regulated by MAP3K8 include 
COPD, asthma and rheumatoid arthritis. Among the MAP3K8 regulated genes related 
to airway diseases, genes associated with inflammatory cytokines/chemokines (IL-6 
and CCL20) and matrix metalloproteinases (MMPs) (MMP-1, MMP-3 and MMP-12) 
are the two most abundant groups.  
    IL-6 is a pleiotropic pro-inflammatory and immunomodulatory cytokine secreted 
by interstitial fibroblasts, alveolar macrophages and bronchial epithelial cells as well 
as other tissues
195
. In COPD, high levels of IL-6 have been found in the induced 
sputum of patients, especially during exacerbation. IL-6 has also been related to 
skeletal muscle weakness in COPD as well as pulmonary function decline and 
infection
196,197
. In patients with allergic asthma, IL-6 has been reviewed as an 
inflammatory marker and may contribute to asthma severity, poorer asthma control 
and associated systemic inflammatory response of asthma
195
. A strong negative 
correlation between forced expiratory volume (FEV1) and sputum IL-6 levels in 
asthma patients also indicates an inverse relationship between IL-6 levels and lung 
function as in COPD
198
.  
    In this study, one chemokine regulated significantly by MAP3K8 was CCL20, a 
chemokine that has been shown to be the most potent chemokine known in attracting 
dendritic cell (DC) and is highly expressed in inflamed epithelium in the skin and 
tonsil crypts
199
. CCL20 is also expressed and released by primary human bronchial 
epithelial cells in response to cytokines including TNF-α and IL-1β200. The role of 
DCs in the pathogenesis of asthma has been studied extensively
201
. An early event of 
allergic asthma is presentation of antigen by DCs to T cells leading to an increase in  
Th2 cell numbers which secret IL-4, IL-5 and IL-13 that in turn regulate the synthesis 
of allergen-specific IgE and control tissue eosinophilic airway inflammation and 
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remodelling of the airways
201
. The DCs present in the human lung and lymphoid 
organs linking innate and adaptive immune responses, could also be a key element in 
the pathogenesis of COPD
202
. The airways of COPD patients have been shown to 
contain more DCs. Furthermore, increased numbers of DCs in the epithelium and 




    MMPs, a family of zinc-dependent endopeptidases, not only play an important 
role in invasion of inflammatory cells, by degrading the extracellular matrix (ECM), 
but MMPs also directly interact with enzyme cascades and cytokine regulation
203
. For 
example, MMP-9 has been shown to cleave the neutrophil chemoattractant CXCL8 
thereby increasing its activity 10-fold
34
. In airway diseases, MMPs are produced in 
the respiratory tract from different inflammatory and structural cells and are involved 
in wound healing, inflammatory cell trafficking and tissue remodelling and repair. 
There is increasing evidence that MMPs may contribute to airway wall remodelling 
by modulating airway smooth muscle proliferation and migration
204
. MMPs regulate 
airway smooth muscle hyperplasia by causing the release of immobilised growth 
factors, such as the release of transforming growth factor (TGF)-β when the ECM 
proteoglycan decorin is degraded by MMPs including MMP-2, -3 and -7
205
.  
Increased secretion and expression of MMP-1, MMP-3 and MMP-12, which 
were down-regulated significantly by MAP3K8 in this study, has been reported in 
asthma and COPD. In COPD, MMPs from lung macrophages play an important role 
in degradation of matrix leading to emphysema. An increase in expression of MMP-1, 
detected by immunostaining, has been observed in lung tissue of COPD patients, 
particularly in the lung parenchyma of emphysema patients
41
. An immunological 
study of endobronchial biopsy specimens from patients with chronic asthma also 
identified the presence of MMP-3 in the submucosal matrix and it showed 
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    Another MMP regulated significantly by MAP3K8 is MMP-12, a metalloelastase 
which is mainly secreted from alveolar macrophages in the lung, and it can be 
released from bronchial epithelial cells in response to TNF-α or cigarette smoke207. 
MMP-12 may facilitate airway inflammation by stimulating migration of 
inflammatory cells such as monocytes and macrophages. MMP-12 can also activate 
the latent form of TNF-α on the surface of macrophages and induce IL-8 secretion in 
alveolar epithelial cells, which in turn amplifies the chronic inflammation in patients 
with asthma and those with COPD
208,209
. Overproduction of MMP-12 also causes the 
degradation of ECM proteins through its enzyme activity and excessive airway 
remodelling
210
. MMP-12 protein levels and enzymatic activity have been shown to be 
higher in induced sputum from patients with COPD
42
. Furthermore, a functional 
variant in the promoter of MMP-12 (aguanine residue; -82A→G) has been reported to 
have a positive association with FEV1 in children with asthma and in adult smokers 
with COPD or at risk of COPD
43
. In a recent report, pharmacologic inhibition of 
MMP-12 was shown to down-regulate both the early and late allergic airway 
bronchoconstriction in allergen-sensitized sheep
211
. These findings indicate that 
reduced MMP-12 expression might thus have a beneficial effect on lung function in 
children with asthma and on the pathogenesis of COPD. 
    In this study, a very potent pro-inflammatory stimulus, IL-1β, was used to 
challenge the A549 cells, and the response followed by measurement of global gene 
expression. A549 cells are derived from a lung cancer and are widely used in airway 
research because they contain most of the inflammatory functions of normal cells. 
Airway epithelial cells are key participants in the inflammatory response in airway 
diseases. Although A549 cells can be used to throw light on important processes, they 
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are derived from a lung cancer, and are therefore not the same as normal cells. 
Consequently it will be important and necessary to confirm the results of this study by 
performing direct measurement of key genes in primary airway epithelial cells that are 
readily available commercially. 
    MAP3K8 shows to regulate IL-1β-induced inflammatory response via a series of 
genes involved in inflammation. The data revealed in this study provide not only new 
networks between the genes for understanding the biological properties of MAP3K8 
but also useful common pathway maps increasing our understanding of the role of 
MAP3K8 in inflammation. The data has also identified that MAP3K8 regulated a 
number of inflammation-related genes which have been linked with airway diseases, 
indicating that MAP3K8 may potentially be a novel therapeutic target for airway 





The Role of MAP3K8 in IL-1β-induced Activation of ERK, JNK, and 
Transcription Factors in A549 Cells 
 
7.1 Introduction 
    The role of MAP3K8 in regulation of the IL-1β-induced inflammatory response 
has started to be investigated through the various experiments conducted in this thesis. 
In Chapter 4, IL-1β has been shown to induce all MAP kinase pathways in A549 cells. 
MAP3K8 appears to regulate inflammatory mediators by ERK1/2 and JNK but not 
p38 MAPK signalling pathways (Chapter 4, Section 4.3.3.2). In addition, MAP3K8 
has been shown to activate the NF-κB pathway in a cell-type and stimulus-specific 
manner
125
. The signal transduction mechanisms and speciﬁcally the role of MAP3K8 
in transcription factor-mediated regulation of inflammatory mediator expressions 
however are poorly understood. The next step therefore is to investigate the role of 
MAP3K8 in IL-1β-induced activation of ERK, JNK and transcription factors.    
    The effect of IL-1β involves several signal transduction mechanisms, including 
the NF-κB and activating protein 1 (AP-1) pathways (Chapter 1, Section 1.2.5 and 
Section 1.2.6). The NF-κB signalling transduction pathway is mediated by the 
ubiquitination and proteolysis of IκB, which is initiated by the activation of an IκB 
kinase which then releases NF-κB to promote gene transcription98. NF-κB is a key 
transcriptional regulator of multiple pro-inflammatory cytokine mediators such as 
TNF-α, interleukins, induced expression of pro-inflammatory cytokines (ICAMs) and 
MMPs. NF-κB has also been implicated in asthma and COPD212,213.  
    IL-1β is known to induce AP-1 transcriptional activity in several cell types59. 
AP-1 is composed of a mixture of heterodimeric complexes of proteins derived from 
the Fos, Jun, ATF and MAF families (Chapter 1, Section 1.2.5.1). Primarily, AP-1 
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dimers bind to DNA on a TPA-response element (TRE) and Jun-Fos heterodimers 
form more stable complexes with TREs and display stronger transactivating activity
62
. 
IL-1β is reported to activate all MAP kinases (MAPKs) which have been shown to 
regulate AP-1 transcription activity by many mechanisms (Chapter 1, Section 1.2.5.2).  
    MAP3K8 is hypothesized to regulate inflammatory response of airway 
inflammation through the activation of inflammatory transcription factors including 
NF-κB and activating protein 1 (AP-1). The aim of this Chapter is to determine the 
link between MAP3K8 regulated MAP kinase signalling and transcription factors by 
monitoring IL-6 and MMP-1 release. Pathway-specific MAP kinase inhibitors will be 
used to modulate the various MAP kinase pathways in an attempt to delineate their 
role in this regulation.  
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7.2 Materials and Methods 
7.2.1 Culture of Cell Lines 
    A549 cells were obtained from the American Type Culture Collection (ATCC). 
They were cultured as described in Chapter 2, Section 2.2.1. A549 cells were used at 
passage numbers 90-110. Cell viability was determined microscopically by trypan 
blue (Sigma-Aldrich) exclusion, and the number of cells was counted using a 
haemocytometer (see Section 2.2.2). Cells were sub-seeded in appropriate culture 
vessels (6- or 24-well plates) and incubated at 37°C for 24 hrs prior to all treatments if 
necessary. 
 
7.2.2 RNA Interference 
    RNA interference (RNAi) was carried using ON-TARGETplus SMARTpool, 
against MAP3K8 (Dharmacon Research Inc., Lafayette, CO). ON-TARGETplus 
Non-targeting Pool negative control (Dharmacon Research Inc., Lafayette, CO) were 
used as controls in the experiments. RNAi transfection of A549 cells was carried out 
with using Lipofectamine RNAiMAX (Invitrogen Corp.) as described in Chapter 2, 
Section 2.2.9. Knockdown efficiency of MAP3K8 was then confirmed on RNA and 
protein level using quantitative real-time PCR and protein blot analysis, respectively. 
 
7.2.3 Treatment with Inhibitors 
After starvation to obtain cell cycle synchronization, cells were pre-treated for 1 
hr with specific inhibitors of signalling pathways before the addition of the IL-1 
stimulus. The MEK1/2 inhibitor used was U0126 whilst the c-Jun NH2-terminal 
kinase (JNK) inhibitor was SP 6001125 (Chapter 2, Section 2.2.12). Stock solutions of 
10
-2
 M were prepared for each inhibitor and these were then used at 1, 5 or 10 µM 
concentrations in serum-free medium. A set of baseline experiments with control cells 
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treated with carrier alone (DMSO) alone with the respective concentrations was 
completed alongside each stimulation experiment. After pre-treatment with inhibitors, 
IL-1 was added and plates were incubated at 37 oC with 5% CO2 for the appropriate 
length of time and then cell-free supernatants were harvested for cytokine 
determinations. Cell viability was also assessed at each time point using MTT as 
described in Chapter 2, Section 2.2.4.  
 
7.2.4 IL-6 and MMP-1 Measurement by ELISA 
Cell-free supernatants post-stimulation were harvested and stored at -80
o
C for 
further cytokine measurements using enzyme-linked immunosorbent assays (ELISA). 
IL-6 and MMP-1 were measured using ELISA kits as described in Chapter 2, Section 
2.2.5. 
 
7.2.5 Western Blotting 
    The phosphorylation of MAPKs including p44/42 MAPK, phospho-p44/42 
MAPK; SAPK/JNK, phospho-SAPK/JNK and p38 MAPK, phospho-p38 MAPK were 
assessed by Western blot analysis according to the protocol as described in Chapter 2, 
Section 2.2.8. 
 
7.2.6 Determination of Transcription Factor Activation by ELISA 
    The preparation of nuclear extracts was performed using the Nuclear Extract kit 
(Chapter 2, Section 2.2.13.1). For the AP-1 DNA binding activity assay, after 
removing the cytoplasmic fraction, the nuclei were lysed and nuclear proteins 
solubilized in 60 µl complete lysis buffer containing 1 μl of 1 M Dithiothreitol (DTT) 
and 10 μl Protease Inhibitor Cocktail per ml of Lysis Buffer AM1 which contains 
phosphatase inhibitors to prevent dephosphorylation of AP-1 during the extract 
 204 
 
preparation and the assay. The protein concentrations of all samples were then 
determined by using a Bradford-based assay (Chapter 2, Section 2.2.13.2).  
    Nuclear extracts (5 μg) were evaluated for the presence of NF-κB p65 subunits 
using TransAM
TM
 NF-κB p65 Transcription Factor Assay kits (Chapter 2, Section 
2.2.13.3). Nuclear extracts (5 μg) were also evaluated for the presence of AP-1 
subunits using TransAM
TM
 AP-1 c-Fos or c-Jun Transcription Factor Assay kits 
(Chapter 2, Section 2.2.13.4). The optical density of chromogenic reaction was 
measured at 450 nm in a SpectraMax
TM




7.3.1 Selective Inhibitors 
7.3.1.1 ERK1/2 Pathway Inhibitor (MEK1/2 Inhibitor) – U0126 
    Cells were pre-treated for 1 hr with various concentrations of MEK1/2 inhibitor 
U0126 and cell viability assessed by MTT assay after IL-β stimulation for 8 hr. As 
shown in Figure 7.3.1 there was significantly 50% decrease in cell viability at 20 μM 
of U0126 pre-treatment. 
 
Figure 7.3.1 Cell Viability of A549 Cells after IL-β Stimulation following 
Pre-treatment with Varying Concentrations of Inhibitor U0126. A significant 
decrease in cell viability was found at 20 μM of U0126 pre-treatment. The 
experiments were performed in triplicate and data shown are mean  SEM of three 
experiments. *P<0.05 as compared to DMSO alone. DMSO, dimethyl sulfoxide. 
 
    The phosphorylation of MAPKs regulated by U0126 (1 - 10 μM) was assessed at 
30 min after IL-1β stimulation (1 - 10 μM pre-treatment of U0126). As shown in 
Figure 7.3.2, there was a significant decrease in the phosphorylation of ERK1/2 at 5 
and 10 μM of U0126 pre-treatment without influence on the relative P-SAPK/JNK 
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and P-p38 MAPK. This indicates that U0126 is a specific inhibitor for ERK1/2. For 
subsequent experiments 10 μM of U0126 pre-treatment was selected.  
       
Figure 7.3.2 MAPKs Phosphorylation in A549 Cells after IL-β Stimulation 
following Pre-treatment with Varying Concentrations of MEK1/2 Inhibitor 
U0126. A significant decrease in the phosphorylation of ERK1/2 was found at 5 and 
10 μM of U0126 pre-treatment without influence on the relative P-SAPK/JNK and 
P-p38 MAPK. 
 
7.3.1.2 SAPK/JNK Pathway Inhibitor (SAPK/JNK Inhibitor) – SP600125 
    Cells were pre-treated for 1 hr with various concentrations of JNK inhibitor 
SP600125 and cell viability assessed by MTT assay after IL-β stimulation for 8 hr. As 
shown in Figure 7.3.3 there was significantly 30% decrease in cell viability at 20 μM 





Figure 7.3.3 Cell Viability in A549 Cells after IL-β Stimulation following 
Pre-treatment with Varying Concentrations of SAPK/JNK Inhibitor SP600125. A 
significant decrease in cell viability was found at 20 μM of SP600125 pre-treatment. 
The experiments were performed in triplicate and data shown are mean  SEM of 
three experiments. *P<0.05 as compared to DMSO alone. DMSO, dimethyl sulfoxide.  
 
    The phosphorylation of MAPKs regulated by SP600125 was assessed at 30 min 
after IL-1β stimulation (1 - 10 μM pre-treatment of SP600125). As shown in Figure 
7.3.4, there was a significant decrease in the phosphorylation of SAPK/JNK at 5 and 
10 μM of SP600125 pre-treatment but no influence on the phosphorylation of ERK1/2 
and p38 MAPK. This indicates that SP600125 is a specific inhibitor for SAPK/JNK. 
For subsequent experiments 10 μM of SP600125 was selected.  
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Figure 7.3.4 MAPKs Phosphorylation of A549 Cells after IL-β Stimulation 
following Pre-treatment with Varying Concentrations of Inhibitor SP600125. A 
significant decrease in the phosphorylation of SAPK/JNK was found at 5 and 10 μM 
of SP600125 pre-treatment without influence on the relative P-ERK1/2 and P-p38 
MAPK. 
  
7.3.2 Effect of U0126 and SP600125 on IL-6 and MMP-1 Release 
    After pre-treatment with U0126 or SP600125 for one hour, IL-1 was added and 
incubated at 37
 o
C with 5% CO2 for 8 hrs and cell-free supernatants were then 
harvested for IL-6 and MMP-1 measurements. As shown in Figure 7.3.5, no 
difference in IL-6 release was found at different concentrations of U0126 
pre-treatment. There was however a significant decrease in IL-6 release at 5 and 10 




Figure 7.3.5 Comparison of IL-6 Release after IL-β Stimulation following 
Pre-treatment with Varying Concentrations of MEK1/2 Inhibitor U0126. No 
difference in IL-6 release was found at different concentrations of U0126 
pre-treatment. The experiments were done in triplicate and data shown are mean  





Figure 7.3.6 Comparison of IL-6 Release after IL-β Stimulation following 
Pre-treatment with Varying Concentrations of SAPK/JNK Inhibitor SP600125. A 
significant decrease in IL-6 release was found at 5 and 10 μM of SP600125 
pre-treatment. Data shown are mean  SEM of four separate experiments. *P<0.05 as 
compared to DMSO alone. DMSO, dimethyl sulfoxide. 
 
    Regarding the release of MMP-1, a concentration-dependent decrease in MMP-1 
expression was found in A549 cells with differing concentrations of U0126 or 
SP600125 pre-treatment. There was a significant decrease in MMP-1 release at 5 and 
10 μM of U0126 pre-treatment (Figure 7.3.7). Similar results were obtained with 
SP600125 pre-treatment (Figure 7.3.8). 
 
Figure 7.3.7 Comparison of MMP-1 Release after IL-β Stimulation following 
Pre-treatment with Varying Concentrations of MEK1/2 Inhibitor U0126. A 
significant decrease in MMP-1 release was found at 5 and 10 μM of U0126 
pre-treatment. Data shown are mean  SEM of four separate experiments. *P<0.05 as 




Figure 7.3.8 Comparison of MMP-1 Release after IL-β Stimulation following 
Pre-treatment with Varying Concentrations of SAPK/JNK Inhibitor SP600125. A 
significant decrease in MMP-1 release was found at 5 and 10 μM of SP600125 
pre-treatment. Data shown are mean  SEM of four separate experiments. *P<0.05 as 
compared to DMSO alone. DMSO, dimethyl sulfoxide. 
 
7.3.3 Effect of MAP3K8 Gene Silencing on Transcription Factor Activity 
7.3.3.1 Effect of MAP3K8 Gene Silencing on NF-κB Activity 
    NF-κB activation depends on the phosphorylation and activation of the IKK 
complex by upstream kinases. A time series analysis of IKK complex phosphorylation 
after IL-1β stimulation was therefore conducted. After IL-1β stimulation, the A549 
cells were harvested and proteins extracted at 5, 10, 20, 30, 45 and 60 min. As shown 
in Figure 7.3.9 the phosphorylation of IKKα/β significantly increased after 10 min of 




Figure 7.3.9 P-IKKα/β Phosphorylation in IL-1β-treated A549 Cells. A significant 
increase in the phosphorylation of IKKα/β was found at 20 min after IL-1β 
stimulation. Data shown are mean  SEM of three separate experiments. *P<0.05 as 
compared to 0 min. 
 
    A comparison of P-IKKα/β between MAP3K8 gene silencing and controls was 
then conducted at time points of 20 and 30 min. Compared with non-targeting siRNA, 
a significant (20%) decrease in the phosphorylation of IKKα/β was found in A549 
cells with MAP3K8 gene silencing at 20 and 30 min after IL-1β stimulation (Figure 
7.3.10). Similar results were also obtained using TransAM
TM
 NF-κB p65 
Transcription Factor Assay kits. A significant increase in NF-κB p65 DNA binding 
activity was found at 1 hr after IL-1β stimulation in A549 cells. In addition there was 
a significant (20%) decrease in NF-κB p65 DNA binding activity following MAP3K8 





Figure 7.3.10 Comparison of P-IKKα/β between MAP3K8 Gene Silencing and 
Controls at Varying Time Points after IL-1β Stimulation. A significant decrease in 
the phosphorylation of IKKα/β was found at 20 and 30 min after IL-1β stimulation 
following MAP3K8 gene silencing. Data shown are mean  SEM of three separate 




               
Figure 7.3.11 Comparison of NF-κB p65 Binding Activity between MAP3K8 
Gene Silencing and Controls. A significant decrease in NF-κB p65 DNA binding 
activity was found following MAP3K8 gene silencing. Data shown are mean  SEM 
of three separate experiments. *P<0.05 as compared to NT. NT, non-tarheting siRNA. 
 
7.3.3.2 Effect of MAP3K8 Gene Silencing on AP-1 Activity 
    A comparison of the AP-1 activity between MAP3K8 gene silencing and controls 
was assessed using TransAM
TM
 AP-1 Transcription Factor Assay kits. A significant 
increase in AP-1 DNA binding activity was found at 1 hr after IL-1β stimulation in 
A549 cells. Compared with non-targeting siRNA, a significant (40%) decrease in 
AP-1 c-Fos DNA binding activity was found in A549 cells with MAP3K8 gene 
silencing (Figure 7.3.12 A). Similar results (40% decrease) were also obtained with 




Figure 7.3.12 Comparison of AP-1 c-Fos (A) and c-Jun (B) Binding Activity 
between MAP3K8 Gene Silencing and Controls. A significant decrease in AP-1 
c-Fos (A) and c-Jun (B) DNA binding activity was found after MAP3K8 gene 
silencing. Data shown are mean  SEM of four separate experiments. *P<0.05 as 
compared to NT. NT, non-tarheting siRNA. 
 
7.3.4 Effect of ERK1/2 and JNK Signalling on Transcription Factor Activity 
7.3.4.1 Effect of ERK1/2 and JNK Signalling on NF-κB Activity 
    Cells were pre-treated with U0126 (10 µM) or SP600125 (10 µM) for 2 hrs to 
ensure full effect of the inhibitors. The NF-κB p65 binding activity was then assessed 
using TransAM
TM
 NF-κB p65 Transcription Factor Assay kits at 1 hr after IL-1β 
stimulation. As shown in Figure 7.3.13, no significant difference in NF-κB p65 




            
Figure 7.3.13 Comparison of NF-κB p65 Binding Activity in A549 Cells with 
U0126 or SP600125 Pre-treatment. No significant difference in NF-κB p65 binding 
activity was found in cells with either U0126 or SP600125 pre-treatment for 2 hrs. 
The experiments were performed in triplicate and data shown are mean  SEM of the 
three experiments. DMSO, dimethyl sulfoxide. 
 
7.3.4.2 Effect of ERK1/2 and JNK Signalling on AP-1 Activity 
    The AP-1 c-Fos or c-Jun binding activity was assessed using TransAM
TM
 AP-1 
Transcription Factor Assay kits at 1 hr after IL-1β stimulation. As shown in Figure 
7.3.14 compared with non-targeting siRNA, there was a significant (30%) decrease in 
AP-1 c-Fos binding activity in A549 cells with U0126 but not with SP600125 
pre-treatment. In contrast, a significant (60%) decrease in AP-1 c-Jun binding activity 




              
Figure 7.3.14 Comparison of AP-1 c-Fos Binding Activity in A549 Cells with 
U0126 or SP600125 Pre-treatment. A significant decrease in AP-1 c-Fos binding 
activity was found in cells after pre-treatment with U0126 but not with SP600125 for 
2 hrs. Data shown are mean  SEM of four experiments. *P<0.05 as compared to 
DMSO alone. DMSO, dimethyl sulfoxide. 
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Figure 7.3.15 Comparison of AP-1 c-Jun Binding Activity in A549 Cells with 
U0126 or SP600125 Pre-treatment. A significant decrease in AP-1 c-Jun binding 
activity was found in cells after pre-treatment with SP600125 but not with U0126 for 
2 hrs. Data shown are mean  SEM of four experiments. *P<0.05 as compared to 





    IL-1β, a strong inflammatory mediator, is reported to activate two distinct 
signalling pathways in turn leading to the activation of transcription factors, NF-κB 
p50/p65 and AP-1 whose pre-dominant roles are in the regulation of immune and 
inflammatory response
214
. NF-κB regulates the expression of many genes involved in 
the inflammatory response in the lungs
215,216
. Similarly, AP-1 is also involved in the 
transcriptional control of many inflammatory mediators
217
. Even though NF-κB and 
AP-1 transcription factors are regulated by different mechanisms, many genes require 
the concomitant activation of AP-1 and NF-κB, suggesting that these two transcription 
factors work co-operatively
218
. For example, in synoviocytes NF-κB and MAP 
kinases/AP-1 pathways have been shown to both be involved in IL-6 and IL-8 
expression
219
. Furthermore, NF-κB and AP-1 also co-operate to mediate IL-1-induced 
MMP-1 and MMP-9 transcription in synovial fibroblasts and mesangial cells 
respectively
220,221
. In the previous study (Chapter 6), the cytokine IL-6 and matrix 
metalloproteinases MMP-1 were the two main inflammatory genes most significantly 
regulated by MAP3K8. Moreover, NF-κB and AP-1 transcription factors were found 
to be regulated by MAP3K8 simultaneously in response to IL-1β stimulation in this 
present study. Overall these findings indicate that MAP3K8 regulates IL-6 and 
MMP-1 expression through a simultaneous activation of NF-κB and AP-1 pathways.  
    In Chapter 4, the results suggested that MAP3K8 regulates inflammatory 
mediators by the ERK1/2 and SAPK/JNK signalling pathways. The phosphorylation 
of these MAPKs however does not imply their direct involvement in the 
IL-1β-induced inflammatory mediator expression. The roles of these MAPKs 
involved in the IL-1β-induced IL-6 and MMP-1 release were therefore investigated by 
using selective pharmacological inhibitors in this present study. IL-6 release was 
significantly blocked by JNK but not ERK1/2 signalling inhibitors, whereas MMP-1 
 220 
 
release was significantly blocked by both ERK1/2 and JNK signalling inhibitors. 
These findings indicate that MAP3K8 regulated ERK1/2 and JNK signalling 
pathways are required for the IL-1β-induced IL-6 and MMP-1 release in A549 cells. 
Furthermore, IL-1β is known to induce AP-1 transcriptional activity through MAPK 
pathway activation
59
. MAP kinase signalling pathways influence AP-1 activity by 
both increasing the abundance of AP-1 components (c-Fos/c-Jun) and by stimulating 
their activity directly
64
. In this study, ERK1/2 and JNK signalling inhibitors also 
significantly decreased AP-1 c-Fos and c-Jun activation respectively, suggesting that 
MAP3K8 regulates IL-1β-induced IL-6 and MMP-1 up-regulations by the AP-1 
transcription factor through ERK1/2 and JNK signalling pathways. 
    IL-1β has been reported not only to activate the MAP kinases/AP-1 pathway but 
also the NF-κB pathway. Additionally MAP3K8 was found to regulate NF-κB and 
AP-1 transcription factors simultaneously in response to IL-1β stimulation in this 
study. Since MAPK activation and NF-κB translocation has been shown to be 
necessary for inflammatory mediator expression induced by IL-1β in A549 cells59, 
MAP3K8 regulated MAPK activation may not only regulate AP-1 but also involve 
NF-κB activation. IL-1β-stimulated DNA binding activity of NF-κB however was not 
significantly inhibited by ERK1/2 and JNK signalling inhibitors in this study. These 
results demonstrate that NF-κB binding activation regulated by MAP3K8 participated 
in IL-6 and MMP-1 up-regulations but was independent of ERK1/2 and JNK 
activation in IL-1β-stimulated A549 cells. The up-regulations of IL-6 and MMP-1 
regulated by MAP3K8-mediated NF-κB activation may therefore involve other 
mechanisms.   
    In this study, IL-1β clearly induced NF-κB nuclear translocation and DNA 
binding but pre-treatment with ERK1/2 and JNK pathway inhibitors did not affect 
IL-1β-induced NF-κB DNA binding activity, indicating that NF-κB activation 
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regulated by MAP3K8 was not influenced at this level by MAPKs’ activity. Certain 
proteins, MAP3K-related kinases, have been reported to be involved in NF-κB 
induction by TNF, CD95 and IL-1 through MAP kinase kinase rather than MAPK
222
.  
The MAP kinase pathway is composed of three consecutive kinases. MAPK 
kinase kinase (MAP3K) phosphorylates and activates MAP kinase kinase (MAP2K), 
which in turn phosphorylates and activates MAPK. A member of the 
mitogen-activating protein kinase kinase kinase family, MAP3K1 and MAP3K3 are 
able to activate IκB kinase α and β (IKKα/β) which in turn leads to the 
phosphorylation of IκBα and NF-κB transcriptional activation223,224, indicating that 
other MAP3Ks might also activate IKKα/β activity. Furthermore, this present study 
has demonstrated that MAP3K8 is involved in the phosphorylation of IKKα/β. These 
results suggest that MAP3K8 regulates NF-κB DNA binding activity through IKKα/β 
activation independent of the MAPK pathway regulated by itself. 
    On the other hand, MAP3K8-mediated MAPKs such as ERK1/2 and JNK may 
regulate the transcriptional activity of NF-κB without affecting DNA binding activity. 
In this present study, IL-1β-induced DNA binding activity of NF-κB p65 was not 
significantly inhibited by ERK1/2 and JNK signalling inhibitors. A previous study has 
also demonstrated that inhibition of all MAPK phosphorylation had no effect on the 
nuclear translocation of NF-κB (p65) determined by immunofluorescence staining in 
IL-1β-induced A549 cells59. Another study reported that neither ERK1/2 nor p38 
inhibition had a significant impact on NF-κB DNA binding activity225. It has however 
been demonstrated that the ERK1/2 pathway contributes to transcriptional activation 
of NF-κB by modulating the transactivation capacity of the NF-κB p65 subunit in 
response to TNF or IL-1β225,226. NF-κB (p50/p65) is a ubiquitous, constitutive and 
inducible heterodimer. In the nucleus, the p65 NF-κB subunit is a strong activator for 
a wide variety of genes and plays a crucial role in inflammatory and immune 
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responses. The p65 subunit of NF-κB undergoes phosphorylation for regulating DNA 
binding and/or transactivation after exposure to various stimuli at three sites: Ser529 
and Ser536 in the transactivation domain and Ser276 in the DNA-binding Rel 
homology domain
164,227,228
. The phosphorylation of Ser276 has been shown to be 
essential for IL-1β-induced NF-κB-mediated gene expression225. It has also been 
demonstrated that MAP3K8 activates NF-κB pathway by regulating phosphorylation 
of p65 at Ser276
125
. Furthermore mitogen- and stress-activated protein kinase 1 
(MSK1), a substrate of ERK1/2 and p38 MAPK, has been found to phosphorylate the 
p65 subunit of NF-κB at Ser276 during TNF-α or IL-1β stimulation229,230. These 
findings suggest that MAP3K8-mediated MAPKs may regulate NF-κB transactivation 
capacity by phosphorylating the NF-κB p65 subnuit at Ser276 but without affecting 
its DNA binding activity. 
    In this study, MAP3K8 shows to regulate inflammatory response through the 
activation of NF-κB and AP-1 pathways. MAP3K8 regulates AP-1 transcription factor 
through ERK1/2 and JNK signalling pathways. In contrast, MAP3K8 regulates 
NF-κB DNA binding activity through IKKα/β activation independent of the MAPK 
pathway regulated by itself. The overview of MAP3K8 regulated MAP kinase 
signalling and transcription factors in IL-6 and MMP-1 expression based on the 




Figure 7.4.1 Overview of MAP3K8 Regulated MAP Kinase Signalling and 
Transcription Factors Involved in IL-6 and MMP-1 Expression in A549 Cells. 
Stimulation with IL-1β induces the phosphorylation of MAP3K8, which activate 
MEK1/2-ERK1/2 (red arrow) and MKK4-SAPK/JNK (green arrow) pathways but not 
the p38 MAPK (blue arrow) pathway. Activated MEK1/2-ERK1/2 pathway regulates 
activating protein 1 (AP-1) transcription factor through c-Fos activation and involves 
the release of MMP-1. Activated MKK4-SAPK/JNK pathway regulates AP-1 
transcription factor through c-Jun activation and involves the release of both MMP-1 
and IL-6. Activated MAP3K8 also shows to regulate NF-κB DNA binding activity 
through IKKα/β activation independent of the MAPK pathway. The activation of IKK 
complex (black arrow) results in the phosphorylation of IκB proteins and 
consequently their degradation by the proteasome. Released NF-κB dimers (p50/p65) 
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translocate to the nucleus and are believed to co-operate with AP-1 for mediating 
IL-1β-induced MMP-1 and IL-6 transcription in A549 cells. , phosphorylated; 






General Discussion and Future Research Directions 
 
8.1 General Discussion 
    In the Molecular Genetics and Genomics Group previous pilot study of global 
gene expression following IL-1β stimulation, MAP3K8 was found to be highly 
associated with inflammatory gene expression in the acute response to the 
inflammatory stimulus in A549 and BEAS-2B cells. MAP3K8 is a member of the 
serine/threonine protein kinase family and has been demonstrated to be involved in 
the MAP kinase pathway. The MAP kinase signal transduction pathway plays an 
important role in many aspects of the immune mediated inflammatory response. The 
inhibition of MAP3K8 kinase has already been shown to have the potential to be an 
effective therapy for rheumatoid arthritis
162
. It is also believed that MAP3K8 may 
play a role in airway inflammation. Consequently the inhibition of MAP3K8 may 
potentially be a new therapeutic strategy for diseases such as asthma and COPD that 
involve airway inflammation. 
 
8.1.1 Effect of MAP3K8 on Airway Inflammation 
    MAP3K8 has predominantly a pro-inflammatory function and its role in 
inflammatory disorders has been studied extensively. In a LPS-induced septic shock 
mouse model, serum levels of TNF-α and IL-1β reduced by MAP3K8 suppression 
showed to be resistant to endotoxin shock
117
. In mouse models, the absence of 
MAP3K8 delayed the onset and progression of inflammatory bowel disease by 
maintaining low number of memory CD4
+





Furthermore, the inhibition of MAP3K8 significantly reduced TNF-α and IL-1 
expression in a mechanically induced periodontal inflammation
232
. Additionally, in an 
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acute pancreatitis mouse model, MAP3K8 suppression attenuated pancreatic and lung 
inflammation by reducing the amounts of neutrophil chemoattractant chemokines 
macrophage inflammatory protein 2 (MIP-2), monocyte chemoattractant protein-1 
(MCP-1) and IL-6
233
. MAP3K8 is also expressed in various T cell subsets with Th1 
expressing higher levels than Th2. T cell receptor (TCR) signalling has been shown to 
depend heavily on MAP3K8 in Th1 but not in Th2 cells
161,234
. In a mouse model of 
ovalbumin-induced bronchoalveolar inflammation, MAP3K8 ablation resulted in Th2 
polarization of the T cell response with concomitant increase in eosinophils and IgE 
levels
234
. Despite this, MAP3K8 is essential for the gene expression of Th2-type 
cytokines, such as IL-5, IL-10 and IL-13 in LPS-stimulated bone marrow-derived 
mast cells of MAP3K8 gene-deficient mice
235
. MAP3K8 seems to favor a Th1 
immune response
234
 and may therefore play a crucial role in severe asthma and COPD 
in which Th1 cells are predominant and accumulate in the airways.  
    In this current research project, the investigation of the effect of MAP3K8 on 
airway inflammation was based on an in vitro IL-1β-induced inflammatory response 
in A549 cells. A549 cells are adenocarcinomic human alveolar basal epithelial cells 
and are widely used in airway research because they contain most of the inflammatory 
functions of normal cells. In this study, A549 cells were selected as the cells because 
they not only express inflammatory mediators such as IL-6, IL-8 and RANTES but 
also express a similar fold-change of MAP3K8 gene expression in comparison with 
primary bronchial epithelial cells in response to IL-1β (Chapter 3). Most biological 
functions of MAP3K8 are obtained using mouse embryonic fibroblasts derived from 
MAP3K8 knockout mice. These results however are not recapitulated in the mature 
intact MAP3K8 knockout animal and are not an appropriate surrogate for human 
cells. siRNA silencing is one of the most widely used methods for functional 
 227 
 
genomics and it provides a reliable method to investigate gene function of MAP3K8 
in human cell lines.  
    In the present study it has been shown that MAP3K8 plays a key role in the 
inflammatory cytokine response post IL-1β stimulation. Despite the limitations of 
approximately 40% reduction in MAP3K8 gene silencing, a significant decrease in 
the release of inflammatory mediators, including IL-6, IL-8 and RANTES was still 
observed. IL-6 has been reported to be associated with the inflammatory amplification 
in asthma and COPD
19,23
. IL-8 plays a crucial role in the recruitment of neutrophils 
into the airways and the resulting neutrophilic inflammation is the predominant 
feature in corticosteroid-resistant severe asthma and COPD
137
. RANTES is expressed 
in airway epithelial cells and is involved in the migration of eosinophils from blood to 
airways the latter being a characteristic feature of asthmatic airways. These results 
strongly indicate that MAP3K8 may have substantial effects on airway inflammation. 
    The suppression of MAP3K8 also shows an additive effect on the therapeutic 
effect of steroids. Corticosteroids are widely used to treat various immune and 
inflammatory diseases, such as rheumatoid arthritis and asthma. In chronic airway 
inflammatory diseases, however, they are ineffective in treating severe asthma and 
COPD
169,170
. Corticosteroids reduce the number of inflammatory cells that are 
critically involved in airways inflammation, by suppressing the production of 
chemotactic mediators. In this present study, the inhibition of MAP3K8 gene 
expression not only reduced the release of chemotactic cytokines, IL-8 and RANTES 
but it also resulted in the enhancement of the effect of corticosteroids on the reduction 
of these inflammatory mediators. These results suggest that MAP3K8 inhibition may 
be an alternative means for the treatment of corticosteroid-resistant airway diseases, 
such as severe asthma and COPD. MAP3K8 inhibitors are therefore potentially a new 
therapeutic strategy for airway inflammation. 
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8.1.2 Signal Transduction and Regulation of MAP3K8 on Airway Inflammation 
    MAP3K8 is a potent kinase with broad range substrate specificity. The 
predominant pathway activated by ectopic expression of MAP3K8 is the activation of 
ERK1/2 with MEK1/2 being its direct substrate. MAP3K8 can also stimulate the 
activation of JNK and to a lesser extent p38γ and ERK5236,237. Ectopically expressed 
MAP3K8 has also been found in a higher order complex that supposedly directly 
activates NF-κB inducing kinase (NIK) and IκB kinase-α (IKKα), leading to NF-κB 
activation
238
. On the other hand, MAP3K8 ablation has revealed an important role in 
ERK signalling by a plethora of receptors including TLRs, TNFR1, CD40 and the 
IL-1 receptor
117,125,239
. In addition to ERK, MAP3K8 has been shown to contribute to 





.  MAP3K8 is a member of the serine/threonine protein 
kinase family and has been demonstrated to be involved in MAP kinase pathways 
which regulate many aspects of immune mediated inflammatory responses
56
. 
MAP3K8 activated signalling pathways have been identified and are believed to be in 
a cell-type and stimulus-specific manner. The molecular regulation of MAP3K8 
kinase in IL-1β-induced airway epithelial cells however remains unclear.  
    In this present study, the activation of MAP3K8 in A549 cells was followed by 
the rapid proteolytic degradation of the 58 kDa form of the kinase, but not the 52 kDa 
isoform, after IL-1β stimulation. This phenomenon was also found in response to LPS 
or TNF in macrophages from MAP3K8 knockout mice
78
. MAP3K8 appears to 
regulate inflammatory mediators by ERK1/2 and JNK but not p38 MAPK signalling 
pathways in A549 cells, which is also confirmed by the results of the canonical 
pathway-based microarray analysis in this current study.  
    Microarray measurements at multiple time points are used widely for the 
systematic identification of altered gene expression. Advances in microarray 
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technology and data processing enable the application of time-series microarray 
analyses as the basis for a systematic investigation of the cellular response to 
inflammatory and anti-inflammatory stimuli
181,182
. Furthermore, a systems biology 
approach for studying gene function and pathways by integrating data from 
microarray experiments, functional annotations and comparative genomics has been 
shown to greatly eliminate noises contained in samples
188
. In this current study, 
microarray analysis of MAP3K8-regulated genes in inflammatory response networks 
reinforces the Molecular Genetics and Genomics Group previous findings related to 
the presence of genes involved in airway inflammation, such as IL-6, CCL20, MMP-1, 
MMP-3 and MMP-12. IL-6 has been related to pulmonary function decline and 
infection in patients with COPD
196,197
 and may also contribute to asthma severity and 
poor asthma control
195
. MMPs are produced in the respiratory tract from different 
inflammatory and structural cells and are involved in wound healing, inflammatory 
cell trafficking and tissue remodelling and repair
33
. The MAP3K8 significantly 
down-regulated genes MMP-1, MMP-3 and MMP-12 in this study have previously 
been reported to be involved in asthma and COPD. Among them, reduced MMP-12 
protein expression is believed to have a beneficial effect on lung function in childhood 
asthma and on the pathogenesis of COPD
241
.  
    The role of MAP3K8 in IL-1β-induced activation of MAP kinases/AP-1 and 
NF-κB pathways was also investigated in this present study by monitoring IL-6 and 
MMP-1 expression. Transcription factors NF-κB and AP-1 have both been reported to 
be involved in IL-6 and MMP-1 transcription
219,220
. In this study MAP3K8 was found 
to regulate IL-6 and MMP-1 up-regulations by AP-1 transcription factor through 
ERK1/2 and JNK signalling pathways. In addition MAP3K8 regulated NF-κB DNA 
binding activity through activation of IKKα/β independent of the MAP kinase 
pathways. These findings suggest that MAP3K8 regulates inflammatory mediators 
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through the simultaneous activation of NF-κB and AP-1 pathways.  
    The inhibition of MAP3K8 expression was found to enhance the effect of 
corticosteroids on the reduction of airway inflammation in this current study. 
Corticosteroids regulate airway inflammation via multiple mechanisms (Chapter 1, 
Section 1.3). Corticosteroids reduce airway inflammation through the inhibition of 
MAP kinase pathways by the production of MKP-1. In this present study, the 
interaction of MAP3K8 with corticosteroid suppression of the inflammatory response 
via MKP-1 was assessed. MAP3K8 was found to regulate the inflammatory response 
by ERK1/2 and SAPK/JNK but not p38 MAPK signalling pathways. Furthermore, 
dexamethasone reduced IL-1β-induced phosphorylation of ERK1/2 and SAPK/JNK 
but not their upstream kinases MEK1/2 and MKK4. These findings indicate that the 
suppression of MAP3K8 enhances the anti-inflammation effect of dexamethasone 
through enhancement of the inhibition of MAP kinase pathways by inhibition of their 
upstream kinases. 
In this project, MAP3K8 shows to play an important role in the regulation of 
airway epithelial cells in response to inflammation. MAP3K8 regulates the 
inflammatory response by ERK1/2 and SAPK/JNK pathways but not the p38 MAPK 
pathway. MAP3K8 also shows to regulate inflammatory response through the 
activation of NF-κB and AP-1 pathways. MAP3K8 regulates AP-1 transcription factor 
through ERK1/2 and JNK signalling pathways. In contrast, MAP3K8 regulates 
NF-κB DNA binding activity through IKKα/β activation independent of the MAPK 
pathway regulated by itself. The suppression of MAP3K8 shows to provide additive 
therapeutic effect of corticosteroid on airway inflammation via additive inhibition of 
MAPK signalling pathways through inhibition of the upstream kinases of MAP 
kinases. MAP3K8 also shows to regulate IL-1β-induced inflammatory response via a 
series of genes involved in inflammation. MAP3K8 regulated a number of 
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inflammation-related genes which have been linked with airway diseases, indicating 
that MAP3K8 may potentially be a novel therapeutic target for airway diseases.  
    In this study, a very potent pro-inflammatory stimulus, IL-1β, was used to 
challenge the A549 cells, and the response followed by measurement of inflammatory 
cytokine release. Although A549 cells contain most of the inflammatory functions of 
normal cells and are used to throw light on important processes, they are derived from 
a lung cancer, and are therefore not the same as normal cells. Consequently it will be 
important and necessary to confirm the results of this study in primary airway 





8.2 Future Research Directions 
    The observations of MAP3K8 in this study are predominantly based on A549 
cell lines. A549 cells are widely used in airway research because they contain most of 
the inflammatory functions of normal cells. They however are not the same as 
primary airway epithelial cells. It is therefore necessary to confirm important results 
by direct measurement of key genes in primary airway epithelial cells that are readily 
available commercially. In order to validate the effect of MAP3K8 on inflammatory 
response, a MAP3K8 gene knockdown experiment in primary airway epithelial cells 
needs to be performed to clarify the relationship between MAP3K8 and the 
inflammatory mediators including IL-6 and MMP-1. 
In this study, MAP3K8 appears to regulate inflammatory mediators by ERK1/2 
and JNK but not p38 MAPK signalling pathways. MAP3K8 also appears to regulate 
NF-κB DNA binding activity through activation of IKKα/β independent of the MAP 
kinase pathways. The role of MAP3K8 in regulating the MEK kinase activity is well 
established as confirmed in this current study. The understanding however of whether 
MAP3K8 regulates MKK4 or IKKα/β in airway epithelial cells is less clear. In order 
to more fully understand the role and function of MAP3K8 in the regulation of 
MAPK and NF-κB signalling pathways, an in vitro assay of catalytic activity of 
MAP3K8 using immunoprecipitation would clarify the relationship between 
MAP3K8 and its possible substrates including MKK4 and IKKα/β and this 
experiment would be worthwhile conducting. 
    In this study, it has been shown that MAP3K8 inhibition can not only suppress 
key inflammatory cytokines but it can also enhance the therapeutic effect of steroids. 
MAP3K8 inhibition might therefore be an alternative in the treating of 
corticosteroid-resistant airway diseases such as severe asthma and COPD. The 
importance of MAP3K8 in airway inflammation needs to be assessed in clinical 
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samples and the best samples would be obtained from airway epithelial cells. 
Immunohistochemistry (IHC) is the localization of antigens or proteins in tissue 
sections by the use of labeled antibodies as specific reagents through antigen-antibody 
interactions. These interactions are then visualized by a marker, either a fluorescent 
dye or an enzyme that can catalyse a colour-producing reaction. IHC is widely used in 
basic research to understand the distribution and localization of biomarkers and 
differentially expressed proteins in different parts of a biological tissue. The logical 
next effort would therefore be to evaluate the protein expression of MAP3K8 in 
addition to investigating how it regulates inflammation in human airway tissues 




A. Genes Up-regulated by IL-1β 







7947462 ABTB2 ankyrin repeat and BTB (POZ) domain containing 2 
8064779 ADRA1D adrenergic, alpha-1D-, receptor 
7926531 ARL5B ADP-ribosylation factor-like 5B 
8080878 ATXN7 ataxin 7 
8084206 B3GNT5 betaGal beta-1,3-N-acetylglucosaminyltransferase 5 
7926875 BAMBI BMP and activin membrane-bound inhibitor homolog 
7978595 BAZ1A bromodomain adjacent to zinc finger domain, 1A 
7990818 BCL2A1 BCL2-related protein A1 
7943424 BIRC2 baculoviral IAP repeat-containing 2 
7943413 BIRC3 baculoviral IAP repeat-containing 3 
8136341 BPGM 2,3-bisphosphoglycerate mutase 
7909425 CAMK1G calcium/calmodulin-dependent protein kinase IG 
8006433 CCL2 chemokine (C-C motif) ligand 2 
8048864 CCL20 chemokine (C-C motif) ligand 20 
8097461 CCRN4L CCR4 carbon catabolite repression 4-like (S. cerevisiae) 
8116983 CD83 CD83 molecule 
8150592 CEBPD CCAAT/enhancer binding protein (C/EBP), delta 
8095187 CEP135 centrosomal protein 135kDa 
7986250 CHD2 chromodomain helicase DNA binding protein 2 
8161255 CKAP2 cytoskeleton associated protein 2 
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8058127 CLK1 CDC-like kinase 1 
7997427 CMIP c-Maf-inducing protein 
8130422 CNKSR3 CNKSR family member 3 
7903786 CSF1 colony stimulating factor 1 (macrophage) 
8107887 CSF2 colony stimulating factor 2 (granulocyte-macrophage) 
7996027 CX3CL1 chemokine (C-X3-C motif) ligand 1 
8100994 CXCL2 chemokine (C-X-C motif) ligand 2 
8100984 CXCL3 chemokine (C-X-C motif) ligand 3 
8148476 DENND3 DENN/MADD domain containing 3 
7989849 DENND4A DENN/MADD domain containing 4A 
7938702 DKFZp hypothetical protein DKFZp 
8024391 DOT1L DOT1-like, histone H3 methyltransferase (S. cerevisiae) 
7945641 DUSP8 dual specificity phosphatase 8 
7905929 EFNA1 ephrin-A1 
7949264 EHD1 EH-domain containing 1 
7952601 ETS1 v-ets erythroblastosis virus E26 oncogene homolog 1 
8068593 ETS2 v-ets erythroblastosis virus E26 oncogene homolog 2 
7921228 ETV3 ets variant 3 
7910997 EXO1 exonuclease 1 
8130032 FBXO30 F-box protein 30 
7950248 FCHSD2 FCH and double SH3 domains 2 
8109981 FGF18 fibroblast growth factor 18 
7949532 FOSL1 FOS-like antigen 1 
8041048 FOSL2 FOS-like antigen 2 
8023995 FSTL3 follistatin-like 3 (secreted glycoprotein) 
7988687 GABPB1 GA binding protein transcription factor, beta subunit 1 
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8020455 GATA6 GATA binding protein 6 
7979269 GCH1 GTP cyclohydrolase 1 
8112668 GCNT4 glucosaminyl (N-acetyl) transferase 4, core 2 
8016094 GJC1 gap junction protein, gamma 1, 45kDa 
8115391 HAND1 heart and neural crest derivatives expressed 1 
8114572 HBEGF heparin-binding EGF-like growth factor 
7956894 HELB helicase (DNA) B 
8116910 HIVEP1 HIV type I enhancer binding protein 1 
8129953 HIVEP2 HIV type I enhancer binding protein 2 
8072678 HMOX1 heme oxygenase (decycling) 1 
7975076 HSPA2 heat shock 70kDa protein 2 
8025601 ICAM1 intercellular adhesion molecule 1 
8025612 ICAM4 intercellular adhesion molecule 4 
8178435 IER3 immediate early response 3 
8068280 IFNGR2 interferon gamma receptor 2 
8068254 IL10RB interleukin 10 receptor, beta 
8054712 IL1A interleukin 1, alpha 
7956251 IL23A interleukin 23, alpha subunit p19 
7997128 IL34 interleukin 34 
8131803 IL6 interleukin 6 (interferon, beta 2) 
8095680 IL8 interleukin 8 
8139207 INHBA inhibin, beta A 
8137526 INSIG1 insulin induced gene 1 
8114010 IRF1 interferon regulatory factor 1 
8064978 JAG1 jagged 1 (Alagille syndrome) 
8143341 JHDM1D jumonji C domain containing histone demethylase 1 
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8076128 JOSD1 Josephin domain containing 1 
8138922 KBTBD2 kelch repeat and BTB (POZ) domain containing 2 
8004671 KDM6B lysine (K)-specific demethylase 6B 
8170420 MAMLD1 mastermind-like domain containing 1 
8005707 MAP2K3 mitogen-activated protein kinase kinase 3 
8122672 MAP3K7IP2 MAP kinase kinase kinase 7 interacting protein 2 
7926900 MAP3K8 mitogen-activated protein kinase kinase kinase 8 
8149258 MFHAS1 malignant fibrous histiocytoma amplified sequence 1 
7915861 MKNK1 MAP kinase interacting serine/threonine kinase 1 
8151334 MSC musculin (activated B-cell factor-1) 
8111153 MYO10 myosin X 
7956287 NAB2 NGFI-A binding protein 2 (EGR1 binding protein 2) 
8021376 NEDD4L NPC expressed, developmentally down-regulated 4-like 
8021866 NFATC1 nuclear factor of activated T-cells, calcineurin-dependent 1 
8067040 NFATC2 nuclear factor of activated T-cells, calcineurin-dependent 2 
8056977 NFE2L2 nuclear factor (erythroid-derived 2)-like 2 
8096635 NFKB1 NF of kappa in B-cells 1 
7978644 NFKBIA NF of kappa in B-cells inhibitor, alpha 
8036207 NFKBID NF of kappa in B-cells inhibitor, delta 
8081386 NFKBIZ NF of kappa in B-cells inhibitor, zeta 
8162455 NINJ1 ninjurin 1 
8149811 NKX3-1 NK3 homeobox 1 
8033818 OLFM2 olfactomedin 2 
8075529 PISD phosphatidylserine decarboxylase 
8150509 PLAT plasminogen activator, tissue 
8028656 PLEKHG2 pleckstrin homology domain containing, family G 
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8112202 PLK2 polo-like kinase 2 (Drosophila) 
8021470 PMAIP1 phorbol-12-myristate-13-acetate-induced protein 1 
8121076 PNRC1 proline-rich nuclear receptor coactivator 1 
8058127 PPIL3 peptidylprolyl isomerase (cyclophilin)-like 3 
7923659 PPP1R15B protein phosphatase 1, regulatory (inhibitor) subunit 15B 
7966345 PPTC7 PTC7 protein phosphatase homolog (S. cerevisiae) 
8080487 PRKCD protein kinase C, delta 
7903188 PTBP2 polypyrimidine tract binding protein 2 
7922976 PTGS2 prostaglandin-endoperoxide synthase 2 
8083594 PTX3 pentraxin-related gene, rapidly induced by IL-1 beta 
8166098 RAB9A RAB9A, member RAS oncogene family 
8058390 RAPH1 Ras association and pleckstrin homology domains 1 
7933149 RASGEF1A RasGEF domain family, member 1A 
7987405 RASGRP1 RAS guanyl releasing protein 1 
7909214 RASSF5 Ras association domain family member 5 
7994161 RBBP6 retinoblastoma binding protein 6 
8020468 RBBP8 retinoblastoma binding protein 8 
8042144 REL v-rel reticuloendotheliosis viral oncogene homolog  
8140151 RFC2 replication factor C (activator 1) 2, 40kDa 
8014189 RFFL ring finger and FYVE-like domain containing 1 
7914603 RNF19B ring finger protein 19B 
7979033 SAV1 salvador homolog 1 (Drosophila) 
8032157 SBNO2 strawberry notch homolog 2 (Drosophila) 
8066513 SDC4 syndecan 4 
7922229 SELE selectin E 
8123609 SERPINB9 serpin peptidase inhibitor, clade B, member 9 
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8135069 SERPINE1 serpin peptidase inhibitor, clade E, member 1 
8161255 SHB Src homology 2 domain containing adaptor protein B 
8110755 SLC12A7 solute carrier family 12, member 7 
8151223 SLCO5A1 solute carrier organic anion transporter family, member 5 
8060745 SMOX spermine oxidase 
8017651 SMURF2 SMAD specific E3 ubiquitin protein ligase 2 
8150698 SNAI2 snail homolog 2 (Drosophila) 
7957551 SOCS2 suppressor of cytokine signalling 2 
8018864 SOCS3 suppressor of cytokine signalling 3 
8007212 STAT5A signal transducer and activator of transcription 5A 
8122457 STX11 syntaxin 11 
8122672 TAB2 TGF-beta activated kinase 1/MAP3K7 binding protein 2 
8045933 TANK TRAF family member-associated NFKB activator 
8075332 TBC1D10A TBC1 domain family, member 10A 
8032899 TICAM1 toll-like receptor adaptor molecule 1 
8102362 TIFA TRAF-interacting protein with forkhead-associated domain 
7990033 TLE3 transducin-like enhancer of split 3 
8156897 TMEFF1 transmembrane protein with EGF-like domains 1 
8099850 TMEM156 transmembrane protein 156 
8118142 TNF tumor necrosis factor (TNF superfamily, member 2) 
8177983 TNF tumor necrosis factor (TNF superfamily, member 2) 
8179263 TNF tumor necrosis factor (TNF superfamily, member 2) 
8122265 TNFAIP3 tumor necrosis factor, alpha-induced protein 3 
8107520 TNFAIP8 tumor necrosis factor, alpha-induced protein 8 
8149733 TNFRSF10B tumor necrosis factor receptor superfamily, member 10b 
8099029 TNIP2 TNFAIP3 interacting protein 2 
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7924526 TP53BP2 tumor protein p53 binding protein, 2 
8163825 TRAF1 TNF receptor-associated factor 1 
7928189 UNC5B unc-5 homolog B (C. elegans) 
8004905 USP43 ubiquitin specific peptidase 43 
7903358 VCAM1 vascular cell adhesion molecule 1 
7962689 VDR vitamin D (1,25- dihydroxyvitamin D3) receptor 
8147040 ZBTB10 zinc finger and BTB domain containing 10 
7943715 ZC3H12C zinc finger CCCH-type containing 12C 
8143279 ZC3HAV1 zinc finger CCCH-type, antiviral 1 
7962794 ZNF641 zinc finger protein 641 
 
B. Inflammation-related Genes Regulated by MAP3K8 










7951271 MMP1 1.65E-08 -2.64646 matrix metallopeptidase 1 
8054722 IL1B 3.64E-09 -2.45465 interleukin 1, beta 
8149825 STC1 9.98E-16 -2.38121 stanniocalcin 1 
7951284 MMP3 1.31E-08 -2.32029 matrix metallopeptidase 3 
8062927 PI3 0.000421466 -2.01234 peptidase inhibitor 3 
7951259 MMP10 1.29E-06 -2.00762 matrix metallopeptidase 10 
8141094 PDK4 3.36E-08 -1.9342 
pyruvate dehydrogenase kinase, 
isozyme 4 
8139207 INHBA 2.03E-07 -1.84071 inhibin, beta A 
8054712 IL1A 8.14E-06 -1.82905 interleukin 1, alpha 
8131803 IL6 5.27E-06 -1.80396 interleukin 6 (interferon, beta 2) 
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8104901 IL7R 0.000964311 -1.80072 interleukin 7 receptor 
7922229 SELE 0.00158625 -1.74345 selectin E 
8017843 SLC16A6 9.02E-07 -1.70425 
solute carrier family 16, 
member 6 
7951309 MMP13 7.45E-05 -1.64675 matrix metallopeptidase 13 
8009502 KCNJ2 0.000225555 -1.60361 
potassium inwardly-rectifying 
channel 
7956251 IL23A 0.000217596 -1.60256 
interleukin 23, alpha subunit 
p19 
8083594 PTX3 0.00377646 -1.6018 pentraxin 3, long 
7958147 TDG 0.00521979 -1.56597 thymine-DNA glycosylase 
8055952 NR4A2 3.64E-06 -1.55809 
nuclear receptor subfamily 4, 
group A, member 2 
7991335 ANPEP 8.47E-09 -1.54682 
alanyl (membrane) 
aminopeptidase 
8152617 HAS2 6.07E-09 -1.54476 hyaluronan synthase 2 
8096361 HERC5 5.98E-05 -1.52213 hect domain and RLD 5 
8095744 AREG 6.06E-07 -1.5205 amphiregulin 
8114778 GCSH 4.28E-10 -1.50857 
glycine cleavage system protein 
H (aminomethyl carrier) 
8027002 GDF15 6.08E-07 -1.50595 growth differentiation factor 15 
8095736 AREG 5.00E-08 -1.5022 amphiregulin 
8097628 HHIP 8.78E-05 -1.50143 hedgehog interacting protein 
7956009 METTL7B 1.48E-05 -1.49787 methyltransferase like 7B 
8046895 FAM171B 2.97E-08 -1.48948 
family with sequence similarity 
171, member B 
8007043 RAPGEFL1 0.0037071 -1.4889 
Rap guanine nucleotide 
exchange factor (GEF)-like 1 
7935521 AVPI1 1.13E-07 -1.4836 arginine vasopressin-induced 1 
8171624 GPR64 0.00027372 -1.48188 G protein-coupled receptor 64 
7961142 OLR1 0.00852302 -1.48152 
oxidized low density lipoprotein 
(lectin-like) receptor 1 
7914809 KIAA0319L 3.30E-13 -1.47317 KIAA0319-like 
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8059680 HTR2B 0.0026173 -1.47231 
5-hydroxytryptamine 
(serotonin) receptor 2B 
8105495 PART1 0.00386243 -1.47155 
prostate androgen-regulated 
transcript 1 
7902512 DNAJB4 1.89E-07 -1.47066 
DnaJ (Hsp40) homolog, 
subfamily B, member 4 
8026456 CYP4F3 5.61E-06 -1.46966 
cytochrome P450, family 4, 
subfamily F, polypeptide 3 
8100984 CXCL3 0.00319355 -1.46566 
chemokine (C-X-C motif) 
ligand 3 
7906061 SYT11 0.000211071 -1.46259 synaptotagmin XI 
8096116 AGPAT9 2.14E-08 -1.45001 
1-acylglycerol-3-phosphate 
O-acyltransferase 9 
8056184 ITGB6 0.00827502 -1.44227 integrin, beta 6 
8048864 CCL20 0.00142879 -1.4414 
chemokine (C-C motif) ligand 
20 
7918426 SLC16A4 7.73E-09 -1.44132 
solute carrier family 16, 
member 4 
8042503 MXD1 0.00020962 -1.44093 MAX dimerization protein 1 
8016099 EFTUD2 1.10E-09 -1.43953 
elongation factor Tu GTP 
binding domain containing 2 
7915861 MOBKL2C 0.000143755 -1.43785 
MOB1, Mps One Binder kinase 
activator-like 2C (yeast) 
8092707 LEPREL1 3.85E-07 -1.43659 leprecan-like 1 
7966779 NOS1 0.000934801 -1.43471 
nitric oxide synthase 1 
(neuronal) 
8146921 RDH10 5.92E-10 -1.43311 
retinol dehydrogenase 10 
(all-trans) 
8113369 SLCO4C1 0.00101642 -1.42995 
solute carrier organic anion 
transporter family 
8105302 FST 9.68E-05 -1.42677 follistatin 
7960177 SLC6A12 0.000367287 -1.42555 solute carrier family 6 
8095728 EREG 3.67E-08 -1.42006 epiregulin 
8131949 CBX3 1.63E-07 -1.4127 
chromobox homolog 3 (HP1 
gamma homolog, Drosophila) 
8134880 MOSPD3 1.77E-05 -1.41201 
motile sperm domain containing 
3 




7938559 RASSF10 0.000535587 -1.40617 
Ras association (RalGDS/AF-6) 
domain family 
8097282 SPRY1 0.00211707 1.40148 
sprouty homolog 1, antagonist 
of FGF signalling 
7936494 GFRA1 0.000794855 1.40223 GDNF family receptor alpha 1 
8145977 PLEKHA2 0.000260663 1.40373 
pleckstrin homology domain 
containing, family A 
7996772 SLC7A6 7.37E-11 1.40729 solute carrier family 7 
8010188 TNRC6C 6.93E-06 1.41036 
trinucleotide repeat containing 
6C 
8041206 LBH 0.000123196 1.41184 
limb bud and heart development 
homolog (mouse) 
8104912 SKP2 2.85E-07 1.41533 
S-phase kinase-associated 
protein 2 (p45) 
8030403 PRR12 7.87E-07 1.4191 proline rich 12 
7923753 NUAK2 1.94E-07 1.42198 
NUAK family, SNF1-like 
kinase, 2 
8162533 PTCH1 0.000205189 1.42232 patched homolog 1 (Drosophila) 
8023220 SMAD7 0.000108809 1.42335 SMAD family member 7 
8120826 IRAK1BP1 0.000333555 1.4239 
interleukin-1 
receptor-associated kinase 1 
binding protein 1 
7899870 ZNF362 8.59E-08 1.42675 zinc finger protein 362 
8084794 IL1RAP 0.000155656 1.42944 
interleukin 1 receptor accessory 
protein 
7963333 KRT80 7.61E-05 1.43431 keratin 80 
8173457 ZMYM3 1.72E-08 1.43456 zinc finger, MYM-type 3 
8041582 PKDCC 1.32E-05 1.44026 
protein kinase domain 
containing, cytoplasmic 
homolog 
7927876 TET1 0.00027372 1.44414 tet oncogene 1 
7964033 ANKRD52 1.13E-07 1.4473 ankyrin repeat domain 52 
7900438 ZNF643 0.000260917 1.46509 zinc finger protein 643 
7977854 JUB 1.10E-09 1.46792 




8111922 LOC648987 2.30E-06 1.47229 hypothetical LOC648987 
7950743 RAB30 4.08E-06 1.48153 
RAB30, member RAS 
oncogene family 
7975095 PLEKHG3 3.99E-05 1.49395 
pleckstrin homology domain 
containing, family G 
8007637 FZD2 1.13E-07 1.4984 frizzled homolog 2 (Drosophila) 
7899534 EPB41 1.39E-06 1.50987 
erythrocyte membrane protein 
band 4.1 
7902227 GADD45A 2.40E-05 1.51244 
growth arrest and 
DNA-damage-inducible, alpha 
8075897 C1QTNF6 1.37E-06 1.51359 
C1q and tumor necrosis factor 
related protein 6 
7917649 TGFBR3 2.23E-08 1.52614 
transforming growth factor, beta 
receptor III 
8062319 TGIF2 4.06E-06 1.53157 
TGFB-induced factor 
homeobox 2 
7905789 IL6R 1.41E-05 1.54119 interleukin 6 receptor 
7964834 CPM 2.85E-07 1.54646 carboxypeptidase M 
8080964 GXYLT2 2.68E-07 1.56029 glucoside xylosyltransferase 2 
8076185 CBX7 9.20E-05 1.57966 chromobox homolog 7 
8133062 ZNF273 4.10E-06 1.5856 zinc finger protein 273 
7999909 GPRC5B 1.30E-12 1.61927 
G protein-coupled receptor, 
family C, group 5, member B 
8056323 FIGN 8.66E-10 1.6829 fidgetin 
7987454 BMF 1.70E-10 1.77656 Bcl2 modifying factor 
7977270 LOC388022 2.39E-07 1.81091 
hypothetical gene supported by 
AK131040 
8138741 HOXA6 4.00E-07 1.84713 homeobox A6 
8133057 ZNF138 4.31E-08 1.85876 zinc finger protein 138 
7967318 GPR109A 8.78E-05 1.94968 
G protein-coupled receptor 
109A 
7967322 GPR109B 0.000432042 2.44917 
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